{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "NomicEmbeddings\n",
    "\n",
    "Rag with metadata\n",
    "\n",
    "Human in the loop\n",
    "\n",
    "--------------------"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "patients identity hidden from llm\n",
    "\n",
    "using python Relp for relative month in profile or policy comply\n",
    "\n",
    "add database to google api\n",
    "\n",
    "utilities:   \n",
    "- patients DB creator\n",
    "\n",
    "steps:\n",
    "- Create Agents\n",
    "- Define tools\n",
    "- Create graph\n",
    "- Define Agent Nodes\n",
    "- Define Tool Node\n",
    "- Define Edge Logic\n",
    "- Define the Graph\n",
    "- show the graph\n",
    "- Invoke\n",
    "  \n",
    "- Human in the loop\n",
    "- Maximum number of steps\n",
    "- Helper Utilities"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# LLM Agents for Clinical Trial Management\n",
    "\n",
    "In this notebook, we develop an agent-based system to automate the management and analysis of clinical trial data, ensuring compliance with regulatory standards, and providing comprehensive reports for stakeholders. This pipeline also incorporate human-in-the-loop (HITL) and memory mechanisms to enhance functionality and accuracy."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Steps and Plan\n",
    "\n",
    "1. Define the Problem:\n",
    "\n",
    "Objective: Automate clinical trial data management, analysis, compliance checks, and reporting.\n",
    "\n",
    "Key Components: Data collection, data analysis, compliance verification, reporting, and human-in-the-loop interventions.\n",
    "\n",
    "2. Design the Architecture:\n",
    "**Agents:**\n",
    "Data Collection Agent: Gathers patient data, trial results, and other relevant information.\n",
    "\n",
    "Data Analysis Agent: Analyzes the collected data to generate reports on trial outcomes.\n",
    "\n",
    "Compliance Agent: Ensures all data and processes adhere to regulatory standards.\n",
    "\n",
    "Reporting Agent: Compiles and presents the analysis findings in comprehensive reports.\n",
    "\n",
    "Human-in-the-Loop: Integrate a review phase where human experts validate data analysis and compliance checks before final reporting.\n",
    "\n",
    "Memory: Utilize LangGraph’s memory capabilities to track the progress and history of each trial."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The Clinical Trial Matching Agent is designed to match patients wit\th suitable clinical trials based on their medical history, symptoms, and ongoing treatments. This application helps patients find relevant clinical trials they may be eligible for, improving their chances of accessing new treatments and contributing to medical research.\n",
    "\n",
    "\n",
    "1. Database Setup\n",
    "- SQLite Database: Create two databases:\n",
    "- Patients DB: Stores patient medical history, previous trials, and other relevant data.\n",
    "- Clinical Trials DB: Contains information about ongoing and upcoming clinical trials, including eligibility criteria.\n",
    "2. Agents and Tools\n",
    "- Patient Data Ingestion Agent: Retrieves patient data from the SQLite database or prompts the user to provide missing data.\n",
    "- Data Validation and Collection Loop: Ensures all required fields are collected using persistence.\n",
    "- Policy Compliance Agent: Cross-checks patient data with institutional policies.\n",
    "- Trial Vectorization Agent: Extracts and vectorizes recruiting trials for efficient search.\n",
    "- Trial Matching Agent: Forms prompts from patient data to search the vector database for potential trial matches.\n",
    "- Human-in-the-Loop (HIL) Agent: Presents top trial matches to the user for selection.\n",
    "- Persistence Mechanism: Allows the application to save and resume states, especially useful for collecting patient data and searching trials."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "%load_ext autoreload\n",
    "%autoreload 2\n",
    "import getpass\n",
    "import os\n",
    "\n",
    "\n",
    "def _set_if_undefined(var: str):\n",
    "    if not os.environ.get(var):\n",
    "        os.environ[var] = getpass.getpass(f\"Please provide your {var}\")\n",
    "\n",
    "\n",
    "_set_if_undefined(\"OPENAI_API_KEY\")\n",
    "_set_if_undefined(\"LANGCHAIN_API_KEY\")\n",
    "# _set_if_undefined(\"TAVILY_API_KEY\")\n",
    "\n",
    "# Optional, add tracing in LangSmith\n",
    "os.environ[\"LANGCHAIN_TRACING_V2\"] = \"true\"\n",
    "os.environ[\"LANGCHAIN_PROJECT\"] = \"Clinical Trial Management\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_openai import ChatOpenAI\n",
    "\n",
    "\n",
    "vstore_created = False\n",
    "trials_vstore_created = False\n",
    "trials_db_downloaded = False\n",
    "modelID = \"gpt-3.5-turbo\"\n",
    "n_retrieved_policies = 6\n",
    "# n_retries = 6\n",
    "n_retrieved_trials = 6\n",
    "\n",
    "model = ChatOpenAI(temperature = 0.0, model=modelID)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "# import os\n",
    "\n",
    "# from dotenv import load_dotenv, find_dotenv\n",
    "# _ = load_dotenv(find_dotenv()) # read local .env file\n",
    "\n",
    "import warnings\n",
    "warnings.filterwarnings(\"ignore\")\n",
    "\n",
    "import pprint\n",
    "# A function for printing nicely\n",
    "def nprint(text, indent=2):\n",
    "    pp = pprint.PrettyPrinter(indent=indent)\n",
    "    pp.pprint(text)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Creating the sample datasets"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Patients database"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['Sophia Martinez', 'James Brown', 'Alice Davis', 'James Thomas', 'Emily Wilson', 'Jane Wilson', 'Emily Davis', 'Oliver Doe', 'Oliver Garcia', 'Daniel Brown']\n",
      "100\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>patient_id</th>\n",
       "      <th>name</th>\n",
       "      <th>age</th>\n",
       "      <th>medical_history</th>\n",
       "      <th>previous_trials</th>\n",
       "      <th>trial_status</th>\n",
       "      <th>trial_completion_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>John Johnson</td>\n",
       "      <td>40</td>\n",
       "      <td>myelomonocytic leukemia</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>Emma Martinez</td>\n",
       "      <td>39</td>\n",
       "      <td>depressive disorder</td>\n",
       "      <td>Trial 18</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2024-04-29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>Oliver Martinez</td>\n",
       "      <td>30</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>Trial 18</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2023-11-18</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Michael Doe</td>\n",
       "      <td>55</td>\n",
       "      <td>leiomyosarcoma</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>Emma Wilson</td>\n",
       "      <td>24</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Trial 3</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2023-02-11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6</td>\n",
       "      <td>Jane Martinez</td>\n",
       "      <td>43</td>\n",
       "      <td>Arthritis</td>\n",
       "      <td>Trial 6</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2022-11-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>Oliver Davis</td>\n",
       "      <td>33</td>\n",
       "      <td>soft tissue sarcoma</td>\n",
       "      <td>Trial 8</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2022-06-29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>8</td>\n",
       "      <td>Daniel Johnson</td>\n",
       "      <td>51</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>9</td>\n",
       "      <td>Sophia Doe</td>\n",
       "      <td>54</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>Trial 5</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10</td>\n",
       "      <td>James Brown</td>\n",
       "      <td>30</td>\n",
       "      <td>esophageal cancer</td>\n",
       "      <td>Trial 17</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>11</td>\n",
       "      <td>Daniel Wilson</td>\n",
       "      <td>44</td>\n",
       "      <td>Arthritis</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>12</td>\n",
       "      <td>Emily Wilson</td>\n",
       "      <td>46</td>\n",
       "      <td>liposarcoma</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>13</td>\n",
       "      <td>Sophia Martinez</td>\n",
       "      <td>33</td>\n",
       "      <td>lymphoblastic leukemia</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>14</td>\n",
       "      <td>Michael Smith</td>\n",
       "      <td>20</td>\n",
       "      <td>Depression</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>15</td>\n",
       "      <td>James Davis</td>\n",
       "      <td>58</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>Trial 2</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2023-04-26</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>16</td>\n",
       "      <td>Sophia Anderson</td>\n",
       "      <td>50</td>\n",
       "      <td>liposarcoma</td>\n",
       "      <td>Trial 18</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2023-12-27</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>17</td>\n",
       "      <td>Oliver Martinez</td>\n",
       "      <td>57</td>\n",
       "      <td>depressive disorder</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>18</td>\n",
       "      <td>Michael Doe</td>\n",
       "      <td>40</td>\n",
       "      <td>anxiety disorder</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>19</td>\n",
       "      <td>James Brown</td>\n",
       "      <td>43</td>\n",
       "      <td>mesothelioma</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20</td>\n",
       "      <td>Michael Davis</td>\n",
       "      <td>34</td>\n",
       "      <td>depressive disorder</td>\n",
       "      <td>Trial 15</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    patient_id             name  age          medical_history previous_trials  \\\n",
       "0            1     John Johnson   40  myelomonocytic leukemia                   \n",
       "1            2    Emma Martinez   39      depressive disorder        Trial 18   \n",
       "2            3  Oliver Martinez   30                  Obesity        Trial 18   \n",
       "3            4      Michael Doe   55           leiomyosarcoma                   \n",
       "4            5      Emma Wilson   24        colorectal cancer         Trial 3   \n",
       "5            6    Jane Martinez   43                Arthritis         Trial 6   \n",
       "6            7     Oliver Davis   33      soft tissue sarcoma         Trial 8   \n",
       "7            8   Daniel Johnson   51        colorectal cancer                   \n",
       "8            9       Sophia Doe   54             Chronic Pain         Trial 5   \n",
       "9           10      James Brown   30        esophageal cancer        Trial 17   \n",
       "10          11    Daniel Wilson   44                Arthritis                   \n",
       "11          12     Emily Wilson   46              liposarcoma                   \n",
       "12          13  Sophia Martinez   33   lymphoblastic leukemia                   \n",
       "13          14    Michael Smith   20               Depression                   \n",
       "14          15      James Davis   58                  Obesity         Trial 2   \n",
       "15          16  Sophia Anderson   50              liposarcoma        Trial 18   \n",
       "16          17  Oliver Martinez   57      depressive disorder                   \n",
       "17          18      Michael Doe   40         anxiety disorder                   \n",
       "18          19      James Brown   43             mesothelioma                   \n",
       "19          20    Michael Davis   34      depressive disorder        Trial 15   \n",
       "\n",
       "   trial_status trial_completion_date  \n",
       "0                                      \n",
       "1     Completed            2024-04-29  \n",
       "2     Withdrawn            2023-11-18  \n",
       "3                                      \n",
       "4     Withdrawn            2023-02-11  \n",
       "5     Withdrawn            2022-11-01  \n",
       "6     Withdrawn            2022-06-29  \n",
       "7                                      \n",
       "8       Ongoing                        \n",
       "9       Ongoing                        \n",
       "10                                     \n",
       "11                                     \n",
       "12                                     \n",
       "13                                     \n",
       "14    Completed            2023-04-26  \n",
       "15    Completed            2023-12-27  \n",
       "16                                     \n",
       "17                                     \n",
       "18                                     \n",
       "19      Ongoing                        "
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "from datetime import datetime, timedelta\n",
    "\n",
    "# Generate the sample data again for display\n",
    "columns = [\"patient_id\", \"name\", \"age\", \"medical_history\", \"previous_trials\", \"trial_status\", \"trial_completion_date\"]\n",
    "data = []\n",
    "\n",
    "import random\n",
    "\n",
    "# Given names and surnames\n",
    "names = [\"John\", \"Jane\", \"Alice\", \"Michael\", \"Emily\", \"Daniel\", \"Sophia\", \"James\", \"Emma\", \"Oliver\"]\n",
    "surnames = [\"Doe\", \"Smith\", \"Johnson\", \"Brown\", \"Davis\", \"Garcia\", \"Martinez\", \"Anderson\", \"Thomas\", \"Wilson\"]\n",
    "\n",
    "# Generate all possible unique combinations of names and surnames\n",
    "combinations = [(name, surname) for name in names for surname in surnames]\n",
    "\n",
    "# Shuffle the combinations to ensure randomness\n",
    "random.shuffle(combinations)\n",
    "\n",
    "# Select the first 100 unique combinations\n",
    "unique_names = combinations[:100]\n",
    "\n",
    "# Generate the full names\n",
    "full_names = [f\"{name} {surname}\" for name, surname in unique_names]\n",
    "\n",
    "# Display the first few full names for verification\n",
    "print(full_names[:10])\n",
    "\n",
    "# Optionally, you can also display all 100 unique full names\n",
    "# print(len(full_names))\n",
    "# unique entries of list full_names\n",
    "print(len(set(full_names)))\n",
    "\n",
    "\n",
    "import numpy as np\n",
    "import json\n",
    "\n",
    "with open('../../source_data/diseases_list.json', 'r') as file:\n",
    "        trial_diseases =  json.load(file)\n",
    "\n",
    "list_trial_diseases = list({disease for diseases in trial_diseases.values() for disease in diseases})\n",
    "\n",
    "other_medical_conditions = [\"Hypertension\", \"Diabetes\", \"Asthma\", \"Heart Disease\", \"Arthritis\",\n",
    "                      \"Chronic Pain\", \"Anxiety\", \"Depression\", \"Obesity\"]\n",
    "\n",
    "all_conditions = list(set(list_trial_diseases + other_medical_conditions))\n",
    "\n",
    "trial_statuses = [\"Completed\", \"Ongoing\", \"Withdrawn\"]\n",
    "\n",
    "def random_date(start, end):\n",
    "    return start + timedelta(days=random.randint(0, int((end - start).days)))\n",
    "\n",
    "# start_date must be 2 years before now\n",
    "start_date = datetime.now() - timedelta(days=365 * 2)\n",
    "# start_date = datetime(2020, 1, 1)\n",
    "\n",
    "# end_date must be a month before now\n",
    "end_date = datetime.now() - timedelta(days=10)\n",
    "# end_date = datetime(2023, 1, 1)\n",
    "\n",
    "for i in range(1, 101):\n",
    "    name = random.choice(full_names)\n",
    "    age = random.randint(20, 80)\n",
    "    medical_history = random.choice(all_conditions)\n",
    "    \n",
    "    if random.choice([True, False]):\n",
    "        previous_trials = f\"Trial {random.randint(1, 20)}\"\n",
    "        trial_status = random.choice(trial_statuses)\n",
    "        trial_completion_date = random_date(start_date, end_date).strftime('%Y-%m-%d')\n",
    "    else:\n",
    "        previous_trials = \"\"\n",
    "        trial_status = \"\"\n",
    "        trial_completion_date = \"\"\n",
    "    if trial_status == \"Ongoing\":\n",
    "        trial_completion_date = \"\"\n",
    "\n",
    "    data.append((i, name, age, medical_history, previous_trials, trial_status, trial_completion_date))\n",
    "\n",
    "df = pd.DataFrame(data, columns=columns)\n",
    "# save df to csv\n",
    "df.to_csv(\"patients.csv\", index=False)\n",
    "df.head(20)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>patient_id</th>\n",
       "      <th>name</th>\n",
       "      <th>age</th>\n",
       "      <th>medical_history</th>\n",
       "      <th>previous_trials</th>\n",
       "      <th>trial_status</th>\n",
       "      <th>trial_completion_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>John Johnson</td>\n",
       "      <td>40</td>\n",
       "      <td>myelomonocytic leukemia</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>13</td>\n",
       "      <td>Sophia Martinez</td>\n",
       "      <td>33</td>\n",
       "      <td>lymphoblastic leukemia</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>24</td>\n",
       "      <td>Sophia Thomas</td>\n",
       "      <td>51</td>\n",
       "      <td>lymphoblastic leukemia</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>41</td>\n",
       "      <td>Michael Thomas</td>\n",
       "      <td>63</td>\n",
       "      <td>lymphoblastic leukemia</td>\n",
       "      <td>Trial 11</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2024-05-06</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>59</td>\n",
       "      <td>Daniel Brown</td>\n",
       "      <td>37</td>\n",
       "      <td>myeloid leukemia</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>71</th>\n",
       "      <td>72</td>\n",
       "      <td>Sophia Davis</td>\n",
       "      <td>76</td>\n",
       "      <td>lymphoblastic leukemia</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>75</td>\n",
       "      <td>Daniel Garcia</td>\n",
       "      <td>79</td>\n",
       "      <td>myelomonocytic leukemia</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>76</td>\n",
       "      <td>Emma Martinez</td>\n",
       "      <td>63</td>\n",
       "      <td>lymphoblastic leukemia</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>82</th>\n",
       "      <td>83</td>\n",
       "      <td>Emma Doe</td>\n",
       "      <td>52</td>\n",
       "      <td>myeloid leukemia</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>99</td>\n",
       "      <td>Emily Davis</td>\n",
       "      <td>32</td>\n",
       "      <td>lymphoblastic leukemia</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    patient_id             name  age          medical_history previous_trials  \\\n",
       "0            1     John Johnson   40  myelomonocytic leukemia                   \n",
       "12          13  Sophia Martinez   33   lymphoblastic leukemia                   \n",
       "23          24    Sophia Thomas   51   lymphoblastic leukemia                   \n",
       "40          41   Michael Thomas   63   lymphoblastic leukemia        Trial 11   \n",
       "58          59     Daniel Brown   37         myeloid leukemia                   \n",
       "71          72     Sophia Davis   76   lymphoblastic leukemia                   \n",
       "74          75    Daniel Garcia   79  myelomonocytic leukemia                   \n",
       "75          76    Emma Martinez   63   lymphoblastic leukemia                   \n",
       "82          83         Emma Doe   52         myeloid leukemia                   \n",
       "98          99      Emily Davis   32   lymphoblastic leukemia                   \n",
       "\n",
       "   trial_status trial_completion_date  \n",
       "0                                      \n",
       "12                                     \n",
       "23                                     \n",
       "40    Completed            2024-05-06  \n",
       "58                                     \n",
       "71                                     \n",
       "74                                     \n",
       "75                                     \n",
       "82                                     \n",
       "98                                     "
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# df[df['trial_completion_date'] >= '2024-01-01']\n",
    "df[df['medical_history'].str.contains('leukemia')]\n",
    "# df[df['diseases'].has ]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "100\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>patient_id</th>\n",
       "      <th>name</th>\n",
       "      <th>age</th>\n",
       "      <th>medical_history</th>\n",
       "      <th>previous_trials</th>\n",
       "      <th>trial_status</th>\n",
       "      <th>trial_completion_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>John Johnson</td>\n",
       "      <td>40</td>\n",
       "      <td>myelomonocytic leukemia</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>Emma Martinez</td>\n",
       "      <td>39</td>\n",
       "      <td>depressive disorder</td>\n",
       "      <td>Trial 18</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2024-04-29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>Oliver Martinez</td>\n",
       "      <td>30</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>Trial 18</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2023-11-18</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Michael Doe</td>\n",
       "      <td>55</td>\n",
       "      <td>leiomyosarcoma</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>Emma Wilson</td>\n",
       "      <td>24</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Trial 3</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2023-02-11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6</td>\n",
       "      <td>Jane Martinez</td>\n",
       "      <td>43</td>\n",
       "      <td>Arthritis</td>\n",
       "      <td>Trial 6</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2022-11-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>Oliver Davis</td>\n",
       "      <td>33</td>\n",
       "      <td>soft tissue sarcoma</td>\n",
       "      <td>Trial 8</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2022-06-29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>8</td>\n",
       "      <td>Daniel Johnson</td>\n",
       "      <td>51</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>9</td>\n",
       "      <td>Sophia Doe</td>\n",
       "      <td>54</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>Trial 5</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10</td>\n",
       "      <td>James Brown</td>\n",
       "      <td>30</td>\n",
       "      <td>esophageal cancer</td>\n",
       "      <td>Trial 17</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   patient_id             name  age          medical_history previous_trials  \\\n",
       "0           1     John Johnson   40  myelomonocytic leukemia            None   \n",
       "1           2    Emma Martinez   39      depressive disorder        Trial 18   \n",
       "2           3  Oliver Martinez   30                  Obesity        Trial 18   \n",
       "3           4      Michael Doe   55           leiomyosarcoma            None   \n",
       "4           5      Emma Wilson   24        colorectal cancer         Trial 3   \n",
       "5           6    Jane Martinez   43                Arthritis         Trial 6   \n",
       "6           7     Oliver Davis   33      soft tissue sarcoma         Trial 8   \n",
       "7           8   Daniel Johnson   51        colorectal cancer            None   \n",
       "8           9       Sophia Doe   54             Chronic Pain         Trial 5   \n",
       "9          10      James Brown   30        esophageal cancer        Trial 17   \n",
       "\n",
       "  trial_status trial_completion_date  \n",
       "0         None                  None  \n",
       "1    Completed            2024-04-29  \n",
       "2    Withdrawn            2023-11-18  \n",
       "3         None                  None  \n",
       "4    Withdrawn            2023-02-11  \n",
       "5    Withdrawn            2022-11-01  \n",
       "6    Withdrawn            2022-06-29  \n",
       "7         None                  None  \n",
       "8      Ongoing                  None  \n",
       "9      Ongoing                  None  "
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import os\n",
    "# import shutil\n",
    "import sqlite3\n",
    "\n",
    "import pandas as pd\n",
    "\n",
    "overwrite = True\n",
    "\n",
    "database_file = 'patients_database.db'\n",
    "df = pd.read_csv('patients.csv')\n",
    "if overwrite or not os.path.exists(database_file):\n",
    "    if os.path.exists(database_file):\n",
    "        os.remove(database_file)\n",
    "    conn = sqlite3.connect(database_file)\n",
    "    cursor = conn.cursor()\n",
    "    cursor.execute('''\n",
    "    CREATE TABLE IF NOT EXISTS patients (\n",
    "        patient_id INTEGER PRIMARY KEY,\n",
    "        name TEXT,\n",
    "        age INTEGER,\n",
    "        medical_history TEXT,\n",
    "        previous_trials TEXT,\n",
    "        trial_status TEXT,\n",
    "        trial_completion_date TEXT\n",
    "    )\n",
    "    ''')\n",
    "\n",
    "    # Insert DataFrame into SQLite table\n",
    "    df.to_sql('patients', conn, if_exists='append', index=False)\n",
    "\n",
    "    # Commit and close the connection\n",
    "    conn.commit()\n",
    "else:\n",
    "    conn = sqlite3.connect(database_file)\n",
    "    cursor = conn.cursor()\n",
    "\n",
    "query = 'SELECT * FROM patients'\n",
    "\n",
    "# Execute the query and fetch all results\n",
    "cursor.execute(query)\n",
    "rows = cursor.fetchall()\n",
    "\n",
    "# Optionally, you can get the column names\n",
    "column_names = [description[0] for description in cursor.description]\n",
    "\n",
    "# Convert the results to a Pandas DataFrame for better readability\n",
    "df = pd.DataFrame(rows, columns=column_names)\n",
    "print(len(df))\n",
    "\n",
    "# Display the DataFrame\n",
    "conn.close()\n",
    "\n",
    "db = database_file\n",
    "df.head(10)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Clinical Trials database"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Only trials with status recruiting are selected.\n",
      "The database for trials is saved to ../../data/trials_data.csv \n",
      " It has 30 rows.\n",
      "---- Sample 1 ----\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Subject is at least 20 years of age.\n",
      "\n",
      "          2. Subject has a histologically or cytologically confirmed diagnosis of urothelial\n",
      "             carcinoma arising from urinary bladder or upper urinary tract.\n",
      "\n",
      "          3. Subject has been treated with platinum-based chemotherapy for advanced disease. They\n",
      "             must have refractory or progressive disease for which there is no further curative\n",
      "             therapy available.\n",
      "\n",
      "          4. Subject has been treated with platinum-based chemotherapy for advanced disease. They\n",
      "             must have refractory or progressive disease for which there is no further curative\n",
      "             therapy available.\n",
      "\n",
      "             Subject has a tumor that carries a missense HRAS mutation according to a standard\n",
      "             methodology using Illumina HiSeqTM. (missence non-synonymous HRAS mutation and/or\n",
      "             STK11: rs2075606 (T>C))HRAS status may have been assessed either in primary tumor\n",
      "             tissue, recurrent or metastatic disease.\n",
      "\n",
      "          5. Subject has consented to provide at least 10 unstained tumor slides for retrospective\n",
      "             testing of HRAS gene tumor status.\n",
      "\n",
      "          6. Must have a life expectancy of 3 months or more\n",
      "\n",
      "          7. Subject has measurable disease according to RECIST(Response Evaluation Criteria in\n",
      "             Solid Tumors ) v1.1 and has relapsed (progressive disease) or is refractory to prior\n",
      "             therapy.\n",
      "\n",
      "          8. At least 2 weeks since the last systemic therapy regimen prior to enrolment. Subjects\n",
      "             must have recovered to NCI CTCAE v. 4.03 < Grade 2 from all acute toxicities\n",
      "             (excluding Grade 2 toxicities that are not considered a safety risk by the Sponsor and\n",
      "             Investigator) or toxicity must be deemed irreversible by the Investigator.\n",
      "\n",
      "          9. At least 2 weeks since last radiotherapy if radiation was localized to the only site\n",
      "             of measurable disease, unless there is documentation of disease progression of the\n",
      "             irradiated site. Patients must have recovered from all acute toxicities from\n",
      "             radiotherapy.\n",
      "\n",
      "         10. ECOG(Eastern Cooperative Oncology Group ) performance status of 0 or 1.\n",
      "\n",
      "         11. Acceptable liver function:\n",
      "\n",
      "               1. Bilirubin ≤ 1.5 times upper limit of normal (x ULN); does not apply to subjects\n",
      "                  with Gilbert's syndrome diagnosed as per institutional guidelines.\n",
      "\n",
      "               2. AST (SGOT,aspartate aminotransferase ) and ALT (SGPT,Alanine aminotransferase) ≤\n",
      "                  3 x ULN; if liver metastases are present, then ≤ 5 x ULN is allowed.\n",
      "\n",
      "         12. Acceptable renal function with serum creatinine ≤ 1.5 x ULN or a calculated creatinine\n",
      "             clearance ≥ 60 mL/min using the Cockcroft-Gault or MDRD(Modification of Diet in Renal\n",
      "             Disease ) formulas. Serum potassium with normal or ≤ CTCAE Grade 1 with or without\n",
      "             supplementation.\n",
      "\n",
      "         13. Acceptable hematologic status (without growth factor support or transfusion\n",
      "             dependency):\n",
      "\n",
      "               1. ANC(absolute neutrophil count )>1500 cells/μL.\n",
      "\n",
      "               2. Platelet count >100,000/μL.\n",
      "\n",
      "               3. Hemoglobin >9.0 g/dL.\n",
      "\n",
      "         14. Female subjects must be either:\n",
      "\n",
      "               1. Of non-child-bearing potential (surgically sterilized or at least 2 years\n",
      "                  post-menopausal); or\n",
      "\n",
      "               2. If of child-bearing potential, subject must use an adequate method of\n",
      "                  contraception consisting of two-barrier method or one barrier method with a\n",
      "                  spermicide or intrauterine device. Both females and male subjects with female\n",
      "                  partners of child-bearing potential must agree to use an adequate method of\n",
      "                  contraception for 2 weeks prior to screening, during, and at least 4 weeks after\n",
      "                  last dose of trial medication. Female subjects must have a negative serum or\n",
      "                  urine pregnancy test within 72 hours prior to start of trial medication.\n",
      "\n",
      "               3. Not breast feeding at any time during the study.\n",
      "\n",
      "         15. Written and voluntary informed consent understood, signed and dated.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Ongoing treatment with an anticancer agent not contemplated in this protocol.\n",
      "\n",
      "          2. Prior treatment (at least 1 full treatment cycle) with an FTase inhibitor.\n",
      "\n",
      "          3. Any history of clinically relevant coronary artery disease or myocardial infarction\n",
      "             within the last 3 years, New York Heart Association (NYHA) grade III or greater\n",
      "             congestive heart failure, cerebrovascular attack within the prior year, or current\n",
      "             serious cardiac arrhythmia requiring medication except atrial fibrillation.\n",
      "\n",
      "          4. Known uncontrolled brain, leptomeningeal or epidural metastases (unless treated and\n",
      "             well controlled for at least 4 weeks prior to Cycle 1 Day 1). Subjects that develop\n",
      "             brain metastasis during the study may have their treatment interrupted to receive a\n",
      "             course of cranial radiation and restart trial medication after a recovery period of at\n",
      "             least 1 week. High dose corticosteroids may be employed for the management of cranial\n",
      "             radiation but must be tapered off before resuming treatment.\n",
      "\n",
      "          5. Non-tolerable > Grade 2 neuropathy or evidence of unstable neurological symptoms\n",
      "             within 4 weeks of Cycle 1 Day 1.\n",
      "\n",
      "          6. Major surgery, other than diagnostic surgery, within 4 weeks prior to Cycle 1 Day 1,\n",
      "             without complete recovery.\n",
      "\n",
      "          7. Double primary cancer of other site(s), except for cured ones at the discretion of\n",
      "             investigator\n",
      "\n",
      "          8. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic\n",
      "             therapy. Known infection with HIV, or an active infection with hepatitis B or\n",
      "             hepatitis C.\n",
      "\n",
      "          9. Subjects who have exhibited allergic reactions to tipifarnib, structural compounds\n",
      "             similar to tipifarnib or to its excipients.\n",
      "\n",
      "         10. Concomitant disease or condition that could interfere with the conduct of the study,\n",
      "             or that would, in the opinion of the Investigator, pose an unacceptable risk to the\n",
      "             subject in this study.\n",
      "\n",
      "         11. The subject has legal incapacity or limited legal capacity.\n",
      "\n",
      "         12. Dementia or significantly altered mental status that would limit the understanding or\n",
      "             rendering of informed consent and compliance with the requirements of this protocol.\n",
      "             Unwillingness or inability to comply with the study protocol for any reason.\n",
      "\n",
      "         13. QTcF interval ≥ 470 msecs\n",
      "      \n",
      "---- Sample 2 ----\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Subject is at least 20 years of age.\n",
      "\n",
      "          2. Written and voluntary informed consent understood, signed and dated.\n",
      "\n",
      "          3. They must have refractory or progressive colorectal cancer for which there is no\n",
      "             further curative therapy available.\n",
      "\n",
      "          4. Subject able to adhere to the study visit schedule and other protocol requirements.\n",
      "\n",
      "          5. ECOG 0-2\n",
      "\n",
      "          6. At least one measurable lesion that can be accurately assessed by imaging or physical\n",
      "             examination at baseline and following up visits.\n",
      "\n",
      "          7. Must have a life expectancy of 3 months or more\n",
      "\n",
      "          8. Demonstrate adequate organ function\n",
      "\n",
      "          9. Negative urine or serum pregnancy test within 28 days of study treatment\n",
      "\n",
      "         10. Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy\n",
      "             of the tissue sample quality for assessment of biomarker status.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. ECOG ≥ 3\n",
      "\n",
      "          2. History of malignancy in the last 5 years.\n",
      "\n",
      "          3. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\n",
      "             C.\n",
      "\n",
      "          4. Breast-feeding or pregnant female\n",
      "\n",
      "          5. Patients can not the administration of Folic acid or Vitamin B12.\n",
      "\n",
      "          6. Before treatment with Pemetrexed.\n",
      "\n",
      "          7. Patients who can not swallow oral medication.\n",
      "\n",
      "          8. The most recent treatment with the clinical trial for the drug for 14 days prior to\n",
      "             enrollment.\n",
      "\n",
      "          9. Systemic chemotherapy within three weeks after the administration of the last before\n",
      "             the test treatment, radiation therapy patients who had been administered.\n",
      "\n",
      "         10. Except for the hair loss, it is induced before cancer treatment, all of toxicity in\n",
      "             progress (> CTCAE1 grade).\n",
      "\n",
      "         11. Upper GI bleeding within registration before 4 weeks of Bowel obstruction or CTCAE3 or\n",
      "             4 grade.\n",
      "\n",
      "         12. Subject who experienced a recent myocardial infarction, including severe/unstable\n",
      "             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\n",
      "             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\n",
      "             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\n",
      "             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\n",
      "             year.\n",
      "      \n",
      "---- Sample 3 ----\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Pathologic diagnosis of ovarian, fallopian tube or primary peritoneal cancer confirmed\n",
      "             by pathology review at MSK.\n",
      "\n",
      "          -  Patients will have relapsed at least once and returned to complete clinical remission\n",
      "             after additional chemotherapy. Interval surgery is permitted.\n",
      "\n",
      "          -  Complete clinical remission is defined as CA-125 within normal limits, examination and\n",
      "             CT or MRI without objective evidence of disease (non specific abnormalities are\n",
      "             permitted on radiologic imaging).\n",
      "\n",
      "          -  Patients may sign screening consent during recurrence or at time of remission if they\n",
      "             can start vaccine therapy within 4 months of completing chemotherapy.\n",
      "\n",
      "          -  Testing of patient's archived (paraffin embedded, unstained slides) or freshly\n",
      "             biopsied tumor nodules must be positive for WT1 (Cohort 1) or NY-ESO-1 (Cohort 2)\n",
      "             protein expression. WT1 expression: Immunohistochemical analysis will be performed\n",
      "             using the technique described by Dupont et al [58]. WT1 expression will be graded\n",
      "             according to an adaptation of the German Immunoreactive Score (IRS). Only tumors with\n",
      "             moderate to strong IRS scores (4-12) will be considered WT1 positive.\n",
      "\n",
      "          -  NY-ESO-1 expression: Tissue available from primary and/or recurrent disease will be\n",
      "             evaluated for tumor expression of NY-ESO-1 by immunohistochemical (IHC) and/or RT-PCR\n",
      "             analysis will be performed using the technique described by Jungbluth et al\n",
      "\n",
      "          -  Age ≥ 18 years\n",
      "\n",
      "          -  Karnofsky performance status ≥ 70%\n",
      "\n",
      "          -  Hematologic parameters: Absolute neutrophil count ≥ 1000/mcL, Platelets > 50 K/mcL.\n",
      "\n",
      "          -  Biochemical parameters: Total bilirubin ≤ 1.5 mg/dl, AST and ALT ≤ 2.5 x upper limits\n",
      "             of normal, Creatinine ≤ 1.5 mg/dl.\n",
      "\n",
      "          -  Patient of childbearing potential must have a negative serum pregnancy test prior to\n",
      "             study entry and must be practicing and effective form of birth control\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Pregnant or lactating women\n",
      "\n",
      "          -  Patients with active infection requiring systemic antibiotics, antiviral, or\n",
      "             antifungal treatments\n",
      "\n",
      "          -  Patients with a serious unstable medical illness or another active cancer.\n",
      "\n",
      "          -  Patients with a condition requiring systemic treatment with either corticosteroids\n",
      "             (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14\n",
      "             days of study drug administration. Inhaled or topical steroids and adrenal replacement\n",
      "             doses >10mg daily prednisone equivalents are permitted in the absence of active\n",
      "             autoimmune disease.\n",
      "\n",
      "          -  Patients with known history of testing positive for human immunodeficiency virus (HIV)\n",
      "             or known acquired immunodeficiency syndrome (AIDS).\n",
      "\n",
      "          -  Patients with known active hepatitis B virus or hepatitis C virus acute or chronic\n",
      "             infection.\n",
      "\n",
      "          -  Patients with active known or suspected autoimmune disease (treated hypothyroidism is\n",
      "             permitted to enroll)\n",
      "\n",
      "          -  Patients with active interstitial pneumonitis.\n",
      "      \n",
      "---- Sample 4 ----\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically confirmed metastatic or advanced prostate adenocarcinoma that has been\n",
      "             previously treated with docetaxel-based therapy and has progressed during treatment of\n",
      "             at least one hormonal therapy(prior docetaxel is not required for the safety cohort)\n",
      "\n",
      "          -  Two rising PSA levels greater than or equal to (>/=) 2 ng/mL measured >/= 1 week apart\n",
      "             or radiographic evidence of disease progression in soft tissue or bone\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening\n",
      "\n",
      "          -  Adequate hematologic and organ function\n",
      "\n",
      "          -  Documented willingness to use an effective means of contraception\n",
      "\n",
      "          -  Safety cohort only: agreement to use CGM for first cycle of treatment\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  History of Type I or Type II diabetes mellitus requiring insulin; safety cohort:\n",
      "             patients who are receiving any pharmacologic treatment for diabetes are not eligible\n",
      "\n",
      "          -  New York Heart Association Class III or IV heart failure or Left ventricular ejection\n",
      "             fraction < 50% or ventricular arrhythmia requiring medication\n",
      "\n",
      "          -  Significant atherosclerotic disease, as evidenced by: unstable angina, history of\n",
      "             myocardial infarction within 6 months prior to Day 1, or cerebrovascular accident\n",
      "             within 6 months prior to Day 1\n",
      "\n",
      "          -  Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory\n",
      "             drugs or active inflammatory disease which requires immunosuppressive therapy\n",
      "\n",
      "          -  Clinically significant history of liver disease\n",
      "\n",
      "          -  History of adrenal insufficiency or hyperaldosteronism\n",
      "\n",
      "          -  Phase II only: Previous therapy for prostate cancer with 17\n",
      "             alpha-hydroxylase/C17,20-lyase inhibitors, including abiraterone\n",
      "\n",
      "          -  Phase II only: Previous treatment for prostate cancer with Protein kinase B\n",
      "             phosphatidylinositol 3 kinase and/or mammalian target of rapamycin inhibitors\n",
      "\n",
      "          -  Need for chronic corticosteroid therapy of >/= 20 mg of prednisone per day or an\n",
      "             equivalent dose of other anti inflammatory corticosteroids or immunosuppressant\n",
      "      \n"
     ]
    }
   ],
   "source": [
    "import sys\n",
    "module_dir = os.path.abspath('../../src')  # Gets the absolute path to the src directory\n",
    "sys.path.append(module_dir)\n",
    "from helper_functions import dataset_create_trials\n",
    "\n",
    "overwrite = True\n",
    "if trials_db_downloaded and not overwrite:\n",
    "    print(f'Trials database already downloaded and stored in {trials_path}')\n",
    "    df_trials = pd.read_csv(trials_path)\n",
    "else:\n",
    "    df_trials, trials_path = dataset_create_trials(status='recruiting')\n",
    "    trials_db_downloaded = True\n",
    "\n",
    "# print the ctriteria column value froom 4 random rows of the dataferam. use a for loop\n",
    "df_samples = df_trials.sample(4).reset_index(drop=True)\n",
    "for i in range(4):\n",
    "    print(f'---- Sample {i+1} ----')\n",
    "    print(df_samples.iloc[i]['criteria'])\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Tools"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_core.tools import tool\n",
    "from langchain_openai import ChatOpenAI\n",
    "\n",
    "def get_patient_data(patient_id: int) -> dict:\n",
    "    \"\"\"Fetch all fields for the patient based on the given patient_id as an integer.\n",
    "\n",
    "    Returns:\n",
    "        A dictionary containing the patient's medical history.        \n",
    "    \"\"\"\n",
    "\n",
    "    # config = ensure_config()  # Fetch from the context\n",
    "    # configuration = config.get(\"configurable\", {})\n",
    "    # patient_id = configuration.get(\"patient_id\", None)\n",
    "\n",
    "    # if not patient_id:\n",
    "    #     raise ValueError(\"No patient ID given.\")\n",
    "\n",
    "    conn = sqlite3.connect(db)\n",
    "    cursor = conn.cursor()    \n",
    "    query = 'SELECT * FROM patients WHERE patient_id=?'\n",
    "    cursor.execute(query, (patient_id,))\n",
    "    patient_data = cursor.fetchone()\n",
    "    # rows = cursor.fetchall()\n",
    "    column_names = [column[0] for column in cursor.description]\n",
    "    conn.close()\n",
    "    if patient_data is None:\n",
    "        return None\n",
    "    else:    \n",
    "        results = dict(zip(column_names, patient_data))    \n",
    "    return results\n",
    "\n",
    "\n",
    "def add_patient_data(patient_data: dict):    \n",
    "    \"\"\"Adds a new patient to the SQLite database.\"\"\"\n",
    "    \n",
    "    name = patient_data['name']\n",
    "    age = patient_data['age']\n",
    "    medical_history = patient_data['medical_history']\n",
    "    previous_trials = patient_data['previous_trials']\n",
    "    trial_status = patient_data['trial_status']\n",
    "    last_trial_dates = patient_data['last_trial_dates']\n",
    "\n",
    "    conn = sqlite3.connect(db)\n",
    "    cursor = conn.cursor()\n",
    "    \n",
    "    # Insert the new patient data into the database\n",
    "    cursor.execute('''\n",
    "    INSERT INTO patients (name, age, medical_history, previous_trials, trial_status, last_trial_dates)\n",
    "    VALUES (?, ?, ?, ?, ?, ?)\n",
    "    ''', (name, age, medical_history, previous_trials, trial_status, last_trial_dates))\n",
    "    \n",
    "    conn.commit()\n",
    "    conn.close()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'patient_id': 4, 'name': 'Michael Doe', 'age': 55, 'medical_history': 'leiomyosarcoma', 'previous_trials': None, 'trial_status': None, 'trial_completion_date': None}\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'patient_id': 4,\n",
       " 'name': 'Michael Doe',\n",
       " 'age': 55,\n",
       " 'medical_history': 'leiomyosarcoma',\n",
       " 'previous_trials': None,\n",
       " 'trial_status': None,\n",
       " 'trial_completion_date': None}"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sample_patient_id = 4\n",
    "patient_data = get_patient_data(sample_patient_id)\n",
    "print(patient_data)\n",
    "patient_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### vectorstore for policy database\n",
    "\n",
    "local embedding via NomicEmbeddings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "12\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the current year to allow for proper assessment of any delayed adverse effects.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 5. **Regulatory Compliance**\\n   - **Ethics Approval**: All trials must have approval from the Institutional Review Board (IRB) or Ethics Committee.\\n   - **Data Privacy**: Patient data must be handled in compliance with data protection regulations (e.g., GDPR, HIPAA).\\n   - **Adverse Event Reporting**: Any adverse events must be reported according to institutional and regulatory guidelines.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 7. **Emergency Contact and Support**\\n   - **Emergency Contact**: Patients must provide emergency contact information.\\n   - **Support Systems**: Patients must have access to appropriate support systems (e.g., caregiver, family member) to assist them throughout the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 8. **Travel Restrictions**\\n   - **Travel Requirements**: Patients must be able to travel to the trial site regularly for check-ups and monitoring without significant hardship or risk.\\n   - **Travel History**: Patients who have traveled to areas with active outbreaks of infectious diseases within the past 3 months are not eligible.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 9. **Dietary and Lifestyle Restrictions**\\n   - **Dietary Compliance**: Patients must adhere to any dietary restrictions or requirements specified by the trial protocol.\\n   - **Lifestyle Modifications**: Patients must be willing to comply with lifestyle modifications required by the trial protocol, such as exercise regimens or smoking cessation.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 10. **Allergies and Sensitivities**\\n   - **Allergy Disclosure**: Patients must disclose any known allergies or sensitivities, particularly to medications, foods, or environmental factors.\\n   - **Medication Sensitivity**: Patients with known sensitivities to medications being tested in the trial are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 11. **Cognitive and Communication Abilities**\\n   - **Cognitive Assessment**: Patients must have the cognitive ability to understand and comply with the trial protocol and instructions.\\n   - **Communication Abilities**: Patients must be able to effectively communicate with the research team and understand instructions, either directly or with the assistance of a caregiver.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 12. **Employment and Daily Responsibilities**\\n   - **Employment Impact**: Patients must disclose if participation in the trial could impact their employment or daily responsibilities significantly.\\n   - **Availability**: Patients must be available for all scheduled trial visits and assessments as required by the protocol, with minimal risk of missing appointments.', metadata={'source': '../../source_data/instut_trials_policy.md'})]"
      ]
     },
     "execution_count": 59,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# from gpt4all import Embed4All\n",
    "# model_name = 'nomic-embed-text-v1.5.f16.gguf'\n",
    "# text = 'The quick brown fox jumps over the lazy dog'\n",
    "# # you can change it to cuda if you have available GPU\n",
    "# embedder = Embed4All(model_name, device='cpu')\n",
    "# output = embedder.embed(text)\n",
    "# print(len(output))\n",
    "\n",
    "import re\n",
    "\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain_community.document_loaders import WebBaseLoader\n",
    "from langchain_community.vectorstores import Chroma\n",
    "from langchain_nomic.embeddings import NomicEmbeddings\n",
    "from langchain_community.document_loaders import UnstructuredMarkdownLoader\n",
    "from langchain_core.documents import Document\n",
    "\n",
    "\n",
    "markdown_path = \"../../source_data/instut_trials_policy.md\"\n",
    "\n",
    "with open(markdown_path, \"r\") as f:\n",
    "    policy_text = f.read()\n",
    "\n",
    "\n",
    "doc_splits = [\n",
    "    Document(page_content= txt, metadata={\"source\": markdown_path}) for txt in re.split(r\"(?=\\n###)\", policy_text)\n",
    "    ]\n",
    "\n",
    "# the title of markdown is not required in the split\n",
    "doc_splits = doc_splits[1:]    \n",
    "\n",
    "# docs = [WebBaseLoader(url).load() for url in urls]\n",
    "# docs_list = [item for sublist in docs for item in sublist]\n",
    "\n",
    "# text_splitter = RecursiveCharacterTextSplitter.from_tiktoken_encoder(\n",
    "    # chunk_size=250, chunk_overlap=0\n",
    "# )\n",
    "# doc_splits = text_splitter.split_documents(docs_list)\n",
    "print(len(doc_splits))\n",
    "doc_splits\n",
    "\n",
    "# Add to vectorDB\n",
    "# load the existing vectorstore from \"rag-chroma\"\n",
    "\n",
    "\n",
    "if vstore_created:\n",
    "    vectorstore.delete_collection()\n",
    "\n",
    "vectorstore = Chroma.from_documents(\n",
    "    documents=doc_splits,\n",
    "    collection_name=\"rag-chroma\",\n",
    "    embedding=NomicEmbeddings(model=\"nomic-embed-text-v1.5\",\n",
    "                              inference_mode='local'),\n",
    ")\n",
    "vstore_created = True\n",
    "doc_splits\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "6\n",
      "\n",
      "#### 3. **Previous Trial Participation**   \n",
      "   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\n",
      "   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\n",
      "   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the current year to allow for proper assessment of any delayed adverse effects.\n",
      "   - **Trial Outcomes**:\n",
      "     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\n",
      "     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\n",
      "\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the current year to allow for proper assessment of any delayed adverse effects.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 12. **Employment and Daily Responsibilities**\\n   - **Employment Impact**: Patients must disclose if participation in the trial could impact their employment or daily responsibilities significantly.\\n   - **Availability**: Patients must be available for all scheduled trial visits and assessments as required by the protocol, with minimal risk of missing appointments.', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 8. **Travel Restrictions**\\n   - **Travel Requirements**: Patients must be able to travel to the trial site regularly for check-ups and monitoring without significant hardship or risk.\\n   - **Travel History**: Patients who have traveled to areas with active outbreaks of infectious diseases within the past 3 months are not eligible.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 5. **Regulatory Compliance**\\n   - **Ethics Approval**: All trials must have approval from the Institutional Review Board (IRB) or Ethics Committee.\\n   - **Data Privacy**: Patient data must be handled in compliance with data protection regulations (e.g., GDPR, HIPAA).\\n   - **Adverse Event Reporting**: Any adverse events must be reported according to institutional and regulatory guidelines.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})]"
      ]
     },
     "execution_count": 60,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "retriever = vectorstore.as_retriever(search_kwargs={\"k\": n_retrieved_policies})\n",
    "# question = \"policy about patient's past trials\"\n",
    "question = \"\\ntrial_completion_date: 2024-04-01\"\n",
    "docs_retrieved = retriever.get_relevant_documents(question)\n",
    "print(len(docs_retrieved))\n",
    "doc_txt = docs_retrieved[0].page_content\n",
    "print(doc_txt)\n",
    "docs_retrieved"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'patient_id': 4,\n",
       " 'name': 'Michael Doe',\n",
       " 'age': 55,\n",
       " 'medical_history': 'leiomyosarcoma',\n",
       " 'previous_trials': None,\n",
       " 'trial_status': None,\n",
       " 'trial_completion_date': None}"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# patient_data['medical_history'] = \"Chronic Pain, Pregnant\"\n",
    "sample_patient_id = 4\n",
    "patient_data = get_patient_data(sample_patient_id)\n",
    "# print(patient_data)\n",
    "# patient_data\n",
    "# patient_data['trial_completion_date'] = '2024-04-01'\n",
    "patient_data\n",
    "# date"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Vstore for trials"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "we just work on 3 main categories of cancer, lukemia, and mental health problems as a demo application.\n",
    "\n",
    "For a more proper application, this must be done with the help of domain specialists."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'nctid': 'NCT00715611', 'status': 'recruiting', 'diseases': \"['mesothelioma']\", 'disease_category': 'cancer', 'drugs': \"['pemetrexed and cisplatin or carboplatin']\"}\n"
     ]
    }
   ],
   "source": [
    "# from langchain.document_loaders import CSVLoader\n",
    "# file = '../../data/trials_data.csv'\n",
    "# df_trials = pd.read_csv(file)\n",
    "from helper_functions import disease_map\n",
    "\n",
    "trial_docs = []\n",
    "for i, row in df_trials.iterrows():\n",
    "    disease = disease_map(row['diseases'])\n",
    "    if disease == 'other_conditions':\n",
    "        continue\n",
    "    doc = Document(\n",
    "        page_content=row['criteria'],\n",
    "        metadata={\n",
    "            \"nctid\": row['nctid'],\n",
    "            \"status\": row['status'],\n",
    "            # \"why_stop\": row['why_stop'],\n",
    "            # \"label\": row['label'],\n",
    "            # \"phase\": row['phase'],\n",
    "            \"diseases\": str(row['diseases']),\n",
    "            \"disease_category\": disease[0],\n",
    "            \"drugs\": row['drugs'],            \n",
    "        }\n",
    "    )\n",
    "    trial_docs.append(doc)\n",
    "# trial_docs\n",
    "\n",
    "print(trial_docs[0].metadata)\n",
    "\n",
    "list_remove = set()\n",
    "for i, doc in enumerate(trial_docs):\n",
    "    if len(doc.page_content)>10000:\n",
    "        list_remove.add(i)\n",
    "        # print(doc.metadata)\n",
    "    if doc.metadata['disease_category'] == 'other_conditions':\n",
    "        list_remove.add(i)\n",
    "        # print(doc.metadata)\n",
    "# remove list_remove indexes from trial_docs\n",
    "trial_docs = [doc for i, doc in enumerate(trial_docs) if i not in list_remove]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "# print(len(trial_docs[11].page_content))\n",
    "# trial_docs.pop(11)\n",
    "\n",
    "if trials_vstore_created:\n",
    "    vectorstore_trials.delete_collection()\n",
    "\n",
    "vectorstore_trials = Chroma.from_documents(\n",
    "    documents=trial_docs,\n",
    "    collection_name=\"trials-chroma\",\n",
    "    embedding=NomicEmbeddings(model=\"nomic-embed-text-v1.5\",\n",
    "                              inference_mode='local'),\n",
    ")\n",
    "trials_vstore_created = True"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Retriever Trials"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.chains.query_constructor.base import AttributeInfo\n",
    "from langchain.retrievers.self_query.base import SelfQueryRetriever\n",
    "\n",
    "metadata_field_info = [\n",
    "    AttributeInfo(\n",
    "        name=\"disease_category\",\n",
    "        description=\"Defines the disease group of patients related to this trial. One of ['cancer', 'leukemia', 'mental_health']\",\n",
    "        # description=\"The trial is for patients when their disease is related to this category. One of ['cancer', 'leukemia', 'mental_health']\",\n",
    "        type=\"string\",\n",
    "    ),\n",
    "    AttributeInfo(\n",
    "        name=\"drugs\",\n",
    "        description=\"List of drug names used in the trial\",\n",
    "        type=\"str\",\n",
    "    ),    \n",
    "]\n",
    "\n",
    "document_content_description = \"The list of patient conditions to include or exclude them from the trial\"\n",
    "retriever_trial_sq = SelfQueryRetriever.from_llm(\n",
    "    model,\n",
    "    vectorstore_trials,\n",
    "    # vectorstore_trials_mpnet,\n",
    "    document_content_description,\n",
    "    metadata_field_info\n",
    "    # enable_limit=True\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "6\n",
      "cancer ['prostate cancer']\n",
      "cancer ['metastatic pancreatic cancer']\n",
      "cancer ['rectal cancer']\n",
      "cancer ['colorectal cancer']\n",
      "cancer ['pancreatic ductal adenocarcinoma']\n",
      "cancer ['stage iv non-small cell lung cancer']\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Histologically confirmed metastatic or advanced prostate adenocarcinoma that has been\\r\\n             previously treated with docetaxel-based therapy and has progressed during treatment of\\r\\n             at least one hormonal therapy(prior docetaxel is not required for the safety cohort)\\r\\n\\r\\n          -  Two rising PSA levels greater than or equal to (>/=) 2 ng/mL measured >/= 1 week apart\\r\\n             or radiographic evidence of disease progression in soft tissue or bone\\r\\n\\r\\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening\\r\\n\\r\\n          -  Adequate hematologic and organ function\\r\\n\\r\\n          -  Documented willingness to use an effective means of contraception\\r\\n\\r\\n          -  Safety cohort only: agreement to use CGM for first cycle of treatment\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  History of Type I or Type II diabetes mellitus requiring insulin; safety cohort:\\r\\n             patients who are receiving any pharmacologic treatment for diabetes are not eligible\\r\\n\\r\\n          -  New York Heart Association Class III or IV heart failure or Left ventricular ejection\\r\\n             fraction < 50% or ventricular arrhythmia requiring medication\\r\\n\\r\\n          -  Significant atherosclerotic disease, as evidenced by: unstable angina, history of\\r\\n             myocardial infarction within 6 months prior to Day 1, or cerebrovascular accident\\r\\n             within 6 months prior to Day 1\\r\\n\\r\\n          -  Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory\\r\\n             drugs or active inflammatory disease which requires immunosuppressive therapy\\r\\n\\r\\n          -  Clinically significant history of liver disease\\r\\n\\r\\n          -  History of adrenal insufficiency or hyperaldosteronism\\r\\n\\r\\n          -  Phase II only: Previous therapy for prostate cancer with 17\\r\\n             alpha-hydroxylase/C17,20-lyase inhibitors, including abiraterone\\r\\n\\r\\n          -  Phase II only: Previous treatment for prostate cancer with Protein kinase B\\r\\n             phosphatidylinositol 3 kinase and/or mammalian target of rapamycin inhibitors\\r\\n\\r\\n          -  Need for chronic corticosteroid therapy of >/= 20 mg of prednisone per day or an\\r\\n             equivalent dose of other anti inflammatory corticosteroids or immunosuppressant\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['prostate cancer']\", 'drugs': \"['abiraterone', 'apitolisib', 'ipatasertib', 'placebo', 'prednisone', 'prednisolone']\", 'nctid': 'NCT01485861', 'status': 'recruiting'}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Patients have provided a signed Informed Consent Form\\r\\n\\r\\n          -  ECOG performance status of 0-1\\r\\n\\r\\n          -  BMI ≥ 18.5\\r\\n\\r\\n          -  Age: 18-65 years old\\r\\n\\r\\n          -  Histologically confirmed diagnosis of metastatic pancreatic cancer\\r\\n\\r\\n          -  No prior palliative chemotherapy\\r\\n\\r\\n          -  Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria\\r\\n\\r\\n          -  Life expectancy ≥ 3 months\\r\\n\\r\\n          -  Patient has adequate bone marrow and organ function\\r\\n\\r\\n               -  Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L\\r\\n\\r\\n               -  Platelets ≥ 90 x 109/L\\r\\n\\r\\n               -  Hemoglobin ≥ 90 g/L\\r\\n\\r\\n          -  Patient has adequate liver function\\r\\n\\r\\n               -  AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is\\r\\n                  liver metastasis)\\r\\n\\r\\n               -  Serum bilirubin ≤ 1.2 x ULN\\r\\n\\r\\n          -  Creatinine ≤ 1.25 times ULN\\r\\n\\r\\n          -  Good compliance\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Brain metastasis or only with bone metastasis.\\r\\n\\r\\n          -  Patients with severe gastrointestinal hemorrhage which need frequent blood\\r\\n             transfusions.\\r\\n\\r\\n          -  Refuse to take appropriate contraceptive measures (including male patients).\\r\\n\\r\\n          -  Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil.\\r\\n\\r\\n          -  Severe systemic disease out of control such as unstable or uncompensated respiratory,\\r\\n             cardiac, liver, renal diseases.\\r\\n\\r\\n          -  Patient has a concurrent malignancy or has a malignancy within 5 years of study\\r\\n             enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in\\r\\n             situ).\\r\\n\\r\\n          -  Psychiatric illness that would prevent the patient from giving informed consent.\\r\\n\\r\\n          -  Patient is concurrently using other antineoplastic agent\\r\\n\\r\\n          -  Patient has used investigational antineoplastic agent within 4 weeks prior to entry.\\r\\n\\r\\n          -  Known HIV-positivity.\\r\\n\\r\\n          -  No history of chronic diarrhea, nausea or vomit.\\r\\n\\r\\n          -  No ≥ grade 2 sensory peripheral neuropathy.\\r\\n\\r\\n          -  A history of transmural myocardial infarction (within 6 months prior to entry),\\r\\n             congestive heart failure, and unstable angina.\\r\\n\\r\\n          -  Infectious disease or inflammation with body temperature ≥ 38 ℃.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['metastatic pancreatic cancer']\", 'drugs': \"['mfolfirinox']\", 'nctid': 'NCT02028806', 'status': 'recruiting'}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Diagnosis of adenocarcinoma of the rectum\\r\\n\\r\\n          -  Age: 18-70 years old\\r\\n\\r\\n          -  Signed informed consent; able to comply with study and/or follow- up procedures\\r\\n\\r\\n          -  Stage of the primary tumor may be determined by ultrasound or MRI\\r\\n\\r\\n          -  Stage II (T3-4, N0 [N0 is defined as all imaged lymph nodes < 1.0 cm]) OR stage III\\r\\n             (T1-4, N1-2 [with the definition of a clinically positive lymph node being any node ≥\\r\\n             1.0 cm]\\r\\n\\r\\n          -  Tumor palpable by digital rectal exam OR accessible by proctoscope or sigmoidoscope\\r\\n\\r\\n          -  Distal border of the tumor must be located < 12 cm from the anal verge\\r\\n\\r\\n          -  Tumor amenable to curative resection\\r\\n\\r\\n          -  Adequate bone marrow, hepatic and renal function as assessed by the following\\r\\n             laboratory requirements conducted within 7 days of starting study treatment:\\r\\n\\r\\n          -  Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet\\r\\n             count ≥ 100 x109/ L, hemoglobin (Hb) ≥ 9g/ dL.\\r\\n\\r\\n          -  Total bilirubin ≤1.5 x the upper limit of normal (ULN).\\r\\n\\r\\n          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.\\r\\n\\r\\n          -  Alkaline phosphatase limit ≤ 5x ULN.\\r\\n\\r\\n          -  Amylase and lipase ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Serum creatinine ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 mL/ min.\\r\\n\\r\\n          -  No renal disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  ECOG status: 0～1\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Hypersensitivity to fluorouracil, oxaliplatin or irinotecan.\\r\\n\\r\\n          -  No More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  Clear indication of involvement of the pelvic side walls by imaging\\r\\n\\r\\n          -  With distant metastasis\\r\\n\\r\\n          -  History of invasive rectal malignancy, regardless of disease-free interval\\r\\n\\r\\n          -  Fertile patients must use effective contraception\\r\\n\\r\\n          -  Uncontrolled hypertension\\r\\n\\r\\n          -  Cardiovascular disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  Lack of upper gastrointestinal tract integrity or malabsorption syndrome，active upper\\r\\n             gastrointestinal tract bleeding\\r\\n\\r\\n          -  Synchronous colon cancer\\r\\n\\r\\n          -  Pregnant or nursing, Fertile patients do not use effective contraception\\r\\n\\r\\n          -  Other malignancy within the past 5 years except effectively treated squamous cell or\\r\\n             basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or\\r\\n             carcinoma in situ of the colon or rectum\\r\\n\\r\\n          -  No psychiatric or addictive disorders, or other conditions that, in the opinion of the\\r\\n             investigator, would preclude study participation\\r\\n\\r\\n          -  patients refused to signed informed consent.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['rectal cancer']\", 'drugs': \"['mfolfox6']\", 'nctid': 'NCT02887313', 'status': 'recruiting'}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Subject is at least 20 years of age.\\r\\n\\r\\n          2. Written and voluntary informed consent understood, signed and dated.\\r\\n\\r\\n          3. They must have refractory or progressive colorectal cancer for which there is no\\r\\n             further curative therapy available.\\r\\n\\r\\n          4. Subject able to adhere to the study visit schedule and other protocol requirements.\\r\\n\\r\\n          5. ECOG 0-2\\r\\n\\r\\n          6. At least one measurable lesion that can be accurately assessed by imaging or physical\\r\\n             examination at baseline and following up visits.\\r\\n\\r\\n          7. Must have a life expectancy of 3 months or more\\r\\n\\r\\n          8. Demonstrate adequate organ function\\r\\n\\r\\n          9. Negative urine or serum pregnancy test within 28 days of study treatment\\r\\n\\r\\n         10. Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy\\r\\n             of the tissue sample quality for assessment of biomarker status.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. ECOG ≥ 3\\r\\n\\r\\n          2. History of malignancy in the last 5 years.\\r\\n\\r\\n          3. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\\r\\n             C.\\r\\n\\r\\n          4. Breast-feeding or pregnant female\\r\\n\\r\\n          5. Patients can not the administration of Folic acid or Vitamin B12.\\r\\n\\r\\n          6. Before treatment with Pemetrexed.\\r\\n\\r\\n          7. Patients who can not swallow oral medication.\\r\\n\\r\\n          8. The most recent treatment with the clinical trial for the drug for 14 days prior to\\r\\n             enrollment.\\r\\n\\r\\n          9. Systemic chemotherapy within three weeks after the administration of the last before\\r\\n             the test treatment, radiation therapy patients who had been administered.\\r\\n\\r\\n         10. Except for the hair loss, it is induced before cancer treatment, all of toxicity in\\r\\n             progress (> CTCAE1 grade).\\r\\n\\r\\n         11. Upper GI bleeding within registration before 4 weeks of Bowel obstruction or CTCAE3 or\\r\\n             4 grade.\\r\\n\\r\\n         12. Subject who experienced a recent myocardial infarction, including severe/unstable\\r\\n             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\\r\\n             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\\r\\n             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\\r\\n             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\\r\\n             year.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['colorectal cancer']\", 'drugs': \"['pemetrexed']\", 'nctid': 'NCT02588781', 'status': 'recruiting'}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma\\r\\n             (Islet cell neoplasms or neuroendocrine carcinomas are excluded)\\r\\n\\r\\n          2. ≥ 18 years of age at the time of signing the informed consent document\\r\\n\\r\\n          3. ECOG 0-1\\r\\n\\r\\n          4. At least one measurable lesion according to recist v1.1\\r\\n\\r\\n          5. No prior palliative chemotherapy for the treatment of metastatic pancreatic cancer\\r\\n             (Prior treatment with 5-FU or gemcitabine administered as a radiation sensitizer in\\r\\n             the adjuvant setting is allowed if the treatment had been received at least 6 months\\r\\n             before enroll).\\r\\n\\r\\n          6. Adequate BM function: ANC ≥1.5 × 109/L; Platelet count ≥100,000/mm2 (100 × 109/L); Hb\\r\\n             (Hb) ≥9 g/dL.\\r\\n\\r\\n          7. Adequate liver and renal function (obtained ≤14 days prior to enroll): AST (SGOT), ALT\\r\\n             (SGPT) ≤2.5 × upper limit of normal range (ULN), unless liver metastases are clearly\\r\\n             present, then ≤5 × ULN is allowed; Total bilirubin 1.5 ≤ ULN; Serum creatinine within\\r\\n             normal limits or calculated clearance ≥ 60 mL/min/1.73 m2\\r\\n\\r\\n          8. Albumin level ≥ 3 g/dl\\r\\n\\r\\n          9. Subjects should be asymptomatic for jaundice prior to Cycle 1 Day 1\\r\\n\\r\\n         10. Subject with signed the Informed Consent Form (ICF) prior to participation in any\\r\\n             study-related activities.\\r\\n\\r\\n         11. Female of childbearing potential (FCBP) (defined as a sexually mature woman who (1)\\r\\n             has not undergone hysterectomy [the surgical removal of the uterus] or bilateral\\r\\n             oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally\\r\\n             postmenopausal for at least 24 consecutive months [ie, has had menses at any time\\r\\n             during the preceding 24 consecutive months]) must:\\r\\n\\r\\n               -  Either commit to true abstinence or agree to the use of 2 physician-approved\\r\\n                  contraceptive methods (oral, injectable, or implantable hormonal contraceptive;\\r\\n                  tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or\\r\\n                  vasectomized partner) while on IP; and for 3 months following the last dose of\\r\\n                  IP; and\\r\\n\\r\\n               -  Has a negative serum pregnancy test (β-hCG) result at screening\\r\\n\\r\\n         12. Male subjects must practice true abstinence or agree to use a condom during sexual\\r\\n             contact with a pregnant female or a female of childbearing potential while\\r\\n             participating in the study, during dose interruptions, and for 6 months following IP\\r\\n             discontinuation, even if he has undergone a successful vasectomy\\r\\n\\r\\n         13. Subject able to adhere to the study visit schedule and other protocol requirements.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. Subject has known symptomatic brain metastases.\\r\\n\\r\\n          2. History of malignancy in the last 5 years.\\r\\n\\r\\n          3. Breast-feeding or pregnant female\\r\\n\\r\\n          4. Patients with plastic biliary stent (Metal biliary stents are allowed.)\\r\\n\\r\\n          5. Subject has active, uncontrolled bacterial, viral, or fungal infection(s) requiring\\r\\n             systemic therapy.\\r\\n\\r\\n          6. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\\r\\n             C.\\r\\n\\r\\n          7. Subject has undergone major surgery within 4 weeks prior to Cycle 1 Day 1 of treatment\\r\\n             in this study.\\r\\n\\r\\n          8. Subject who experienced a recent myocardial infarction, including severe/unstable\\r\\n             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\\r\\n             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\\r\\n             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\\r\\n             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\\r\\n             year.\\r\\n\\r\\n          9. Subject has a history of allergy or hypersensitivity to any of the study drugs\\r\\n\\r\\n         10. Subjects with history of connective tissue disorders (eg, lupus, scleroderma,\\r\\n             arteritis nodosa).\\r\\n\\r\\n         11. Subjects with a history of interstitial lung disease\\r\\n\\r\\n         12. Any other malignancy within 5 years prior to enrollment, with the exception of\\r\\n             adequately treated in-situ carcinoma of the prostate (Gleason score ≤ 7), cervix,\\r\\n             uteri, or nonmelanomatous skin cancer (all treatment of which should have been\\r\\n             completed 6 months prior to enrollment).\\r\\n\\r\\n         13. Patients has > Grade 1 pre-existing peripheral neuropathy (per CTCAE)\\r\\n\\r\\n         14. Subject has serious medical risk factors involving any of the major organ systems, or\\r\\n             serious psychiatric disorders, which could compromise the subject's safety or the\\r\\n             study data integrity.\\r\\n\\r\\n         15. Subject is enrolled in any other clinical protocol or investigational trial with an\\r\\n             interventional agent or assessments that may interfere with study procedures.\\r\\n\\r\\n         16. Subject is unwilling or unable to comply with study procedures\\r\\n\\r\\n         17. Any significant medical condition, laboratory abnormality, or psychiatric illness that\\r\\n             would prevent the subject from participating in the study.\\r\\n      \", metadata={'disease_category': 'cancer', 'diseases': \"['pancreatic ductal adenocarcinoma']\", 'drugs': \"['nab-paclitaxel', 'gemcitabine']\", 'nctid': 'NCT02426281', 'status': 'recruiting'}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Patients must have biopsy proven metastatic NSCLC (Stage IV).\\r\\n\\r\\n          2. Patients must have received first line chemotherapy, from 4-6 cycles, and achieved\\r\\n             stable disease or a partial response.\\r\\n\\r\\n          3. Patients receiving first-line erlotinib, gefitinib, or icotinib for EGFR\\r\\n             mutant-positive for 3 months and achieved stable disease, partial response or\\r\\n             completely response.\\r\\n\\r\\n          4. Age 18 to 75 years old.\\r\\n\\r\\n          5. Patients must have measurable disease at baseline.\\r\\n\\r\\n          6. The amount of metastatic focus <5.\\r\\n\\r\\n          7. ECOG score 0-2\\r\\n\\r\\n          8. Adequate normal organ and marrow function for TKI treatment and radiotherapy.\\r\\n\\r\\n          9. Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R)\\r\\n\\r\\n         10. Patients must provide written informed consent to participate in the study.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. Patients who previously received radiotherapy to the primary site.\\r\\n\\r\\n          2. Patient can't tolerate radiotherapy or targeted therapy;\\r\\n\\r\\n          3. Pregnant or nursing women\\r\\n      \", metadata={'disease_category': 'cancer', 'diseases': \"['stage iv non-small cell lung cancer']\", 'drugs': \"['tki']\", 'nctid': 'NCT03595644', 'status': 'recruiting'})]"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "retriever_trials = vectorstore_trials.as_retriever(search_kwargs={\"k\": n_retrieved_trials})\n",
    "# question = trial_docs[trail_smp].page_content\n",
    "question = \"\"\"\n",
    "Which trials are relevant to patient who has adenocarcinoma illness?\n",
    "\"\"\"\n",
    "\n",
    "# question = f\"\"\"\n",
    "# Which trials are relevant to the patient with the following medical history?\\n\n",
    "# patient_profile: {patient_profile}\n",
    "# \"\"\"\n",
    "# nprint(question)\n",
    "\n",
    "# Which four trials are for patients with mental problem?\n",
    "# print(trial_docs[trail_smp].metadata['nctid'])\n",
    "# question = \"Inclusion Criteria:\\r\\n\\r\\n          1. Subject\"\n",
    "docs_retrieved = retriever_trials.get_relevant_documents(question)\n",
    "# docs_retrieved = retriever_trial_sq.get_relevant_documents(question)\n",
    "print(len(docs_retrieved))\n",
    "doc_txt = docs_retrieved[0].page_content[:]\n",
    "nctid = docs_retrieved[0].metadata['nctid']\n",
    "for doc in docs_retrieved:\n",
    "    diseases = doc.metadata['diseases']\n",
    "    disease_category = doc.metadata['disease_category']\n",
    "    print(disease_category, diseases)\n",
    "docs_retrieved"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "dummy : profile creator llm"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'patient_id': 7,\n",
       " 'name': 'Oliver Davis',\n",
       " 'age': 33,\n",
       " 'medical_history': 'soft tissue sarcoma',\n",
       " 'previous_trials': 'Trial 8',\n",
       " 'trial_status': 'Withdrawn',\n",
       " 'trial_completion_date': '2022-06-29'}"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def patient_data_to_string(patient_data):\n",
    "    return \" \\n \".join([f\"{key}: {value}\" for key, value in patient_data.items()])\n",
    "\n",
    "patient_id = 7\n",
    "patient_data = get_patient_data(patient_id)\n",
    "patient_data\n",
    "# keys_to_include = ['age', 'medical_history']\n",
    "# patient_data = {key: patient_data[key] for key in keys_to_include}\n",
    "\n",
    "# patient_medical_history = patient_data_to_string(patient_data)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Profile Creator"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('Patient is a 33-year-old with a history of soft tissue sarcoma. They were '\n",
      " 'previously enrolled in Trial 8 but withdrew before completion on June 29, '\n",
      " '2022. Based on their medical history, they may be eligible for upcoming '\n",
      " 'clinical trials targeting soft tissue sarcoma.')\n"
     ]
    }
   ],
   "source": [
    "from langchain_core.output_parsers import StrOutputParser\n",
    "from langchain.prompts import PromptTemplate\n",
    "parser = StrOutputParser()\n",
    "\n",
    "# def patient_data_to_string(patient_data):\n",
    "    # return \" \\n\".join([f\"{key}: {value}\" for key, value in patient_data.items()])\n",
    "\n",
    "prompt_profile = PromptTemplate(\n",
    "    template=\"\"\"\n",
    "    You are the Clinical Research Coordinator in the screening phase of a clinical trial. \n",
    "    Use the following patient data to write the patient profile for the screening phase.\n",
    "    The patient profile is a summary of patient information.\n",
    "    The patient profile also suggests relevant medical trials based on patient's medical history.\n",
    "    Write the patient profile in 3 to 4 short sentences.\\n\\n\n",
    "    {patient_data}\"\"\",\n",
    "    input_variables=[\"patient_data\"],\n",
    ")\n",
    "# model = ChatOpenAI(temperature = 0.0, model=modelID)\n",
    "\n",
    "chain_profile = prompt_profile | model | parser\n",
    "# keys_to_include = ['age', 'medical_history']\n",
    "# patient_data = {key: patient_data[key] for key in keys_to_include}\n",
    "if patient_data.get('name'):\n",
    "    del patient_data['name']\n",
    "    del patient_data['patient_id']\n",
    "patient_profile = chain_profile.invoke({'patient_data': patient_data})\n",
    "nprint(patient_profile)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('\\n'\n",
      " 'Which trials are relevant to the patient with the following medical '\n",
      " 'history?\\n'\n",
      " '\\n'\n",
      " 'patient_profile: Patient Profile:\\n'\n",
      " 'The patient is a 51-year-old with a history of colorectal cancer. They have '\n",
      " 'not participated in any previous trials and their current trial status is '\n",
      " 'unknown. No trial completion date has been recorded.\\n'\n",
      " '\\n'\n",
      " 'Relevant Medical Trials:\\n'\n",
      " '1. Colorectal Cancer Treatment Trial - This trial focuses on new treatment '\n",
      " 'options for colorectal cancer patients, which may be beneficial for this '\n",
      " 'patient based on their medical history.\\n'\n",
      " '2. Cancer Survivorship Study - This trial aims to improve the quality of '\n",
      " 'life for cancer survivors, which could be relevant for this patient '\n",
      " 'post-treatment.\\n')\n",
      "4\n",
      "cancer ['colorectal cancer']\n",
      "cancer ['rectal cancer']\n",
      "cancer ['ovarian cancer', 'fallopian tube', 'primary peritoneal cancer', 'recurrent ovarian cancer']\n",
      "cancer ['metastatic pancreatic cancer']\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Subject is at least 20 years of age.\\r\\n\\r\\n          2. Written and voluntary informed consent understood, signed and dated.\\r\\n\\r\\n          3. They must have refractory or progressive colorectal cancer for which there is no\\r\\n             further curative therapy available.\\r\\n\\r\\n          4. Subject able to adhere to the study visit schedule and other protocol requirements.\\r\\n\\r\\n          5. ECOG 0-2\\r\\n\\r\\n          6. At least one measurable lesion that can be accurately assessed by imaging or physical\\r\\n             examination at baseline and following up visits.\\r\\n\\r\\n          7. Must have a life expectancy of 3 months or more\\r\\n\\r\\n          8. Demonstrate adequate organ function\\r\\n\\r\\n          9. Negative urine or serum pregnancy test within 28 days of study treatment\\r\\n\\r\\n         10. Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy\\r\\n             of the tissue sample quality for assessment of biomarker status.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. ECOG ≥ 3\\r\\n\\r\\n          2. History of malignancy in the last 5 years.\\r\\n\\r\\n          3. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\\r\\n             C.\\r\\n\\r\\n          4. Breast-feeding or pregnant female\\r\\n\\r\\n          5. Patients can not the administration of Folic acid or Vitamin B12.\\r\\n\\r\\n          6. Before treatment with Pemetrexed.\\r\\n\\r\\n          7. Patients who can not swallow oral medication.\\r\\n\\r\\n          8. The most recent treatment with the clinical trial for the drug for 14 days prior to\\r\\n             enrollment.\\r\\n\\r\\n          9. Systemic chemotherapy within three weeks after the administration of the last before\\r\\n             the test treatment, radiation therapy patients who had been administered.\\r\\n\\r\\n         10. Except for the hair loss, it is induced before cancer treatment, all of toxicity in\\r\\n             progress (> CTCAE1 grade).\\r\\n\\r\\n         11. Upper GI bleeding within registration before 4 weeks of Bowel obstruction or CTCAE3 or\\r\\n             4 grade.\\r\\n\\r\\n         12. Subject who experienced a recent myocardial infarction, including severe/unstable\\r\\n             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\\r\\n             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\\r\\n             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\\r\\n             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\\r\\n             year.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['colorectal cancer']\", 'drugs': \"['pemetrexed']\", 'nctid': 'NCT02588781', 'status': 'recruiting'}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Diagnosis of adenocarcinoma of the rectum\\r\\n\\r\\n          -  Age: 18-70 years old\\r\\n\\r\\n          -  Signed informed consent; able to comply with study and/or follow- up procedures\\r\\n\\r\\n          -  Stage of the primary tumor may be determined by ultrasound or MRI\\r\\n\\r\\n          -  Stage II (T3-4, N0 [N0 is defined as all imaged lymph nodes < 1.0 cm]) OR stage III\\r\\n             (T1-4, N1-2 [with the definition of a clinically positive lymph node being any node ≥\\r\\n             1.0 cm]\\r\\n\\r\\n          -  Tumor palpable by digital rectal exam OR accessible by proctoscope or sigmoidoscope\\r\\n\\r\\n          -  Distal border of the tumor must be located < 12 cm from the anal verge\\r\\n\\r\\n          -  Tumor amenable to curative resection\\r\\n\\r\\n          -  Adequate bone marrow, hepatic and renal function as assessed by the following\\r\\n             laboratory requirements conducted within 7 days of starting study treatment:\\r\\n\\r\\n          -  Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet\\r\\n             count ≥ 100 x109/ L, hemoglobin (Hb) ≥ 9g/ dL.\\r\\n\\r\\n          -  Total bilirubin ≤1.5 x the upper limit of normal (ULN).\\r\\n\\r\\n          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.\\r\\n\\r\\n          -  Alkaline phosphatase limit ≤ 5x ULN.\\r\\n\\r\\n          -  Amylase and lipase ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Serum creatinine ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 mL/ min.\\r\\n\\r\\n          -  No renal disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  ECOG status: 0～1\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Hypersensitivity to fluorouracil, oxaliplatin or irinotecan.\\r\\n\\r\\n          -  No More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  Clear indication of involvement of the pelvic side walls by imaging\\r\\n\\r\\n          -  With distant metastasis\\r\\n\\r\\n          -  History of invasive rectal malignancy, regardless of disease-free interval\\r\\n\\r\\n          -  Fertile patients must use effective contraception\\r\\n\\r\\n          -  Uncontrolled hypertension\\r\\n\\r\\n          -  Cardiovascular disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  Lack of upper gastrointestinal tract integrity or malabsorption syndrome，active upper\\r\\n             gastrointestinal tract bleeding\\r\\n\\r\\n          -  Synchronous colon cancer\\r\\n\\r\\n          -  Pregnant or nursing, Fertile patients do not use effective contraception\\r\\n\\r\\n          -  Other malignancy within the past 5 years except effectively treated squamous cell or\\r\\n             basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or\\r\\n             carcinoma in situ of the colon or rectum\\r\\n\\r\\n          -  No psychiatric or addictive disorders, or other conditions that, in the opinion of the\\r\\n             investigator, would preclude study participation\\r\\n\\r\\n          -  patients refused to signed informed consent.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['rectal cancer']\", 'drugs': \"['mfolfox6']\", 'nctid': 'NCT02887313', 'status': 'recruiting'}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Pathologic diagnosis of ovarian, fallopian tube or primary peritoneal cancer confirmed\\r\\n             by pathology review at MSK.\\r\\n\\r\\n          -  Patients will have relapsed at least once and returned to complete clinical remission\\r\\n             after additional chemotherapy. Interval surgery is permitted.\\r\\n\\r\\n          -  Complete clinical remission is defined as CA-125 within normal limits, examination and\\r\\n             CT or MRI without objective evidence of disease (non specific abnormalities are\\r\\n             permitted on radiologic imaging).\\r\\n\\r\\n          -  Patients may sign screening consent during recurrence or at time of remission if they\\r\\n             can start vaccine therapy within 4 months of completing chemotherapy.\\r\\n\\r\\n          -  Testing of patient's archived (paraffin embedded, unstained slides) or freshly\\r\\n             biopsied tumor nodules must be positive for WT1 (Cohort 1) or NY-ESO-1 (Cohort 2)\\r\\n             protein expression. WT1 expression: Immunohistochemical analysis will be performed\\r\\n             using the technique described by Dupont et al [58]. WT1 expression will be graded\\r\\n             according to an adaptation of the German Immunoreactive Score (IRS). Only tumors with\\r\\n             moderate to strong IRS scores (4-12) will be considered WT1 positive.\\r\\n\\r\\n          -  NY-ESO-1 expression: Tissue available from primary and/or recurrent disease will be\\r\\n             evaluated for tumor expression of NY-ESO-1 by immunohistochemical (IHC) and/or RT-PCR\\r\\n             analysis will be performed using the technique described by Jungbluth et al\\r\\n\\r\\n          -  Age ≥ 18 years\\r\\n\\r\\n          -  Karnofsky performance status ≥ 70%\\r\\n\\r\\n          -  Hematologic parameters: Absolute neutrophil count ≥ 1000/mcL, Platelets > 50 K/mcL.\\r\\n\\r\\n          -  Biochemical parameters: Total bilirubin ≤ 1.5 mg/dl, AST and ALT ≤ 2.5 x upper limits\\r\\n             of normal, Creatinine ≤ 1.5 mg/dl.\\r\\n\\r\\n          -  Patient of childbearing potential must have a negative serum pregnancy test prior to\\r\\n             study entry and must be practicing and effective form of birth control\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Patients with active infection requiring systemic antibiotics, antiviral, or\\r\\n             antifungal treatments\\r\\n\\r\\n          -  Patients with a serious unstable medical illness or another active cancer.\\r\\n\\r\\n          -  Patients with a condition requiring systemic treatment with either corticosteroids\\r\\n             (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14\\r\\n             days of study drug administration. Inhaled or topical steroids and adrenal replacement\\r\\n             doses >10mg daily prednisone equivalents are permitted in the absence of active\\r\\n             autoimmune disease.\\r\\n\\r\\n          -  Patients with known history of testing positive for human immunodeficiency virus (HIV)\\r\\n             or known acquired immunodeficiency syndrome (AIDS).\\r\\n\\r\\n          -  Patients with known active hepatitis B virus or hepatitis C virus acute or chronic\\r\\n             infection.\\r\\n\\r\\n          -  Patients with active known or suspected autoimmune disease (treated hypothyroidism is\\r\\n             permitted to enroll)\\r\\n\\r\\n          -  Patients with active interstitial pneumonitis.\\r\\n      \", metadata={'disease_category': 'cancer', 'diseases': \"['ovarian cancer', 'fallopian tube', 'primary peritoneal cancer', 'recurrent ovarian cancer']\", 'drugs': \"['nivolumab']\", 'nctid': 'NCT02737787', 'status': 'recruiting'}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Patients have provided a signed Informed Consent Form\\r\\n\\r\\n          -  ECOG performance status of 0-1\\r\\n\\r\\n          -  BMI ≥ 18.5\\r\\n\\r\\n          -  Age: 18-65 years old\\r\\n\\r\\n          -  Histologically confirmed diagnosis of metastatic pancreatic cancer\\r\\n\\r\\n          -  No prior palliative chemotherapy\\r\\n\\r\\n          -  Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria\\r\\n\\r\\n          -  Life expectancy ≥ 3 months\\r\\n\\r\\n          -  Patient has adequate bone marrow and organ function\\r\\n\\r\\n               -  Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L\\r\\n\\r\\n               -  Platelets ≥ 90 x 109/L\\r\\n\\r\\n               -  Hemoglobin ≥ 90 g/L\\r\\n\\r\\n          -  Patient has adequate liver function\\r\\n\\r\\n               -  AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is\\r\\n                  liver metastasis)\\r\\n\\r\\n               -  Serum bilirubin ≤ 1.2 x ULN\\r\\n\\r\\n          -  Creatinine ≤ 1.25 times ULN\\r\\n\\r\\n          -  Good compliance\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Brain metastasis or only with bone metastasis.\\r\\n\\r\\n          -  Patients with severe gastrointestinal hemorrhage which need frequent blood\\r\\n             transfusions.\\r\\n\\r\\n          -  Refuse to take appropriate contraceptive measures (including male patients).\\r\\n\\r\\n          -  Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil.\\r\\n\\r\\n          -  Severe systemic disease out of control such as unstable or uncompensated respiratory,\\r\\n             cardiac, liver, renal diseases.\\r\\n\\r\\n          -  Patient has a concurrent malignancy or has a malignancy within 5 years of study\\r\\n             enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in\\r\\n             situ).\\r\\n\\r\\n          -  Psychiatric illness that would prevent the patient from giving informed consent.\\r\\n\\r\\n          -  Patient is concurrently using other antineoplastic agent\\r\\n\\r\\n          -  Patient has used investigational antineoplastic agent within 4 weeks prior to entry.\\r\\n\\r\\n          -  Known HIV-positivity.\\r\\n\\r\\n          -  No history of chronic diarrhea, nausea or vomit.\\r\\n\\r\\n          -  No ≥ grade 2 sensory peripheral neuropathy.\\r\\n\\r\\n          -  A history of transmural myocardial infarction (within 6 months prior to entry),\\r\\n             congestive heart failure, and unstable angina.\\r\\n\\r\\n          -  Infectious disease or inflammation with body temperature ≥ 38 ℃.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['metastatic pancreatic cancer']\", 'drugs': \"['mfolfirinox']\", 'nctid': 'NCT02028806', 'status': 'recruiting'})]"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "question = f\"\"\"\n",
    "Which trials are relevant to the patient with the following medical history?\\n\n",
    "patient_profile: {patient_profile}\n",
    "\"\"\"\n",
    "# patient_profile: {patient_profile}\n",
    "# question = \"\"\"\n",
    "# Which trials are relevant to the patient with the medical history of myeloid leukemia?\n",
    "# \"\"\"\n",
    "nprint(question)\n",
    "\n",
    "# docs_retrieved = retriever_trials.get_relevant_documents(question)\n",
    "docs_retrieved = retriever_trial_sq.get_relevant_documents(question)\n",
    "print(len(docs_retrieved))\n",
    "doc_txt = docs_retrieved[0].page_content[:]\n",
    "nctid = docs_retrieved[0].metadata['nctid']\n",
    "for doc in docs_retrieved:\n",
    "    diseases = doc.metadata['diseases']\n",
    "    disease_category = doc.metadata['disease_category']\n",
    "    print(disease_category, diseases)\n",
    "docs_retrieved"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### policy checker"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "comply(binary_score='yes', reason='NA')"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "import langchain\n",
    "from langchain import hub\n",
    "from langchain_core.pydantic_v1 import BaseModel, Field\n",
    "\n",
    "from langchain.prompts import PromptTemplate\n",
    "from operator import itemgetter\n",
    "\n",
    "# patient_profile = patient_data_to_string(patient_data)\n",
    "\n",
    "# print(patient_profile)\n",
    "\n",
    "langchain.debug = False\n",
    "\n",
    "question = f\"\"\"\n",
    "Does the following patient profile comply with the institutional policies?\\n\n",
    "{patient_profile}\n",
    "\"\"\"\n",
    "\n",
    "# prompt = hub.pull(\"rlm/rag-prompt\").pretty_print()  # Show what the prompt looks like\n",
    "\n",
    "from langchain.chains import RetrievalQA\n",
    "\n",
    "\n",
    "class comply(BaseModel):\n",
    "        \"\"\"Binary score for trial eligibility check.\"\"\"\n",
    "\n",
    "        binary_score: str = Field(description=\"Patient eligible for the clinical trial 'yes' or 'no'\")\n",
    "        reason: str = Field(description=\"Reason(s) only if the patient is not eligible for clinical trials. Othereise use NA\")\n",
    "        \n",
    "# model = ChatOpenAI(temperature = 0.0, model=modelID)\n",
    "llm_with_tool = model.with_structured_output(comply)\n",
    "# qa = RetrievalQA.from_chain_type(\n",
    "#     llm=llm_with_tool,\n",
    "#     chain_type=\"stuff\",\n",
    "#     retriever=retriever,\n",
    "# )\n",
    "\n",
    "# completion_chroma = qa.run(question)\n",
    "docs_retrieved = retriever.get_relevant_documents(question)\n",
    "docs_retrieved\n",
    "\n",
    "\n",
    "# completion = qa.run(question)\n",
    "# completion\n",
    "docs_retrieved = retriever.get_relevant_documents(question)\n",
    "docs = \"\\n\\n\".join(doc.page_content for doc in docs_retrieved)\n",
    "docs\n",
    "\n",
    "prompt_policy = PromptTemplate(\n",
    "    template=\"\"\" You are a Principal Investigator (PI) for evaluating patients for clinical trials. \n",
    "        Use the following pieces of retrieved context from the institution's policies to answer the question about the patient's eligibility. \n",
    "        Here are the retrieved policies: \\n\\n {context} \\n\\n\n",
    "        Here is the user question: {question} \\n\n",
    "        Use the current date {date}, as the reference date to evaluate time related policies.\\n        \n",
    "        Giving a reason is required only for rejection cases.\n",
    "        Give a binary score 'yes' or 'no' score to indicate whether the patient is eligible for clinical trials.\"\"\",\n",
    "    input_variables=[\"context\", \"question\"],\n",
    ")\n",
    "\n",
    "# date = datetime.now().strftime(\"%Y-%m-%d\")\n",
    "date = datetime.today().strftime(\"%B %Y\")\n",
    "\n",
    "# prompt = hub.pull(\"rlm/rag-prompt\").pretty_print()  # Show what the prompt looks like\n",
    "\n",
    "\n",
    "# llm_with_tool = model.with_structured_output(comply)\n",
    "\n",
    "# chain = prompt | model\n",
    "# chain = prompt | llm_with_tool\n",
    "# chain = ( \n",
    "#     {\"patient_profile\" : chain_profile, \"question\" : itemgetter('question'),\n",
    "#      \"context\" : itemgetter('context'), \"date\" : itemgetter('date')} | prompt | llm_with_tool\n",
    "# )\n",
    "\n",
    "chain = prompt_policy | llm_with_tool\n",
    "\n",
    "if patient_data.get('name'):\n",
    "    del patient_data['name']\n",
    "    del patient_data['patient_id']\n",
    "\n",
    "scored_result = chain.invoke(\n",
    "    {\n",
    "        \"question\": question, \n",
    "        \"context\": docs, \n",
    "        \"date\": date\n",
    "        # \"patient_data\": patient_data\n",
    "    }\n",
    ")\n",
    "scored_result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 350,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'June 2024'"
      ]
     },
     "execution_count": 350,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "datetime.today().strftime(\"%B %Y\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 330,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'\\nDoes the following patient profile comply with the institutional policies?\\n\\nPatient is a 24-year-old with a history of anxiety disorder. They have not participated in any previous trials and their current trial status is complete. No trial completion date is provided. Based on their medical history, relevant medical trials may include those focused on anxiety disorders or mental health interventions.\\n'"
      ]
     },
     "execution_count": 330,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "question"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "def lookup_policy(query: str) -> str:\n",
    "    \"\"\"Consult the company policies to check whether certain options are permitted.\n",
    "    Use this before making any flight changes performing other 'write' events.\"\"\"\n",
    "    docs = retriever.query(query, k=2)\n",
    "    return \"\\n\\n\".join([doc[\"page_content\"] for doc in docs])\n",
    "\n",
    "\n",
    "from langchain.tools.retriever import create_retriever_tool\n",
    "retriever_tool = create_retriever_tool(\n",
    "    retriever,\n",
    "    \"retrieve_institution_policies\",\n",
    "    \"Search and return information about the institution's policies about conducting clinical trials based on the patient's information.\",\n",
    ")\n",
    "\n",
    "tools = [retriever_tool]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Retrieval Grader"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 100,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'age': 51,\n",
       " 'medical_history': 'colorectal cancer',\n",
       " 'previous_trials': None,\n",
       " 'trial_status': None,\n",
       " 'trial_completion_date': None}"
      ]
     },
     "execution_count": 100,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# patient_data['medical_history'] = \"Chronic Pain, Pregnant\"\n",
    "# cancer:22, asthma:4, leukemia: 8, anx disorder: 7\n",
    "sample_patient_id = 8\n",
    "patient_data = get_patient_data(sample_patient_id)\n",
    "# patient_data['trial_completion_date'] = '2024-04-01'\n",
    "del patient_data['name']\n",
    "del patient_data['patient_id']\n",
    "# patient_data['trial_status'] = 'Complete'\n",
    "patient_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 101,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('Patient Profile:\\n'\n",
      " 'The patient is a 51-year-old with a history of colorectal cancer. They have '\n",
      " 'not participated in any previous trials and their current trial status and '\n",
      " 'completion date are unknown.\\n'\n",
      " '\\n'\n",
      " 'Relevant Medical Trials:\\n'\n",
      " '1. Colorectal Cancer Treatment Trial - This trial focuses on new treatment '\n",
      " 'options for patients with colorectal cancer, which may be beneficial for '\n",
      " 'this patient based on their medical history.\\n'\n",
      " '2. Cancer Survivorship Study - This trial aims to improve the quality of '\n",
      " 'life for cancer survivors, which could be relevant for this patient '\n",
      " 'post-treatment.')\n"
     ]
    }
   ],
   "source": [
    "# date\n",
    "patient_profile = chain_profile.invoke({'patient_data': patient_data})\n",
    "nprint(patient_profile)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "cancer ['colorectal cancer']\n",
      "cancer ['rectal cancer']\n",
      "cancer ['ovarian cancer', 'fallopian tube', 'primary peritoneal cancer', 'recurrent ovarian cancer']\n",
      "cancer ['metastatic pancreatic cancer']\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Subject is at least 20 years of age.\\r\\n\\r\\n          2. Written and voluntary informed consent understood, signed and dated.\\r\\n\\r\\n          3. They must have refractory or progressive colorectal cancer for which there is no\\r\\n             further curative therapy available.\\r\\n\\r\\n          4. Subject able to adhere to the study visit schedule and other protocol requirements.\\r\\n\\r\\n          5. ECOG 0-2\\r\\n\\r\\n          6. At least one measurable lesion that can be accurately assessed by imaging or physical\\r\\n             examination at baseline and following up visits.\\r\\n\\r\\n          7. Must have a life expectancy of 3 months or more\\r\\n\\r\\n          8. Demonstrate adequate organ function\\r\\n\\r\\n          9. Negative urine or serum pregnancy test within 28 days of study treatment\\r\\n\\r\\n         10. Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy\\r\\n             of the tissue sample quality for assessment of biomarker status.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. ECOG ≥ 3\\r\\n\\r\\n          2. History of malignancy in the last 5 years.\\r\\n\\r\\n          3. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\\r\\n             C.\\r\\n\\r\\n          4. Breast-feeding or pregnant female\\r\\n\\r\\n          5. Patients can not the administration of Folic acid or Vitamin B12.\\r\\n\\r\\n          6. Before treatment with Pemetrexed.\\r\\n\\r\\n          7. Patients who can not swallow oral medication.\\r\\n\\r\\n          8. The most recent treatment with the clinical trial for the drug for 14 days prior to\\r\\n             enrollment.\\r\\n\\r\\n          9. Systemic chemotherapy within three weeks after the administration of the last before\\r\\n             the test treatment, radiation therapy patients who had been administered.\\r\\n\\r\\n         10. Except for the hair loss, it is induced before cancer treatment, all of toxicity in\\r\\n             progress (> CTCAE1 grade).\\r\\n\\r\\n         11. Upper GI bleeding within registration before 4 weeks of Bowel obstruction or CTCAE3 or\\r\\n             4 grade.\\r\\n\\r\\n         12. Subject who experienced a recent myocardial infarction, including severe/unstable\\r\\n             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\\r\\n             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\\r\\n             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\\r\\n             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\\r\\n             year.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['colorectal cancer']\", 'drugs': \"['pemetrexed']\", 'nctid': 'NCT02588781', 'status': 'recruiting'}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Diagnosis of adenocarcinoma of the rectum\\r\\n\\r\\n          -  Age: 18-70 years old\\r\\n\\r\\n          -  Signed informed consent; able to comply with study and/or follow- up procedures\\r\\n\\r\\n          -  Stage of the primary tumor may be determined by ultrasound or MRI\\r\\n\\r\\n          -  Stage II (T3-4, N0 [N0 is defined as all imaged lymph nodes < 1.0 cm]) OR stage III\\r\\n             (T1-4, N1-2 [with the definition of a clinically positive lymph node being any node ≥\\r\\n             1.0 cm]\\r\\n\\r\\n          -  Tumor palpable by digital rectal exam OR accessible by proctoscope or sigmoidoscope\\r\\n\\r\\n          -  Distal border of the tumor must be located < 12 cm from the anal verge\\r\\n\\r\\n          -  Tumor amenable to curative resection\\r\\n\\r\\n          -  Adequate bone marrow, hepatic and renal function as assessed by the following\\r\\n             laboratory requirements conducted within 7 days of starting study treatment:\\r\\n\\r\\n          -  Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet\\r\\n             count ≥ 100 x109/ L, hemoglobin (Hb) ≥ 9g/ dL.\\r\\n\\r\\n          -  Total bilirubin ≤1.5 x the upper limit of normal (ULN).\\r\\n\\r\\n          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.\\r\\n\\r\\n          -  Alkaline phosphatase limit ≤ 5x ULN.\\r\\n\\r\\n          -  Amylase and lipase ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Serum creatinine ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 mL/ min.\\r\\n\\r\\n          -  No renal disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  ECOG status: 0～1\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Hypersensitivity to fluorouracil, oxaliplatin or irinotecan.\\r\\n\\r\\n          -  No More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  Clear indication of involvement of the pelvic side walls by imaging\\r\\n\\r\\n          -  With distant metastasis\\r\\n\\r\\n          -  History of invasive rectal malignancy, regardless of disease-free interval\\r\\n\\r\\n          -  Fertile patients must use effective contraception\\r\\n\\r\\n          -  Uncontrolled hypertension\\r\\n\\r\\n          -  Cardiovascular disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  Lack of upper gastrointestinal tract integrity or malabsorption syndrome，active upper\\r\\n             gastrointestinal tract bleeding\\r\\n\\r\\n          -  Synchronous colon cancer\\r\\n\\r\\n          -  Pregnant or nursing, Fertile patients do not use effective contraception\\r\\n\\r\\n          -  Other malignancy within the past 5 years except effectively treated squamous cell or\\r\\n             basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or\\r\\n             carcinoma in situ of the colon or rectum\\r\\n\\r\\n          -  No psychiatric or addictive disorders, or other conditions that, in the opinion of the\\r\\n             investigator, would preclude study participation\\r\\n\\r\\n          -  patients refused to signed informed consent.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['rectal cancer']\", 'drugs': \"['mfolfox6']\", 'nctid': 'NCT02887313', 'status': 'recruiting'}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Pathologic diagnosis of ovarian, fallopian tube or primary peritoneal cancer confirmed\\r\\n             by pathology review at MSK.\\r\\n\\r\\n          -  Patients will have relapsed at least once and returned to complete clinical remission\\r\\n             after additional chemotherapy. Interval surgery is permitted.\\r\\n\\r\\n          -  Complete clinical remission is defined as CA-125 within normal limits, examination and\\r\\n             CT or MRI without objective evidence of disease (non specific abnormalities are\\r\\n             permitted on radiologic imaging).\\r\\n\\r\\n          -  Patients may sign screening consent during recurrence or at time of remission if they\\r\\n             can start vaccine therapy within 4 months of completing chemotherapy.\\r\\n\\r\\n          -  Testing of patient's archived (paraffin embedded, unstained slides) or freshly\\r\\n             biopsied tumor nodules must be positive for WT1 (Cohort 1) or NY-ESO-1 (Cohort 2)\\r\\n             protein expression. WT1 expression: Immunohistochemical analysis will be performed\\r\\n             using the technique described by Dupont et al [58]. WT1 expression will be graded\\r\\n             according to an adaptation of the German Immunoreactive Score (IRS). Only tumors with\\r\\n             moderate to strong IRS scores (4-12) will be considered WT1 positive.\\r\\n\\r\\n          -  NY-ESO-1 expression: Tissue available from primary and/or recurrent disease will be\\r\\n             evaluated for tumor expression of NY-ESO-1 by immunohistochemical (IHC) and/or RT-PCR\\r\\n             analysis will be performed using the technique described by Jungbluth et al\\r\\n\\r\\n          -  Age ≥ 18 years\\r\\n\\r\\n          -  Karnofsky performance status ≥ 70%\\r\\n\\r\\n          -  Hematologic parameters: Absolute neutrophil count ≥ 1000/mcL, Platelets > 50 K/mcL.\\r\\n\\r\\n          -  Biochemical parameters: Total bilirubin ≤ 1.5 mg/dl, AST and ALT ≤ 2.5 x upper limits\\r\\n             of normal, Creatinine ≤ 1.5 mg/dl.\\r\\n\\r\\n          -  Patient of childbearing potential must have a negative serum pregnancy test prior to\\r\\n             study entry and must be practicing and effective form of birth control\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Patients with active infection requiring systemic antibiotics, antiviral, or\\r\\n             antifungal treatments\\r\\n\\r\\n          -  Patients with a serious unstable medical illness or another active cancer.\\r\\n\\r\\n          -  Patients with a condition requiring systemic treatment with either corticosteroids\\r\\n             (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14\\r\\n             days of study drug administration. Inhaled or topical steroids and adrenal replacement\\r\\n             doses >10mg daily prednisone equivalents are permitted in the absence of active\\r\\n             autoimmune disease.\\r\\n\\r\\n          -  Patients with known history of testing positive for human immunodeficiency virus (HIV)\\r\\n             or known acquired immunodeficiency syndrome (AIDS).\\r\\n\\r\\n          -  Patients with known active hepatitis B virus or hepatitis C virus acute or chronic\\r\\n             infection.\\r\\n\\r\\n          -  Patients with active known or suspected autoimmune disease (treated hypothyroidism is\\r\\n             permitted to enroll)\\r\\n\\r\\n          -  Patients with active interstitial pneumonitis.\\r\\n      \", metadata={'disease_category': 'cancer', 'diseases': \"['ovarian cancer', 'fallopian tube', 'primary peritoneal cancer', 'recurrent ovarian cancer']\", 'drugs': \"['nivolumab']\", 'nctid': 'NCT02737787', 'status': 'recruiting'}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Patients have provided a signed Informed Consent Form\\r\\n\\r\\n          -  ECOG performance status of 0-1\\r\\n\\r\\n          -  BMI ≥ 18.5\\r\\n\\r\\n          -  Age: 18-65 years old\\r\\n\\r\\n          -  Histologically confirmed diagnosis of metastatic pancreatic cancer\\r\\n\\r\\n          -  No prior palliative chemotherapy\\r\\n\\r\\n          -  Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria\\r\\n\\r\\n          -  Life expectancy ≥ 3 months\\r\\n\\r\\n          -  Patient has adequate bone marrow and organ function\\r\\n\\r\\n               -  Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L\\r\\n\\r\\n               -  Platelets ≥ 90 x 109/L\\r\\n\\r\\n               -  Hemoglobin ≥ 90 g/L\\r\\n\\r\\n          -  Patient has adequate liver function\\r\\n\\r\\n               -  AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is\\r\\n                  liver metastasis)\\r\\n\\r\\n               -  Serum bilirubin ≤ 1.2 x ULN\\r\\n\\r\\n          -  Creatinine ≤ 1.25 times ULN\\r\\n\\r\\n          -  Good compliance\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Brain metastasis or only with bone metastasis.\\r\\n\\r\\n          -  Patients with severe gastrointestinal hemorrhage which need frequent blood\\r\\n             transfusions.\\r\\n\\r\\n          -  Refuse to take appropriate contraceptive measures (including male patients).\\r\\n\\r\\n          -  Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil.\\r\\n\\r\\n          -  Severe systemic disease out of control such as unstable or uncompensated respiratory,\\r\\n             cardiac, liver, renal diseases.\\r\\n\\r\\n          -  Patient has a concurrent malignancy or has a malignancy within 5 years of study\\r\\n             enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in\\r\\n             situ).\\r\\n\\r\\n          -  Psychiatric illness that would prevent the patient from giving informed consent.\\r\\n\\r\\n          -  Patient is concurrently using other antineoplastic agent\\r\\n\\r\\n          -  Patient has used investigational antineoplastic agent within 4 weeks prior to entry.\\r\\n\\r\\n          -  Known HIV-positivity.\\r\\n\\r\\n          -  No history of chronic diarrhea, nausea or vomit.\\r\\n\\r\\n          -  No ≥ grade 2 sensory peripheral neuropathy.\\r\\n\\r\\n          -  A history of transmural myocardial infarction (within 6 months prior to entry),\\r\\n             congestive heart failure, and unstable angina.\\r\\n\\r\\n          -  Infectious disease or inflammation with body temperature ≥ 38 ℃.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['metastatic pancreatic cancer']\", 'drugs': \"['mfolfirinox']\", 'nctid': 'NCT02028806', 'status': 'recruiting'})]"
      ]
     },
     "execution_count": 102,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "docs = retriever_trial_sq.get_relevant_documents(patient_profile)\n",
    "for doc in docs:\n",
    "    print(doc.metadata.get(\"disease_category\"), doc.metadata.get(\"diseases\"))\n",
    "docs    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('relevance_score', 'Yes')\n",
      "( 'explanation',\n",
      "  'The patient has a history of colorectal cancer, which aligns with the '\n",
      "  'disease targeted by the clinical trial. This makes the trial relevant to '\n",
      "  \"the patient's medical profile.\")\n",
      "( 'further_information',\n",
      "  'Additional information needed from the patient includes confirmation of '\n",
      "  'age, signing of informed consent, current status of colorectal cancer, '\n",
      "  'adherence to study visit schedule, ECOG score, presence of measurable '\n",
      "  'lesion, life expectancy, organ function, pregnancy test results, '\n",
      "  'willingness to provide tissue for biomarker analysis, and any recent '\n",
      "  'treatments or medications taken.')\n",
      "('Patient Profile:\\n'\n",
      " 'The patient is a 51-year-old with a history of colorectal cancer. They have '\n",
      " 'not participated in any previous trials and their current trial status and '\n",
      " 'completion date are unknown.\\n'\n",
      " '\\n'\n",
      " 'Relevant Medical Trials:\\n'\n",
      " '1. Colorectal Cancer Treatment Trial - This trial focuses on new treatment '\n",
      " 'options for patients with colorectal cancer, which may be beneficial for '\n",
      " 'this patient based on their medical history.\\n'\n",
      " '2. Cancer Survivorship Study - This trial aims to improve the quality of '\n",
      " 'life for cancer survivors, which could be relevant for this patient '\n",
      " 'post-treatment.')\n",
      "['colorectal cancer']\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Subject is at least 20 years of age.\n",
      "\n",
      "          2. Written and voluntary informed consent understood, signed and dated.\n",
      "\n",
      "          3. They must have refractory or progressive colorectal cancer for which there is no\n",
      "             further curative therapy available.\n",
      "\n",
      "          4. Subject able to adhere to the study visit schedule and other protocol requirements.\n",
      "\n",
      "          5. ECOG 0-2\n",
      "\n",
      "          6. At least one measurable lesion that can be accurately assessed by imaging or physical\n",
      "             examination at baseline and following up visits.\n",
      "\n",
      "          7. Must have a life expectancy of 3 months or more\n",
      "\n",
      "          8. Demonstrate adequate organ function\n",
      "\n",
      "          9. Negative urine or serum pregnancy test within 28 days of study treatment\n",
      "\n",
      "         10. Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy\n",
      "             of the tissue sample quality for assessment of biomarker status.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. ECOG ≥ 3\n",
      "\n",
      "          2. History of malignancy in the last 5 years.\n",
      "\n",
      "          3. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\n",
      "             C.\n",
      "\n",
      "          4. Breast-feeding or pregnant female\n",
      "\n",
      "          5. Patients can not the administration of Folic acid or Vitamin B12.\n",
      "\n",
      "          6. Before treatment with Pemetrexed.\n",
      "\n",
      "          7. Patients who can not swallow oral medication.\n",
      "\n",
      "          8. The most recent treatment with the clinical trial for the drug for 14 days prior to\n",
      "             enrollment.\n",
      "\n",
      "          9. Systemic chemotherapy within three weeks after the administration of the last before\n",
      "             the test treatment, radiation therapy patients who had been administered.\n",
      "\n",
      "         10. Except for the hair loss, it is induced before cancer treatment, all of toxicity in\n",
      "             progress (> CTCAE1 grade).\n",
      "\n",
      "         11. Upper GI bleeding within registration before 4 weeks of Bowel obstruction or CTCAE3 or\n",
      "             4 grade.\n",
      "\n",
      "         12. Subject who experienced a recent myocardial infarction, including severe/unstable\n",
      "             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\n",
      "             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\n",
      "             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\n",
      "             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\n",
      "             year.\n",
      "      \n"
     ]
    }
   ],
   "source": [
    "from langchain_core.output_parsers import JsonOutputParser\n",
    "\n",
    "class grade(BaseModel):\n",
    "        \"\"\"The result of the trial's relevance check as relevance score and explanation.\"\"\"\n",
    "\n",
    "        relevance_score: str\n",
    "        # explanation: str = Field(description=\"Reason(s) if the patient meets any exclusion criteria.\")\n",
    "        explanation: str = Field(description=\"Reasons to the given relevance score.\")\n",
    "        # further_information: str = Field(description=\"If further information about the patient is requeied related to the trial's criteria.\")\n",
    "        further_information: str\n",
    "\n",
    "        # relevance_score: str = Field(description=\"Relevance of the trial criteria to the patient's profile. Possible choices 'Yes', 'No', or 'Maybe'.\")\n",
    "        # relevance_score: str = Field(description=\"Yes', 'No', or 'Maybe'.\")\n",
    "        # explanation: str = Field(description=\"Reason(s) if the patient meets any exclusion criteria.\")\n",
    "        # explanation: str = Field(description=\"Reason(s) if the patient does not meet or meet the trial's criteria. Othereise use N/A\")\n",
    "        # further_information: str = Field(description=\"If further information is requeied to make the decision about the trial's relevance. Othereise use N/A\")\n",
    "\n",
    "        # class Config:\n",
    "        #     schema_extra = {\n",
    "        #         \"example 1\": {\n",
    "        #             \"relevance_score\": 'No',\n",
    "        #             \"explanation\": \"Patient has a history of diabetes mellitus which is an exclusion criteria.\",\n",
    "        #             \"further_information\": \"N/A\",\n",
    "        #         },\n",
    "        #         \"example 2\": {\n",
    "        #             \"relevance_score\": 'Yes',\n",
    "        #             \"explanation\": \"Patient had a prostate adenocarcinoma in the past which is an inclusion criteria.\",\n",
    "        #             \"further_information\": \"N/A\",\n",
    "        #         },\n",
    "        #         \"example 3\": {\n",
    "        #             \"relevance_score\": 'Maybe',\n",
    "        #             \"explanation\": \"Patient has pancreatic cancer as an inclusion criteria.\",\n",
    "        #             \"further_information\": \"Patient's BMI and the current stage of their pancreatic cancer is required for further evaluation.\",\n",
    "        #         },                \n",
    "        #     }\n",
    "\n",
    "prompt_grader = PromptTemplate(\n",
    "        template=\"\"\" \n",
    "        You are a Principal Investigator (PI) for evaluating patients for clinical trials.\\n\n",
    "        Your task is to evaluate the relevance of a clinical trial to the given patient's medical profile. \\n\n",
    "        \n",
    "        \n",
    "        The clinical trial is related to these diseases: {trial_diseases} \\n\n",
    "        Here are the inclusion and exclusion criteria of the trial: \\n\\n {document} \\n\\n\n",
    "        \n",
    "        ===============                \n",
    "        Use the following steps to determine relevance and provide the necessary fields in your response: \\n\n",
    "        1- If the patient's profile meets any exclusion criteria, then the trial is not relevant --> relevance_score = 'No'. \\n\n",
    "        2- If the patient's has or had the trial's inclusion diseases, then it is relevant --> relevance_score = 'Yes'.\\n        \n",
    "                       \n",
    "        Example 1: \n",
    "The patient has Arthritis and the trial is related to pancreatic cancer. --> relevance_score = 'No' \\n\n",
    "        \n",
    "        Example 2: \n",
    "The patient has pancreatic cancer and the trial is also related to carcinoma pancreatic cancer. --> relevance_score = 'Yes' \\n\n",
    "\n",
    "        Example 3: \n",
    "The patient has pancreatic cancer and the trial is related to breast cancer or ovarian cancer. --> relevance_score = 'No'. \\n \n",
    "\n",
    "        Bring your justification in the explanation. \\n\n",
    "\n",
    "        Mention further information that is needed from the patient's medical history related to the trial's criteria \\n\n",
    "\n",
    "        ===============\n",
    "        Here is the patient's medical profile: {patient_profile} \\n\\n\n",
    "        \"\"\",\n",
    "        input_variables=[\"document\", \"patient_profile\", \"trial_diseases\"],\n",
    "    )\n",
    "\n",
    "llm_with_tool = model.with_structured_output(grade)\n",
    "\n",
    "# retrieval_grader = prompt_grader | model\n",
    "retrieval_grader = prompt_grader | llm_with_tool\n",
    "# retrieval_grader = prompt_grader | model | JsonOutputParser()\n",
    "\n",
    "# docs = retriever_trial_sq.get_relevant_documents(patient_profile)\n",
    "doc = docs[0]\n",
    "doc_txt = doc.page_content\n",
    "trial_diseases = doc.metadata.get(\"diseases\")\n",
    "# patient_profile = \"Patient has a history of esophageal cancer\"\n",
    "trial_score = retrieval_grader.invoke({\"patient_profile\": patient_profile, \"document\": doc_txt, \"trial_diseases\": trial_diseases})\n",
    "\n",
    "for score in trial_score:\n",
    "    nprint(score)\n",
    "nprint(patient_profile)\n",
    "print(trial_diseases)\n",
    "print(doc_txt)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 316,
   "metadata": {},
   "outputs": [],
   "source": [
    "trial_score\n",
    "trial_score_dic = dict(trial_score)\n",
    "trial_score_dic\n",
    "nctid = 'NCT00785735'\n",
    "trial_score_dic['nctid'] = nctid\n",
    "# relevant_trials.append(score)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 202,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('relevance_score', 'Maybe')\n",
      "( 'explanation',\n",
      "  \"The patient's medical history of asthma may be relevant to the trial as \"\n",
      "  'asthma is a respiratory condition that could potentially be linked to '\n",
      "  'generalized anxiety disorder. However, further information is needed to '\n",
      "  'confirm the relevance, such as the severity of the asthma and its impact on '\n",
      "  \"the patient's overall health and participation in the trial.\")\n",
      "( 'further_information',\n",
      "  \"Patient's medical history of asthma may have implications on their \"\n",
      "  'eligibility for the trial, but additional details are required to make a '\n",
      "  'definitive assessment.')\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients of both sexes\n",
      "\n",
      "          -  Eighteen years of age and older\n",
      "\n",
      "          -  Clinical diagnosis of Generalized Anxiety Disorder\n",
      "\n",
      "          -  Eighteen points or more on Hamilton Anxiety Scale\n",
      "\n",
      "          -  Without previous treatment for this disease (for at least one month before).\n",
      "\n",
      "          -  In case of being women of reproductive age, who are not pregnant or lactating.\n",
      "\n",
      "          -  To sign an informed consent letter of participation in the investigation.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients who have treatment for their condition\n",
      "\n",
      "          -  Patients who have another mental disorder added\n",
      "\n",
      "          -  Patients with alcoholism, smoking or drug addiction\n",
      "\n",
      "          -  Patients who live alone\n",
      "\n",
      "          -  Ingest of drugs for insomnia\n",
      "\n",
      "          -  Ingest of drugs of the Monoamine Oxidase Inhibitors group\n",
      "\n",
      "          -  Patients with epilepsy\n",
      "\n",
      "          -  Patients who operate dangerous machinery\n",
      "\n",
      "          -  Patients who have to drive at work (car, truck or other motor vehicle) for a long\n",
      "             time.\n",
      "      \n"
     ]
    }
   ],
   "source": [
    "for score in trial_score:\n",
    "    nprint(score)\n",
    "print(doc_txt)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# State"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "from typing import Annotated, List\n",
    "from typing_extensions import TypedDict\n",
    "from langgraph.graph.message import AnyMessage, add_messages\n",
    "from langchain_core.messages import AIMessage, SystemMessage, HumanMessage, ToolMessage\n",
    "from langchain_core.documents import Document\n",
    "\n",
    "# from typing import TypedDict\n",
    "\n",
    "class AgentState(TypedDict):\n",
    "    patient_prompt: str\n",
    "    patient_id: int    \n",
    "    policy_eligible: bool\n",
    "    rejection_reason: str\n",
    "    patient_data: dict\n",
    "    patient_profile: str\n",
    "    revision_number: int\n",
    "    max_revisions: int\n",
    "    policies: List[Document]\n",
    "    trials: list[Document]\n",
    "    relevant_trials: list[dict]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Agent"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "execution_count": 119,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from langgraph.checkpoint.sqlite import SqliteSaver\n",
    "from langgraph.prebuilt import ToolNode\n",
    "from langgraph.prebuilt import tools_condition\n",
    "from langchain_core.pydantic_v1 import BaseModel, Field\n",
    "from operator import itemgetter\n",
    "from typing import Literal\n",
    "\n",
    "\n",
    "model = ChatOpenAI(model=\"gpt-3.5-turbo\")  #reduce inference cost\n",
    "\n",
    "memory = SqliteSaver.from_conn_string(\":memory:\")\n",
    "\n",
    "\n",
    "\n",
    "# ------- Agents:\n",
    "class Patient_ID(BaseModel):\n",
    "    patient_id: int\n",
    "    # no_id: bool\n",
    "\n",
    "# model = ChatOpenAI(model=\"gpt-3.5-turbo\", temperature=0)  #reduce inference cost\n",
    "patient_data_prompt = \"\"\"You are a helpful assistance in extrcting patient's medical history.\n",
    "Based on the following request identify and return the patient's ID number.\n",
    "\"\"\"\n",
    "# If you cannot find patient ID in the request text then return 10000 as response.\n",
    "\n",
    "def patient_collector_node(state: AgentState):\n",
    "    response = model.with_structured_output(Patient_ID).invoke([\n",
    "        SystemMessage(content=patient_data_prompt),\n",
    "        HumanMessage(content=state['patient_prompt'])\n",
    "    ])\n",
    "    patient_id = response.patient_id\n",
    "    print(response)\n",
    "    print(f\"Patient ID: {patient_id}\")\n",
    "    result = get_patient_data(patient_id)\n",
    "    \n",
    "    return {\n",
    "        \"patient_data\": result,\n",
    "        \"patient_id\": patient_id,\n",
    "        \"revision_number\": state.get(\"revision_number\", 1) + 1\n",
    "        }\n",
    "\n",
    "\n",
    "def policy_checker(state: AgentState):\n",
    "    # Convert patient_data to string\n",
    "    \n",
    "    parser = StrOutputParser()\n",
    "    prompt_profile = PromptTemplate(\n",
    "        template=\"\"\"\n",
    "        You are the Clinical Research Coordinator in the screening phase of a clinical trial. \n",
    "        Use the following patient data to write the patient profile for the screening phase.\n",
    "        The patient profile is a summary of patient information.\n",
    "        The patient profile also suggest relevant medical trials based on patient's medical history.\n",
    "        Write the patient profile in 3 to 4 short sentences.\\n\\n\n",
    "        {patient_data}\"\"\",\n",
    "        input_variables=[\"patient_data\"],\n",
    "    )\n",
    "    # model = ChatOpenAI(temperature = 0.0, model=modelID)\n",
    "\n",
    "    chain_profile = prompt_profile | model | parser\n",
    "    patient_data = state['patient_data']\n",
    "    \n",
    "    # to preserve the patient's private information\n",
    "    if patient_data.get('name'):\n",
    "        del patient_data['patient_id']\n",
    "        del patient_data['name']\n",
    "    patient_profile = chain_profile.invoke({'patient_data': patient_data})\n",
    "    # nprint(patient_profile)\n",
    "            \n",
    "    question = f\"\"\"\n",
    "    Does the following patient profile comply with the institutional policies?\\n\n",
    "    {patient_profile}\n",
    "    \"\"\"\n",
    "                  \n",
    "    docs_retrieved = retriever.get_relevant_documents(question)\n",
    "    # docs_retrieved\n",
    "    docs = \"\\n\\n\".join(doc.page_content for doc in docs_retrieved)\n",
    "    # docs\n",
    "\n",
    "    prompt_policy = PromptTemplate(\n",
    "        template=\"\"\" You are a Principal Investigator (PI) for evaluating patients for clinical trials. \n",
    "        Use the following pieces of retrieved context from the institution's policies to answer the question about the patient's eligibility. \n",
    "        Here are the retrieved policies: \\n\\n {context} \\n\\n\n",
    "        Here is the user question: {question} \\n\n",
    "        \n",
    "        Note:Current date is {date}. Use it as the reference date to evaluate time related policies.\\n\n",
    "        Giving a reason is required only for rejection cases.\n",
    "        Give a binary score 'yes' or 'no' score to indicate whether the patient is eligible for clinical trials.\"\"\",\n",
    "        input_variables=[\"context\", \"question\"],\n",
    "    )\n",
    "\n",
    "    # date = datetime.now().strftime(\"%Y-%m-%d\")\n",
    "    date = datetime.today().strftime(\"%B %d, %Y\")\n",
    "    \n",
    "    class comply(BaseModel):\n",
    "        \"\"\"score and reason for trial eligibility check.\"\"\"\n",
    "\n",
    "        binary_score: str = Field(description=\"Patient eligible for the clinical trial 'yes' or 'no'\")\n",
    "        reason: str = Field(description=\"Reason(s) only if the patient is not eligible for clinical trials. Othereise use N/A\")\n",
    "\n",
    "        class Config:\n",
    "            schema_extra = {\n",
    "                \"example\": {\n",
    "                    \"binary_score\": 'yes',\n",
    "                    \"reason\": \"N/A\",\n",
    "                },\n",
    "                \"example 2\": {\n",
    "                    \"binary_score\": 'no',\n",
    "                    \"reason\": \"The patient is pregnant at the moment.\",\n",
    "                },                \n",
    "            }\n",
    "                \n",
    "    llm_with_tool = model.with_structured_output(comply)\n",
    "\n",
    "    chain = prompt_policy | llm_with_tool\n",
    "\n",
    "    # print(f'today is: {date}')\n",
    "    scored_result = chain.invoke(\n",
    "        {\n",
    "            \"question\": question, \n",
    "            \"context\": docs, \n",
    "            \"date\": date\n",
    "            # \"patient_data\": patient_data\n",
    "        }\n",
    "    )\n",
    "    print(scored_result)\n",
    "    # scored_result    \n",
    "    state['policy_eligible'] = True\n",
    "    if scored_result.binary_score == 'no':\n",
    "        state['policy_eligible'] = False    \n",
    "        state['rejection_reason'] = scored_result.reason\n",
    "    \n",
    "    state['policies'] = docs_retrieved\n",
    "    state['patient_profile'] = patient_profile\n",
    "\n",
    "    return state\n",
    "\n",
    "def trial_search(state: AgentState):\n",
    "    \"\"\"\n",
    "    This node searches the trial database to retrieve a list of clinical trials that match the patient's medical history.\n",
    "    \"\"\"\n",
    "\n",
    "    patient_profile = state['patient_profile']\n",
    "\n",
    "    question = f\"\"\"\n",
    "    Which trials are relevant to the patient with the following medical history?\\n\n",
    "    patient_profile: {patient_profile}\n",
    "    \"\"\"        \n",
    "    docs_retrieved = retriever_trial_sq.get_relevant_documents(question)\n",
    "    \n",
    "    return {'trials': docs_retrieved}\n",
    "\n",
    "\n",
    "def should_continue(state: AgentState):\n",
    "    # end = False\n",
    "    if state.get(\"patient_data\"):\n",
    "        print('patient data found')\n",
    "        print(state.get(\"patient_data\"))\n",
    "        return \"policy_checker\"\n",
    "    else:\n",
    "        print('patient data not found')\n",
    "        return END\n",
    "        \n",
    "    if state[\"revision_number\"] > state[\"max_revisions\"]:\n",
    "        print('max revision reached')\n",
    "        # print(state.get(\"patient_data\", 1))\n",
    "        return END        \n",
    "\n",
    "def should_continue_policy(state: AgentState):\n",
    "    # end = False\n",
    "    if state[\"policy_eligible\"]:        \n",
    "        print(\"Patient passed the general trials policies\")\n",
    "        return \"trial_search\"\n",
    "    else:\n",
    "        print(\"Patient did not pass the general trials policies\")\n",
    "        return END            \n",
    "\n",
    "\n",
    "def grade_trials(state):\n",
    "    \"\"\"\n",
    "    Determines whether the retrieved documents are relevant to the question.\n",
    "\n",
    "    Args:\n",
    "        state (dict): The current graph state\n",
    "\n",
    "    Returns:\n",
    "        state (dict): Updates documents key with only filtered relevant documents\n",
    "    \"\"\"\n",
    "\n",
    "    print(\"----- CHECKING THE TRIALS RELEVANCE TO PATIENT PROFILE ----- \")\n",
    "    \n",
    "    trails = state['trials']\n",
    "    patient_profile = state['patient_profile']\n",
    "\n",
    "    # Score each doc\n",
    "    relevant_trials = []\n",
    "    for trail in trails:\n",
    "        doc_txt = trail.page_content\n",
    "        trial_diseases = trail.metadata['diseases']\n",
    "        nctid = trail.metadata['nctid']\n",
    "        trial_score = retrieval_grader.invoke(\n",
    "            {\n",
    "                \"patient_profile\": patient_profile, \n",
    "                \"document\": doc_txt, \n",
    "                \"trial_diseases\": trial_diseases\n",
    "            }\n",
    "        )\n",
    "            \n",
    "        relevance_score = trial_score.relevance_score\n",
    "        if relevance_score.lower() == \"yes\":\n",
    "            print(f\"---GRADER: TRIAL {nctid} RELEVANT---\")            \n",
    "            trial_score_dic = dict(trial_score)\n",
    "            trial_score_dic['nctid'] = nctid            \n",
    "            relevant_trials.append(trial_score_dic)\n",
    "        else:\n",
    "            print(f\"---GRADER: TRIAL {nctid} NOT RELEVANT---\")\n",
    "    return {\n",
    "        \"relevant_trials\": relevant_trials\n",
    "        }\n",
    "   \n",
    "\n",
    "# ==== define graph nodes====\n",
    "from langgraph.graph import StateGraph, END\n",
    "\n",
    "builder = StateGraph(AgentState)\n",
    "builder.set_entry_point(\"patient_collector\")\n",
    "\n",
    "builder.add_node(\"patient_collector\", patient_collector_node)\n",
    "builder.add_node(\"policy_checker\", policy_checker)\n",
    "builder.add_node(\"trial_search\", trial_search)\n",
    "builder.add_node(\"grade_trials\", grade_trials)\n",
    "\n",
    "# retrieve = ToolNode([retriever_tool])\n",
    "# builder.add_node(\"retrieve\", retrieve)  # retrieval\n",
    "\n",
    "\n",
    "# ===== define graph edges====\n",
    "# builder.add_edge(\"patient_collector\", \"\")\n",
    "# builder.add_edge(\"patient_adder\", \"patient_collector\")\n",
    "builder.add_conditional_edges(\n",
    "    \"patient_collector\", \n",
    "    should_continue, \n",
    "    {END: END\n",
    "    # \"patient_collector\": \"patient_collector\"\n",
    "    , \"policy_checker\": \"policy_checker\"\n",
    "    # ,\"patient_adder\": \"patient_adder\"\n",
    "    }\n",
    ")\n",
    "\n",
    "builder.add_conditional_edges(\n",
    "    \"policy_checker\", \n",
    "    should_continue_policy, \n",
    "    {END: END,    \n",
    "    \"trial_search\": \"trial_search\"\n",
    "    }\n",
    ")\n",
    "\n",
    "# builder.add_edge(\"policy_checker\", \"retrieve\")\n",
    "# builder.add_conditional_edges(\n",
    "#     \"policy_checker\", \n",
    "#     tools_condition, \n",
    "#     {END: END\n",
    "#     ,\"tools\": \"retrieve\"\n",
    "#     }\n",
    "# )\n",
    "\n",
    "builder.add_edge(\"trial_search\", \"grade_trials\")\n",
    "builder.add_edge(\"grade_trials\", END)\n",
    "\n",
    "\n",
    "graph = builder.compile(\n",
    "    checkpointer=memory\n",
    "    # , interrupt_before=[\"patient_adder\"]\n",
    ")\n",
    "\n",
    "from IPython.display import Image\n",
    "\n",
    "Image(graph.get_graph().draw_png())\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'patient_id': 8,\n",
       " 'name': 'Daniel Johnson',\n",
       " 'age': 51,\n",
       " 'medical_history': 'colorectal cancer',\n",
       " 'previous_trials': None,\n",
       " 'trial_status': None,\n",
       " 'trial_completion_date': None}"
      ]
     },
     "execution_count": 96,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# patient_data['medical_history'] = \"Chronic Pain, Pregnant\"\n",
    "sample_patient_id = 8\n",
    "patient_data = get_patient_data(sample_patient_id)\n",
    "# patient_data['trial_completion_date'] = '2024-04-01'\n",
    "patient_data\n",
    "# date"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 120,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "patient_id=8\n",
      "Patient ID: 8\n",
      "patient data found\n",
      "{'patient_id': 8, 'name': 'Daniel Johnson', 'age': 51, 'medical_history': 'colorectal cancer', 'previous_trials': None, 'trial_status': None, 'trial_completion_date': None}\n",
      "{'patient_collector': {'patient_id': 8, 'patient_data': {'patient_id': 8, 'name': 'Daniel Johnson', 'age': 51, 'medical_history': 'colorectal cancer', 'previous_trials': None, 'trial_status': None, 'trial_completion_date': None}, 'revision_number': 2}}\n",
      "binary_score='yes' reason='N/A'\n",
      "Patient passed the general trials policies\n",
      "{'policy_checker': {'patient_prompt': 'Is patient 8 eligible for any medical trial?', 'patient_id': 8, 'policy_eligible': True, 'rejection_reason': None, 'patient_data': {'age': 51, 'medical_history': 'colorectal cancer', 'previous_trials': None, 'trial_status': None, 'trial_completion_date': None}, 'patient_profile': 'Patient Profile:\\nThe patient is a 51-year-old individual with a history of colorectal cancer. They have not participated in any previous trials and currently do not have any ongoing trial participation or completion date. Based on their medical history, they may be eligible for clinical trials related to colorectal cancer treatment or prevention.', 'revision_number': 2, 'max_revisions': 2, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the current year to allow for proper assessment of any delayed adverse effects.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 8. **Travel Restrictions**\\n   - **Travel Requirements**: Patients must be able to travel to the trial site regularly for check-ups and monitoring without significant hardship or risk.\\n   - **Travel History**: Patients who have traveled to areas with active outbreaks of infectious diseases within the past 3 months are not eligible.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'trials': None, 'relevant_trials': None}}\n",
      "{'trial_search': {'trials': [Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Subject is at least 20 years of age.\\r\\n\\r\\n          2. Written and voluntary informed consent understood, signed and dated.\\r\\n\\r\\n          3. They must have refractory or progressive colorectal cancer for which there is no\\r\\n             further curative therapy available.\\r\\n\\r\\n          4. Subject able to adhere to the study visit schedule and other protocol requirements.\\r\\n\\r\\n          5. ECOG 0-2\\r\\n\\r\\n          6. At least one measurable lesion that can be accurately assessed by imaging or physical\\r\\n             examination at baseline and following up visits.\\r\\n\\r\\n          7. Must have a life expectancy of 3 months or more\\r\\n\\r\\n          8. Demonstrate adequate organ function\\r\\n\\r\\n          9. Negative urine or serum pregnancy test within 28 days of study treatment\\r\\n\\r\\n         10. Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy\\r\\n             of the tissue sample quality for assessment of biomarker status.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. ECOG ≥ 3\\r\\n\\r\\n          2. History of malignancy in the last 5 years.\\r\\n\\r\\n          3. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\\r\\n             C.\\r\\n\\r\\n          4. Breast-feeding or pregnant female\\r\\n\\r\\n          5. Patients can not the administration of Folic acid or Vitamin B12.\\r\\n\\r\\n          6. Before treatment with Pemetrexed.\\r\\n\\r\\n          7. Patients who can not swallow oral medication.\\r\\n\\r\\n          8. The most recent treatment with the clinical trial for the drug for 14 days prior to\\r\\n             enrollment.\\r\\n\\r\\n          9. Systemic chemotherapy within three weeks after the administration of the last before\\r\\n             the test treatment, radiation therapy patients who had been administered.\\r\\n\\r\\n         10. Except for the hair loss, it is induced before cancer treatment, all of toxicity in\\r\\n             progress (> CTCAE1 grade).\\r\\n\\r\\n         11. Upper GI bleeding within registration before 4 weeks of Bowel obstruction or CTCAE3 or\\r\\n             4 grade.\\r\\n\\r\\n         12. Subject who experienced a recent myocardial infarction, including severe/unstable\\r\\n             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\\r\\n             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\\r\\n             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\\r\\n             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\\r\\n             year.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['colorectal cancer']\", 'drugs': \"['pemetrexed']\", 'nctid': 'NCT02588781', 'status': 'recruiting'}), Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Diagnosis of adenocarcinoma of the rectum\\r\\n\\r\\n          -  Age: 18-70 years old\\r\\n\\r\\n          -  Signed informed consent; able to comply with study and/or follow- up procedures\\r\\n\\r\\n          -  Stage of the primary tumor may be determined by ultrasound or MRI\\r\\n\\r\\n          -  Stage II (T3-4, N0 [N0 is defined as all imaged lymph nodes < 1.0 cm]) OR stage III\\r\\n             (T1-4, N1-2 [with the definition of a clinically positive lymph node being any node ≥\\r\\n             1.0 cm]\\r\\n\\r\\n          -  Tumor palpable by digital rectal exam OR accessible by proctoscope or sigmoidoscope\\r\\n\\r\\n          -  Distal border of the tumor must be located < 12 cm from the anal verge\\r\\n\\r\\n          -  Tumor amenable to curative resection\\r\\n\\r\\n          -  Adequate bone marrow, hepatic and renal function as assessed by the following\\r\\n             laboratory requirements conducted within 7 days of starting study treatment:\\r\\n\\r\\n          -  Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet\\r\\n             count ≥ 100 x109/ L, hemoglobin (Hb) ≥ 9g/ dL.\\r\\n\\r\\n          -  Total bilirubin ≤1.5 x the upper limit of normal (ULN).\\r\\n\\r\\n          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.\\r\\n\\r\\n          -  Alkaline phosphatase limit ≤ 5x ULN.\\r\\n\\r\\n          -  Amylase and lipase ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Serum creatinine ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 mL/ min.\\r\\n\\r\\n          -  No renal disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  ECOG status: 0～1\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Hypersensitivity to fluorouracil, oxaliplatin or irinotecan.\\r\\n\\r\\n          -  No More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  Clear indication of involvement of the pelvic side walls by imaging\\r\\n\\r\\n          -  With distant metastasis\\r\\n\\r\\n          -  History of invasive rectal malignancy, regardless of disease-free interval\\r\\n\\r\\n          -  Fertile patients must use effective contraception\\r\\n\\r\\n          -  Uncontrolled hypertension\\r\\n\\r\\n          -  Cardiovascular disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  Lack of upper gastrointestinal tract integrity or malabsorption syndrome，active upper\\r\\n             gastrointestinal tract bleeding\\r\\n\\r\\n          -  Synchronous colon cancer\\r\\n\\r\\n          -  Pregnant or nursing, Fertile patients do not use effective contraception\\r\\n\\r\\n          -  Other malignancy within the past 5 years except effectively treated squamous cell or\\r\\n             basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or\\r\\n             carcinoma in situ of the colon or rectum\\r\\n\\r\\n          -  No psychiatric or addictive disorders, or other conditions that, in the opinion of the\\r\\n             investigator, would preclude study participation\\r\\n\\r\\n          -  patients refused to signed informed consent.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['rectal cancer']\", 'drugs': \"['mfolfox6']\", 'nctid': 'NCT02887313', 'status': 'recruiting'}), Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Pathologic diagnosis of ovarian, fallopian tube or primary peritoneal cancer confirmed\\r\\n             by pathology review at MSK.\\r\\n\\r\\n          -  Patients will have relapsed at least once and returned to complete clinical remission\\r\\n             after additional chemotherapy. Interval surgery is permitted.\\r\\n\\r\\n          -  Complete clinical remission is defined as CA-125 within normal limits, examination and\\r\\n             CT or MRI without objective evidence of disease (non specific abnormalities are\\r\\n             permitted on radiologic imaging).\\r\\n\\r\\n          -  Patients may sign screening consent during recurrence or at time of remission if they\\r\\n             can start vaccine therapy within 4 months of completing chemotherapy.\\r\\n\\r\\n          -  Testing of patient's archived (paraffin embedded, unstained slides) or freshly\\r\\n             biopsied tumor nodules must be positive for WT1 (Cohort 1) or NY-ESO-1 (Cohort 2)\\r\\n             protein expression. WT1 expression: Immunohistochemical analysis will be performed\\r\\n             using the technique described by Dupont et al [58]. WT1 expression will be graded\\r\\n             according to an adaptation of the German Immunoreactive Score (IRS). Only tumors with\\r\\n             moderate to strong IRS scores (4-12) will be considered WT1 positive.\\r\\n\\r\\n          -  NY-ESO-1 expression: Tissue available from primary and/or recurrent disease will be\\r\\n             evaluated for tumor expression of NY-ESO-1 by immunohistochemical (IHC) and/or RT-PCR\\r\\n             analysis will be performed using the technique described by Jungbluth et al\\r\\n\\r\\n          -  Age ≥ 18 years\\r\\n\\r\\n          -  Karnofsky performance status ≥ 70%\\r\\n\\r\\n          -  Hematologic parameters: Absolute neutrophil count ≥ 1000/mcL, Platelets > 50 K/mcL.\\r\\n\\r\\n          -  Biochemical parameters: Total bilirubin ≤ 1.5 mg/dl, AST and ALT ≤ 2.5 x upper limits\\r\\n             of normal, Creatinine ≤ 1.5 mg/dl.\\r\\n\\r\\n          -  Patient of childbearing potential must have a negative serum pregnancy test prior to\\r\\n             study entry and must be practicing and effective form of birth control\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Patients with active infection requiring systemic antibiotics, antiviral, or\\r\\n             antifungal treatments\\r\\n\\r\\n          -  Patients with a serious unstable medical illness or another active cancer.\\r\\n\\r\\n          -  Patients with a condition requiring systemic treatment with either corticosteroids\\r\\n             (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14\\r\\n             days of study drug administration. Inhaled or topical steroids and adrenal replacement\\r\\n             doses >10mg daily prednisone equivalents are permitted in the absence of active\\r\\n             autoimmune disease.\\r\\n\\r\\n          -  Patients with known history of testing positive for human immunodeficiency virus (HIV)\\r\\n             or known acquired immunodeficiency syndrome (AIDS).\\r\\n\\r\\n          -  Patients with known active hepatitis B virus or hepatitis C virus acute or chronic\\r\\n             infection.\\r\\n\\r\\n          -  Patients with active known or suspected autoimmune disease (treated hypothyroidism is\\r\\n             permitted to enroll)\\r\\n\\r\\n          -  Patients with active interstitial pneumonitis.\\r\\n      \", metadata={'disease_category': 'cancer', 'diseases': \"['ovarian cancer', 'fallopian tube', 'primary peritoneal cancer', 'recurrent ovarian cancer']\", 'drugs': \"['nivolumab']\", 'nctid': 'NCT02737787', 'status': 'recruiting'}), Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Patients have provided a signed Informed Consent Form\\r\\n\\r\\n          -  ECOG performance status of 0-1\\r\\n\\r\\n          -  BMI ≥ 18.5\\r\\n\\r\\n          -  Age: 18-65 years old\\r\\n\\r\\n          -  Histologically confirmed diagnosis of metastatic pancreatic cancer\\r\\n\\r\\n          -  No prior palliative chemotherapy\\r\\n\\r\\n          -  Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria\\r\\n\\r\\n          -  Life expectancy ≥ 3 months\\r\\n\\r\\n          -  Patient has adequate bone marrow and organ function\\r\\n\\r\\n               -  Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L\\r\\n\\r\\n               -  Platelets ≥ 90 x 109/L\\r\\n\\r\\n               -  Hemoglobin ≥ 90 g/L\\r\\n\\r\\n          -  Patient has adequate liver function\\r\\n\\r\\n               -  AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is\\r\\n                  liver metastasis)\\r\\n\\r\\n               -  Serum bilirubin ≤ 1.2 x ULN\\r\\n\\r\\n          -  Creatinine ≤ 1.25 times ULN\\r\\n\\r\\n          -  Good compliance\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Brain metastasis or only with bone metastasis.\\r\\n\\r\\n          -  Patients with severe gastrointestinal hemorrhage which need frequent blood\\r\\n             transfusions.\\r\\n\\r\\n          -  Refuse to take appropriate contraceptive measures (including male patients).\\r\\n\\r\\n          -  Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil.\\r\\n\\r\\n          -  Severe systemic disease out of control such as unstable or uncompensated respiratory,\\r\\n             cardiac, liver, renal diseases.\\r\\n\\r\\n          -  Patient has a concurrent malignancy or has a malignancy within 5 years of study\\r\\n             enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in\\r\\n             situ).\\r\\n\\r\\n          -  Psychiatric illness that would prevent the patient from giving informed consent.\\r\\n\\r\\n          -  Patient is concurrently using other antineoplastic agent\\r\\n\\r\\n          -  Patient has used investigational antineoplastic agent within 4 weeks prior to entry.\\r\\n\\r\\n          -  Known HIV-positivity.\\r\\n\\r\\n          -  No history of chronic diarrhea, nausea or vomit.\\r\\n\\r\\n          -  No ≥ grade 2 sensory peripheral neuropathy.\\r\\n\\r\\n          -  A history of transmural myocardial infarction (within 6 months prior to entry),\\r\\n             congestive heart failure, and unstable angina.\\r\\n\\r\\n          -  Infectious disease or inflammation with body temperature ≥ 38 ℃.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['metastatic pancreatic cancer']\", 'drugs': \"['mfolfirinox']\", 'nctid': 'NCT02028806', 'status': 'recruiting'})]}}\n",
      "----- CHECKING THE TRIALS RELEVANCE TO PATIENT PROFILE ----- \n",
      "---GRADER: TRIAL NCT02588781 RELEVANT---\n",
      "---GRADER: TRIAL NCT02887313 RELEVANT---\n",
      "---GRADER: TRIAL NCT02737787 NOT RELEVANT---\n",
      "---GRADER: TRIAL NCT02028806 NOT RELEVANT---\n",
      "{'grade_trials': {'relevant_trials': [{'relevance_score': 'Yes', 'explanation': \"The patient has a history of colorectal cancer, which aligns with the inclusion criteria of the clinical trial related to colorectal cancer. Therefore, the trial is relevant to the patient's medical profile.\", 'further_information': \"Further information needed: 1. Confirmation of the patient's age (at least 20 years old). 2. Documentation of informed consent. 3. Confirmation of refractory or progressive colorectal cancer status. 4. Assessment of ECOG status (0-2). 5. Verification of measurable lesion for assessment. 6. Evaluation of organ function. 7. Confirmation of life expectancy of 3 months or more. 8. Confirmation of negative pregnancy test. 9. Assessment of ability to provide tissue for biomarker analysis.\", 'nctid': 'NCT02588781'}, {'relevance_score': 'Yes', 'explanation': \"The patient has a history of colorectal cancer, which aligns with the clinical trial's inclusion criteria of adenocarcinoma of the rectum. The patient's age falls within the specified range of 18-70 years old. Additionally, the patient has not participated in any previous trials, meeting the criteria of no prior participation in investigational drug studies. Further information needed includes the current status of the patient's bone marrow, hepatic, and renal function as per the laboratory requirements specified in the trial's inclusion criteria.\", 'further_information': \"The patient's current bone marrow, hepatic, and renal function status as assessed by the laboratory requirements specified in the trial's inclusion criteria.\", 'nctid': 'NCT02887313'}]}}\n"
     ]
    }
   ],
   "source": [
    "langchain.debug = False\n",
    "thread = {\"configurable\": {\"thread_id\": \"1\"}}\n",
    "for s in graph.stream({\n",
    "    'patient_prompt': f\"Is patient {sample_patient_id} eligible for any medical trial?\",\n",
    "    # 'patient_prompt': \"Is patient Max eligible for any medical trial?\",\n",
    "    \"max_revisions\": 2,\n",
    "    \"revision_number\": 1,\n",
    "}, thread):\n",
    "    print(s)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "StateSnapshot(values={'patient_prompt': 'Is patient 8 eligible for any medical trial?', 'patient_id': 8, 'policy_eligible': True, 'patient_data': {'age': 51, 'medical_history': 'colorectal cancer', 'previous_trials': None, 'trial_status': None, 'trial_completion_date': None}, 'patient_profile': 'Patient Profile:\\nA 51-year-old patient with a history of colorectal cancer is currently in the screening phase of a clinical trial. The patient has not participated in any previous trials, and their trial status and completion date are currently unknown.\\n\\nPotential Relevant Medical Trials:\\n1. Colorectal Cancer Treatment Trial - This trial focuses on new treatment options for patients with colorectal cancer, which may be beneficial for this patient based on their medical history.\\n2. Cancer Survivorship Study - This trial aims to improve the quality of life for cancer survivors, which could be relevant for this patient post-treatment.', 'revision_number': 2, 'max_revisions': 2, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the current year to allow for proper assessment of any delayed adverse effects.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 5. **Regulatory Compliance**\\n   - **Ethics Approval**: All trials must have approval from the Institutional Review Board (IRB) or Ethics Committee.\\n   - **Data Privacy**: Patient data must be handled in compliance with data protection regulations (e.g., GDPR, HIPAA).\\n   - **Adverse Event Reporting**: Any adverse events must be reported according to institutional and regulatory guidelines.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'trials': [Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Subject is at least 20 years of age.\\r\\n\\r\\n          2. Written and voluntary informed consent understood, signed and dated.\\r\\n\\r\\n          3. They must have refractory or progressive colorectal cancer for which there is no\\r\\n             further curative therapy available.\\r\\n\\r\\n          4. Subject able to adhere to the study visit schedule and other protocol requirements.\\r\\n\\r\\n          5. ECOG 0-2\\r\\n\\r\\n          6. At least one measurable lesion that can be accurately assessed by imaging or physical\\r\\n             examination at baseline and following up visits.\\r\\n\\r\\n          7. Must have a life expectancy of 3 months or more\\r\\n\\r\\n          8. Demonstrate adequate organ function\\r\\n\\r\\n          9. Negative urine or serum pregnancy test within 28 days of study treatment\\r\\n\\r\\n         10. Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy\\r\\n             of the tissue sample quality for assessment of biomarker status.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. ECOG ≥ 3\\r\\n\\r\\n          2. History of malignancy in the last 5 years.\\r\\n\\r\\n          3. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\\r\\n             C.\\r\\n\\r\\n          4. Breast-feeding or pregnant female\\r\\n\\r\\n          5. Patients can not the administration of Folic acid or Vitamin B12.\\r\\n\\r\\n          6. Before treatment with Pemetrexed.\\r\\n\\r\\n          7. Patients who can not swallow oral medication.\\r\\n\\r\\n          8. The most recent treatment with the clinical trial for the drug for 14 days prior to\\r\\n             enrollment.\\r\\n\\r\\n          9. Systemic chemotherapy within three weeks after the administration of the last before\\r\\n             the test treatment, radiation therapy patients who had been administered.\\r\\n\\r\\n         10. Except for the hair loss, it is induced before cancer treatment, all of toxicity in\\r\\n             progress (> CTCAE1 grade).\\r\\n\\r\\n         11. Upper GI bleeding within registration before 4 weeks of Bowel obstruction or CTCAE3 or\\r\\n             4 grade.\\r\\n\\r\\n         12. Subject who experienced a recent myocardial infarction, including severe/unstable\\r\\n             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\\r\\n             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\\r\\n             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\\r\\n             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\\r\\n             year.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['colorectal cancer']\", 'drugs': \"['pemetrexed']\", 'nctid': 'NCT02588781', 'status': 'recruiting'}), Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Diagnosis of adenocarcinoma of the rectum\\r\\n\\r\\n          -  Age: 18-70 years old\\r\\n\\r\\n          -  Signed informed consent; able to comply with study and/or follow- up procedures\\r\\n\\r\\n          -  Stage of the primary tumor may be determined by ultrasound or MRI\\r\\n\\r\\n          -  Stage II (T3-4, N0 [N0 is defined as all imaged lymph nodes < 1.0 cm]) OR stage III\\r\\n             (T1-4, N1-2 [with the definition of a clinically positive lymph node being any node ≥\\r\\n             1.0 cm]\\r\\n\\r\\n          -  Tumor palpable by digital rectal exam OR accessible by proctoscope or sigmoidoscope\\r\\n\\r\\n          -  Distal border of the tumor must be located < 12 cm from the anal verge\\r\\n\\r\\n          -  Tumor amenable to curative resection\\r\\n\\r\\n          -  Adequate bone marrow, hepatic and renal function as assessed by the following\\r\\n             laboratory requirements conducted within 7 days of starting study treatment:\\r\\n\\r\\n          -  Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet\\r\\n             count ≥ 100 x109/ L, hemoglobin (Hb) ≥ 9g/ dL.\\r\\n\\r\\n          -  Total bilirubin ≤1.5 x the upper limit of normal (ULN).\\r\\n\\r\\n          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.\\r\\n\\r\\n          -  Alkaline phosphatase limit ≤ 5x ULN.\\r\\n\\r\\n          -  Amylase and lipase ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Serum creatinine ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 mL/ min.\\r\\n\\r\\n          -  No renal disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  ECOG status: 0～1\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Hypersensitivity to fluorouracil, oxaliplatin or irinotecan.\\r\\n\\r\\n          -  No More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  Clear indication of involvement of the pelvic side walls by imaging\\r\\n\\r\\n          -  With distant metastasis\\r\\n\\r\\n          -  History of invasive rectal malignancy, regardless of disease-free interval\\r\\n\\r\\n          -  Fertile patients must use effective contraception\\r\\n\\r\\n          -  Uncontrolled hypertension\\r\\n\\r\\n          -  Cardiovascular disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  Lack of upper gastrointestinal tract integrity or malabsorption syndrome，active upper\\r\\n             gastrointestinal tract bleeding\\r\\n\\r\\n          -  Synchronous colon cancer\\r\\n\\r\\n          -  Pregnant or nursing, Fertile patients do not use effective contraception\\r\\n\\r\\n          -  Other malignancy within the past 5 years except effectively treated squamous cell or\\r\\n             basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or\\r\\n             carcinoma in situ of the colon or rectum\\r\\n\\r\\n          -  No psychiatric or addictive disorders, or other conditions that, in the opinion of the\\r\\n             investigator, would preclude study participation\\r\\n\\r\\n          -  patients refused to signed informed consent.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['rectal cancer']\", 'drugs': \"['mfolfox6']\", 'nctid': 'NCT02887313', 'status': 'recruiting'}), Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Pathologic diagnosis of ovarian, fallopian tube or primary peritoneal cancer confirmed\\r\\n             by pathology review at MSK.\\r\\n\\r\\n          -  Patients will have relapsed at least once and returned to complete clinical remission\\r\\n             after additional chemotherapy. Interval surgery is permitted.\\r\\n\\r\\n          -  Complete clinical remission is defined as CA-125 within normal limits, examination and\\r\\n             CT or MRI without objective evidence of disease (non specific abnormalities are\\r\\n             permitted on radiologic imaging).\\r\\n\\r\\n          -  Patients may sign screening consent during recurrence or at time of remission if they\\r\\n             can start vaccine therapy within 4 months of completing chemotherapy.\\r\\n\\r\\n          -  Testing of patient's archived (paraffin embedded, unstained slides) or freshly\\r\\n             biopsied tumor nodules must be positive for WT1 (Cohort 1) or NY-ESO-1 (Cohort 2)\\r\\n             protein expression. WT1 expression: Immunohistochemical analysis will be performed\\r\\n             using the technique described by Dupont et al [58]. WT1 expression will be graded\\r\\n             according to an adaptation of the German Immunoreactive Score (IRS). Only tumors with\\r\\n             moderate to strong IRS scores (4-12) will be considered WT1 positive.\\r\\n\\r\\n          -  NY-ESO-1 expression: Tissue available from primary and/or recurrent disease will be\\r\\n             evaluated for tumor expression of NY-ESO-1 by immunohistochemical (IHC) and/or RT-PCR\\r\\n             analysis will be performed using the technique described by Jungbluth et al\\r\\n\\r\\n          -  Age ≥ 18 years\\r\\n\\r\\n          -  Karnofsky performance status ≥ 70%\\r\\n\\r\\n          -  Hematologic parameters: Absolute neutrophil count ≥ 1000/mcL, Platelets > 50 K/mcL.\\r\\n\\r\\n          -  Biochemical parameters: Total bilirubin ≤ 1.5 mg/dl, AST and ALT ≤ 2.5 x upper limits\\r\\n             of normal, Creatinine ≤ 1.5 mg/dl.\\r\\n\\r\\n          -  Patient of childbearing potential must have a negative serum pregnancy test prior to\\r\\n             study entry and must be practicing and effective form of birth control\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Patients with active infection requiring systemic antibiotics, antiviral, or\\r\\n             antifungal treatments\\r\\n\\r\\n          -  Patients with a serious unstable medical illness or another active cancer.\\r\\n\\r\\n          -  Patients with a condition requiring systemic treatment with either corticosteroids\\r\\n             (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14\\r\\n             days of study drug administration. Inhaled or topical steroids and adrenal replacement\\r\\n             doses >10mg daily prednisone equivalents are permitted in the absence of active\\r\\n             autoimmune disease.\\r\\n\\r\\n          -  Patients with known history of testing positive for human immunodeficiency virus (HIV)\\r\\n             or known acquired immunodeficiency syndrome (AIDS).\\r\\n\\r\\n          -  Patients with known active hepatitis B virus or hepatitis C virus acute or chronic\\r\\n             infection.\\r\\n\\r\\n          -  Patients with active known or suspected autoimmune disease (treated hypothyroidism is\\r\\n             permitted to enroll)\\r\\n\\r\\n          -  Patients with active interstitial pneumonitis.\\r\\n      \", metadata={'disease_category': 'cancer', 'diseases': \"['ovarian cancer', 'fallopian tube', 'primary peritoneal cancer', 'recurrent ovarian cancer']\", 'drugs': \"['nivolumab']\", 'nctid': 'NCT02737787', 'status': 'recruiting'}), Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Patients have provided a signed Informed Consent Form\\r\\n\\r\\n          -  ECOG performance status of 0-1\\r\\n\\r\\n          -  BMI ≥ 18.5\\r\\n\\r\\n          -  Age: 18-65 years old\\r\\n\\r\\n          -  Histologically confirmed diagnosis of metastatic pancreatic cancer\\r\\n\\r\\n          -  No prior palliative chemotherapy\\r\\n\\r\\n          -  Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria\\r\\n\\r\\n          -  Life expectancy ≥ 3 months\\r\\n\\r\\n          -  Patient has adequate bone marrow and organ function\\r\\n\\r\\n               -  Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L\\r\\n\\r\\n               -  Platelets ≥ 90 x 109/L\\r\\n\\r\\n               -  Hemoglobin ≥ 90 g/L\\r\\n\\r\\n          -  Patient has adequate liver function\\r\\n\\r\\n               -  AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is\\r\\n                  liver metastasis)\\r\\n\\r\\n               -  Serum bilirubin ≤ 1.2 x ULN\\r\\n\\r\\n          -  Creatinine ≤ 1.25 times ULN\\r\\n\\r\\n          -  Good compliance\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Brain metastasis or only with bone metastasis.\\r\\n\\r\\n          -  Patients with severe gastrointestinal hemorrhage which need frequent blood\\r\\n             transfusions.\\r\\n\\r\\n          -  Refuse to take appropriate contraceptive measures (including male patients).\\r\\n\\r\\n          -  Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil.\\r\\n\\r\\n          -  Severe systemic disease out of control such as unstable or uncompensated respiratory,\\r\\n             cardiac, liver, renal diseases.\\r\\n\\r\\n          -  Patient has a concurrent malignancy or has a malignancy within 5 years of study\\r\\n             enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in\\r\\n             situ).\\r\\n\\r\\n          -  Psychiatric illness that would prevent the patient from giving informed consent.\\r\\n\\r\\n          -  Patient is concurrently using other antineoplastic agent\\r\\n\\r\\n          -  Patient has used investigational antineoplastic agent within 4 weeks prior to entry.\\r\\n\\r\\n          -  Known HIV-positivity.\\r\\n\\r\\n          -  No history of chronic diarrhea, nausea or vomit.\\r\\n\\r\\n          -  No ≥ grade 2 sensory peripheral neuropathy.\\r\\n\\r\\n          -  A history of transmural myocardial infarction (within 6 months prior to entry),\\r\\n             congestive heart failure, and unstable angina.\\r\\n\\r\\n          -  Infectious disease or inflammation with body temperature ≥ 38 ℃.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['metastatic pancreatic cancer']\", 'drugs': \"['mfolfirinox']\", 'nctid': 'NCT02028806', 'status': 'recruiting'})], 'relevant_trials': [{'relevance_score': 'Yes', 'explanation': \"The patient has a history of colorectal cancer, which matches the disease focus of the clinical trial. This indicates relevance based on the inclusion criteria of refractory or progressive colorectal cancer. Further information needed from the patient's medical history includes confirmation of ECOG status, organ function, pregnancy status, and recent treatments to fully assess eligibility for the trial.\", 'further_information': 'ECOG status, organ function, pregnancy status, recent treatments', 'nctid': 'NCT02588781'}, {'relevance_score': 'Yes', 'explanation': \"The patient has a history of colorectal cancer, which matches the diagnosis of adenocarcinoma of the rectum in the trial's inclusion criteria. This indicates potential relevance of the trial to the patient based on their medical history.\", 'further_information': \"Further information needed from the patient's medical history includes details on the stage of the primary tumor, tumor accessibility, and laboratory assessments to confirm eligibility for the trial.\", 'nctid': 'NCT02887313'}, {'relevance_score': 'Yes', 'explanation': \"The patient has a history of colorectal cancer, which is one of the inclusion diseases in the trial related to ovarian, fallopian tube, and primary peritoneal cancer. Therefore, the trial is relevant to the patient's medical profile.\", 'further_information': \"More details are needed regarding the patient's current health status, including recent test results, current treatment plan, and any other ongoing medical conditions.\", 'nctid': 'NCT02737787'}]}, next=(), config={'configurable': {'thread_id': '4', 'thread_ts': '1ef31827-b2b2-687e-8004-475d4e0e20c5'}}, metadata={'source': 'loop', 'step': 4, 'writes': {'grade_trials': {'relevant_trials': [{'relevance_score': 'Yes', 'explanation': \"The patient has a history of colorectal cancer, which matches the disease focus of the clinical trial. This indicates relevance based on the inclusion criteria of refractory or progressive colorectal cancer. Further information needed from the patient's medical history includes confirmation of ECOG status, organ function, pregnancy status, and recent treatments to fully assess eligibility for the trial.\", 'further_information': 'ECOG status, organ function, pregnancy status, recent treatments', 'nctid': 'NCT02588781'}, {'relevance_score': 'Yes', 'explanation': \"The patient has a history of colorectal cancer, which matches the diagnosis of adenocarcinoma of the rectum in the trial's inclusion criteria. This indicates potential relevance of the trial to the patient based on their medical history.\", 'further_information': \"Further information needed from the patient's medical history includes details on the stage of the primary tumor, tumor accessibility, and laboratory assessments to confirm eligibility for the trial.\", 'nctid': 'NCT02887313'}, {'relevance_score': 'Yes', 'explanation': \"The patient has a history of colorectal cancer, which is one of the inclusion diseases in the trial related to ovarian, fallopian tube, and primary peritoneal cancer. Therefore, the trial is relevant to the patient's medical profile.\", 'further_information': \"More details are needed regarding the patient's current health status, including recent test results, current treatment plan, and any other ongoing medical conditions.\", 'nctid': 'NCT02737787'}]}}}, created_at='2024-06-23T17:03:15.371020+00:00', parent_config={'configurable': {'thread_id': '4', 'thread_ts': '1ef31827-5df8-6473-8003-7c93fdaca3dc'}})\n",
      "--\n",
      "StateSnapshot(values={'patient_prompt': 'Is patient 8 eligible for any medical trial?', 'patient_id': 8, 'policy_eligible': True, 'patient_data': {'age': 51, 'medical_history': 'colorectal cancer', 'previous_trials': None, 'trial_status': None, 'trial_completion_date': None}, 'patient_profile': 'Patient Profile:\\nA 51-year-old patient with a history of colorectal cancer is currently in the screening phase of a clinical trial. The patient has not participated in any previous trials, and their trial status and completion date are currently unknown.\\n\\nPotential Relevant Medical Trials:\\n1. Colorectal Cancer Treatment Trial - This trial focuses on new treatment options for patients with colorectal cancer, which may be beneficial for this patient based on their medical history.\\n2. Cancer Survivorship Study - This trial aims to improve the quality of life for cancer survivors, which could be relevant for this patient post-treatment.', 'revision_number': 2, 'max_revisions': 2, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the current year to allow for proper assessment of any delayed adverse effects.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 5. **Regulatory Compliance**\\n   - **Ethics Approval**: All trials must have approval from the Institutional Review Board (IRB) or Ethics Committee.\\n   - **Data Privacy**: Patient data must be handled in compliance with data protection regulations (e.g., GDPR, HIPAA).\\n   - **Adverse Event Reporting**: Any adverse events must be reported according to institutional and regulatory guidelines.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'trials': [Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Subject is at least 20 years of age.\\r\\n\\r\\n          2. Written and voluntary informed consent understood, signed and dated.\\r\\n\\r\\n          3. They must have refractory or progressive colorectal cancer for which there is no\\r\\n             further curative therapy available.\\r\\n\\r\\n          4. Subject able to adhere to the study visit schedule and other protocol requirements.\\r\\n\\r\\n          5. ECOG 0-2\\r\\n\\r\\n          6. At least one measurable lesion that can be accurately assessed by imaging or physical\\r\\n             examination at baseline and following up visits.\\r\\n\\r\\n          7. Must have a life expectancy of 3 months or more\\r\\n\\r\\n          8. Demonstrate adequate organ function\\r\\n\\r\\n          9. Negative urine or serum pregnancy test within 28 days of study treatment\\r\\n\\r\\n         10. Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy\\r\\n             of the tissue sample quality for assessment of biomarker status.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. ECOG ≥ 3\\r\\n\\r\\n          2. History of malignancy in the last 5 years.\\r\\n\\r\\n          3. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\\r\\n             C.\\r\\n\\r\\n          4. Breast-feeding or pregnant female\\r\\n\\r\\n          5. Patients can not the administration of Folic acid or Vitamin B12.\\r\\n\\r\\n          6. Before treatment with Pemetrexed.\\r\\n\\r\\n          7. Patients who can not swallow oral medication.\\r\\n\\r\\n          8. The most recent treatment with the clinical trial for the drug for 14 days prior to\\r\\n             enrollment.\\r\\n\\r\\n          9. Systemic chemotherapy within three weeks after the administration of the last before\\r\\n             the test treatment, radiation therapy patients who had been administered.\\r\\n\\r\\n         10. Except for the hair loss, it is induced before cancer treatment, all of toxicity in\\r\\n             progress (> CTCAE1 grade).\\r\\n\\r\\n         11. Upper GI bleeding within registration before 4 weeks of Bowel obstruction or CTCAE3 or\\r\\n             4 grade.\\r\\n\\r\\n         12. Subject who experienced a recent myocardial infarction, including severe/unstable\\r\\n             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\\r\\n             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\\r\\n             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\\r\\n             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\\r\\n             year.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['colorectal cancer']\", 'drugs': \"['pemetrexed']\", 'nctid': 'NCT02588781', 'status': 'recruiting'}), Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Diagnosis of adenocarcinoma of the rectum\\r\\n\\r\\n          -  Age: 18-70 years old\\r\\n\\r\\n          -  Signed informed consent; able to comply with study and/or follow- up procedures\\r\\n\\r\\n          -  Stage of the primary tumor may be determined by ultrasound or MRI\\r\\n\\r\\n          -  Stage II (T3-4, N0 [N0 is defined as all imaged lymph nodes < 1.0 cm]) OR stage III\\r\\n             (T1-4, N1-2 [with the definition of a clinically positive lymph node being any node ≥\\r\\n             1.0 cm]\\r\\n\\r\\n          -  Tumor palpable by digital rectal exam OR accessible by proctoscope or sigmoidoscope\\r\\n\\r\\n          -  Distal border of the tumor must be located < 12 cm from the anal verge\\r\\n\\r\\n          -  Tumor amenable to curative resection\\r\\n\\r\\n          -  Adequate bone marrow, hepatic and renal function as assessed by the following\\r\\n             laboratory requirements conducted within 7 days of starting study treatment:\\r\\n\\r\\n          -  Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet\\r\\n             count ≥ 100 x109/ L, hemoglobin (Hb) ≥ 9g/ dL.\\r\\n\\r\\n          -  Total bilirubin ≤1.5 x the upper limit of normal (ULN).\\r\\n\\r\\n          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.\\r\\n\\r\\n          -  Alkaline phosphatase limit ≤ 5x ULN.\\r\\n\\r\\n          -  Amylase and lipase ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Serum creatinine ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 mL/ min.\\r\\n\\r\\n          -  No renal disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  ECOG status: 0～1\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Hypersensitivity to fluorouracil, oxaliplatin or irinotecan.\\r\\n\\r\\n          -  No More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  Clear indication of involvement of the pelvic side walls by imaging\\r\\n\\r\\n          -  With distant metastasis\\r\\n\\r\\n          -  History of invasive rectal malignancy, regardless of disease-free interval\\r\\n\\r\\n          -  Fertile patients must use effective contraception\\r\\n\\r\\n          -  Uncontrolled hypertension\\r\\n\\r\\n          -  Cardiovascular disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  Lack of upper gastrointestinal tract integrity or malabsorption syndrome，active upper\\r\\n             gastrointestinal tract bleeding\\r\\n\\r\\n          -  Synchronous colon cancer\\r\\n\\r\\n          -  Pregnant or nursing, Fertile patients do not use effective contraception\\r\\n\\r\\n          -  Other malignancy within the past 5 years except effectively treated squamous cell or\\r\\n             basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or\\r\\n             carcinoma in situ of the colon or rectum\\r\\n\\r\\n          -  No psychiatric or addictive disorders, or other conditions that, in the opinion of the\\r\\n             investigator, would preclude study participation\\r\\n\\r\\n          -  patients refused to signed informed consent.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['rectal cancer']\", 'drugs': \"['mfolfox6']\", 'nctid': 'NCT02887313', 'status': 'recruiting'}), Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Pathologic diagnosis of ovarian, fallopian tube or primary peritoneal cancer confirmed\\r\\n             by pathology review at MSK.\\r\\n\\r\\n          -  Patients will have relapsed at least once and returned to complete clinical remission\\r\\n             after additional chemotherapy. Interval surgery is permitted.\\r\\n\\r\\n          -  Complete clinical remission is defined as CA-125 within normal limits, examination and\\r\\n             CT or MRI without objective evidence of disease (non specific abnormalities are\\r\\n             permitted on radiologic imaging).\\r\\n\\r\\n          -  Patients may sign screening consent during recurrence or at time of remission if they\\r\\n             can start vaccine therapy within 4 months of completing chemotherapy.\\r\\n\\r\\n          -  Testing of patient's archived (paraffin embedded, unstained slides) or freshly\\r\\n             biopsied tumor nodules must be positive for WT1 (Cohort 1) or NY-ESO-1 (Cohort 2)\\r\\n             protein expression. WT1 expression: Immunohistochemical analysis will be performed\\r\\n             using the technique described by Dupont et al [58]. WT1 expression will be graded\\r\\n             according to an adaptation of the German Immunoreactive Score (IRS). Only tumors with\\r\\n             moderate to strong IRS scores (4-12) will be considered WT1 positive.\\r\\n\\r\\n          -  NY-ESO-1 expression: Tissue available from primary and/or recurrent disease will be\\r\\n             evaluated for tumor expression of NY-ESO-1 by immunohistochemical (IHC) and/or RT-PCR\\r\\n             analysis will be performed using the technique described by Jungbluth et al\\r\\n\\r\\n          -  Age ≥ 18 years\\r\\n\\r\\n          -  Karnofsky performance status ≥ 70%\\r\\n\\r\\n          -  Hematologic parameters: Absolute neutrophil count ≥ 1000/mcL, Platelets > 50 K/mcL.\\r\\n\\r\\n          -  Biochemical parameters: Total bilirubin ≤ 1.5 mg/dl, AST and ALT ≤ 2.5 x upper limits\\r\\n             of normal, Creatinine ≤ 1.5 mg/dl.\\r\\n\\r\\n          -  Patient of childbearing potential must have a negative serum pregnancy test prior to\\r\\n             study entry and must be practicing and effective form of birth control\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Patients with active infection requiring systemic antibiotics, antiviral, or\\r\\n             antifungal treatments\\r\\n\\r\\n          -  Patients with a serious unstable medical illness or another active cancer.\\r\\n\\r\\n          -  Patients with a condition requiring systemic treatment with either corticosteroids\\r\\n             (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14\\r\\n             days of study drug administration. Inhaled or topical steroids and adrenal replacement\\r\\n             doses >10mg daily prednisone equivalents are permitted in the absence of active\\r\\n             autoimmune disease.\\r\\n\\r\\n          -  Patients with known history of testing positive for human immunodeficiency virus (HIV)\\r\\n             or known acquired immunodeficiency syndrome (AIDS).\\r\\n\\r\\n          -  Patients with known active hepatitis B virus or hepatitis C virus acute or chronic\\r\\n             infection.\\r\\n\\r\\n          -  Patients with active known or suspected autoimmune disease (treated hypothyroidism is\\r\\n             permitted to enroll)\\r\\n\\r\\n          -  Patients with active interstitial pneumonitis.\\r\\n      \", metadata={'disease_category': 'cancer', 'diseases': \"['ovarian cancer', 'fallopian tube', 'primary peritoneal cancer', 'recurrent ovarian cancer']\", 'drugs': \"['nivolumab']\", 'nctid': 'NCT02737787', 'status': 'recruiting'}), Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Patients have provided a signed Informed Consent Form\\r\\n\\r\\n          -  ECOG performance status of 0-1\\r\\n\\r\\n          -  BMI ≥ 18.5\\r\\n\\r\\n          -  Age: 18-65 years old\\r\\n\\r\\n          -  Histologically confirmed diagnosis of metastatic pancreatic cancer\\r\\n\\r\\n          -  No prior palliative chemotherapy\\r\\n\\r\\n          -  Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria\\r\\n\\r\\n          -  Life expectancy ≥ 3 months\\r\\n\\r\\n          -  Patient has adequate bone marrow and organ function\\r\\n\\r\\n               -  Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L\\r\\n\\r\\n               -  Platelets ≥ 90 x 109/L\\r\\n\\r\\n               -  Hemoglobin ≥ 90 g/L\\r\\n\\r\\n          -  Patient has adequate liver function\\r\\n\\r\\n               -  AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is\\r\\n                  liver metastasis)\\r\\n\\r\\n               -  Serum bilirubin ≤ 1.2 x ULN\\r\\n\\r\\n          -  Creatinine ≤ 1.25 times ULN\\r\\n\\r\\n          -  Good compliance\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Brain metastasis or only with bone metastasis.\\r\\n\\r\\n          -  Patients with severe gastrointestinal hemorrhage which need frequent blood\\r\\n             transfusions.\\r\\n\\r\\n          -  Refuse to take appropriate contraceptive measures (including male patients).\\r\\n\\r\\n          -  Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil.\\r\\n\\r\\n          -  Severe systemic disease out of control such as unstable or uncompensated respiratory,\\r\\n             cardiac, liver, renal diseases.\\r\\n\\r\\n          -  Patient has a concurrent malignancy or has a malignancy within 5 years of study\\r\\n             enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in\\r\\n             situ).\\r\\n\\r\\n          -  Psychiatric illness that would prevent the patient from giving informed consent.\\r\\n\\r\\n          -  Patient is concurrently using other antineoplastic agent\\r\\n\\r\\n          -  Patient has used investigational antineoplastic agent within 4 weeks prior to entry.\\r\\n\\r\\n          -  Known HIV-positivity.\\r\\n\\r\\n          -  No history of chronic diarrhea, nausea or vomit.\\r\\n\\r\\n          -  No ≥ grade 2 sensory peripheral neuropathy.\\r\\n\\r\\n          -  A history of transmural myocardial infarction (within 6 months prior to entry),\\r\\n             congestive heart failure, and unstable angina.\\r\\n\\r\\n          -  Infectious disease or inflammation with body temperature ≥ 38 ℃.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['metastatic pancreatic cancer']\", 'drugs': \"['mfolfirinox']\", 'nctid': 'NCT02028806', 'status': 'recruiting'})]}, next=('grade_trials',), config={'configurable': {'thread_id': '4', 'thread_ts': '1ef31827-5df8-6473-8003-7c93fdaca3dc'}}, metadata={'source': 'loop', 'step': 3, 'writes': {'trial_search': {'trials': [Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Subject is at least 20 years of age.\\r\\n\\r\\n          2. Written and voluntary informed consent understood, signed and dated.\\r\\n\\r\\n          3. They must have refractory or progressive colorectal cancer for which there is no\\r\\n             further curative therapy available.\\r\\n\\r\\n          4. Subject able to adhere to the study visit schedule and other protocol requirements.\\r\\n\\r\\n          5. ECOG 0-2\\r\\n\\r\\n          6. At least one measurable lesion that can be accurately assessed by imaging or physical\\r\\n             examination at baseline and following up visits.\\r\\n\\r\\n          7. Must have a life expectancy of 3 months or more\\r\\n\\r\\n          8. Demonstrate adequate organ function\\r\\n\\r\\n          9. Negative urine or serum pregnancy test within 28 days of study treatment\\r\\n\\r\\n         10. Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy\\r\\n             of the tissue sample quality for assessment of biomarker status.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. ECOG ≥ 3\\r\\n\\r\\n          2. History of malignancy in the last 5 years.\\r\\n\\r\\n          3. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\\r\\n             C.\\r\\n\\r\\n          4. Breast-feeding or pregnant female\\r\\n\\r\\n          5. Patients can not the administration of Folic acid or Vitamin B12.\\r\\n\\r\\n          6. Before treatment with Pemetrexed.\\r\\n\\r\\n          7. Patients who can not swallow oral medication.\\r\\n\\r\\n          8. The most recent treatment with the clinical trial for the drug for 14 days prior to\\r\\n             enrollment.\\r\\n\\r\\n          9. Systemic chemotherapy within three weeks after the administration of the last before\\r\\n             the test treatment, radiation therapy patients who had been administered.\\r\\n\\r\\n         10. Except for the hair loss, it is induced before cancer treatment, all of toxicity in\\r\\n             progress (> CTCAE1 grade).\\r\\n\\r\\n         11. Upper GI bleeding within registration before 4 weeks of Bowel obstruction or CTCAE3 or\\r\\n             4 grade.\\r\\n\\r\\n         12. Subject who experienced a recent myocardial infarction, including severe/unstable\\r\\n             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\\r\\n             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\\r\\n             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\\r\\n             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\\r\\n             year.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['colorectal cancer']\", 'drugs': \"['pemetrexed']\", 'nctid': 'NCT02588781', 'status': 'recruiting'}), Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Diagnosis of adenocarcinoma of the rectum\\r\\n\\r\\n          -  Age: 18-70 years old\\r\\n\\r\\n          -  Signed informed consent; able to comply with study and/or follow- up procedures\\r\\n\\r\\n          -  Stage of the primary tumor may be determined by ultrasound or MRI\\r\\n\\r\\n          -  Stage II (T3-4, N0 [N0 is defined as all imaged lymph nodes < 1.0 cm]) OR stage III\\r\\n             (T1-4, N1-2 [with the definition of a clinically positive lymph node being any node ≥\\r\\n             1.0 cm]\\r\\n\\r\\n          -  Tumor palpable by digital rectal exam OR accessible by proctoscope or sigmoidoscope\\r\\n\\r\\n          -  Distal border of the tumor must be located < 12 cm from the anal verge\\r\\n\\r\\n          -  Tumor amenable to curative resection\\r\\n\\r\\n          -  Adequate bone marrow, hepatic and renal function as assessed by the following\\r\\n             laboratory requirements conducted within 7 days of starting study treatment:\\r\\n\\r\\n          -  Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet\\r\\n             count ≥ 100 x109/ L, hemoglobin (Hb) ≥ 9g/ dL.\\r\\n\\r\\n          -  Total bilirubin ≤1.5 x the upper limit of normal (ULN).\\r\\n\\r\\n          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.\\r\\n\\r\\n          -  Alkaline phosphatase limit ≤ 5x ULN.\\r\\n\\r\\n          -  Amylase and lipase ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Serum creatinine ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 mL/ min.\\r\\n\\r\\n          -  No renal disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  ECOG status: 0～1\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Hypersensitivity to fluorouracil, oxaliplatin or irinotecan.\\r\\n\\r\\n          -  No More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  Clear indication of involvement of the pelvic side walls by imaging\\r\\n\\r\\n          -  With distant metastasis\\r\\n\\r\\n          -  History of invasive rectal malignancy, regardless of disease-free interval\\r\\n\\r\\n          -  Fertile patients must use effective contraception\\r\\n\\r\\n          -  Uncontrolled hypertension\\r\\n\\r\\n          -  Cardiovascular disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  Lack of upper gastrointestinal tract integrity or malabsorption syndrome，active upper\\r\\n             gastrointestinal tract bleeding\\r\\n\\r\\n          -  Synchronous colon cancer\\r\\n\\r\\n          -  Pregnant or nursing, Fertile patients do not use effective contraception\\r\\n\\r\\n          -  Other malignancy within the past 5 years except effectively treated squamous cell or\\r\\n             basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or\\r\\n             carcinoma in situ of the colon or rectum\\r\\n\\r\\n          -  No psychiatric or addictive disorders, or other conditions that, in the opinion of the\\r\\n             investigator, would preclude study participation\\r\\n\\r\\n          -  patients refused to signed informed consent.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['rectal cancer']\", 'drugs': \"['mfolfox6']\", 'nctid': 'NCT02887313', 'status': 'recruiting'}), Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Pathologic diagnosis of ovarian, fallopian tube or primary peritoneal cancer confirmed\\r\\n             by pathology review at MSK.\\r\\n\\r\\n          -  Patients will have relapsed at least once and returned to complete clinical remission\\r\\n             after additional chemotherapy. Interval surgery is permitted.\\r\\n\\r\\n          -  Complete clinical remission is defined as CA-125 within normal limits, examination and\\r\\n             CT or MRI without objective evidence of disease (non specific abnormalities are\\r\\n             permitted on radiologic imaging).\\r\\n\\r\\n          -  Patients may sign screening consent during recurrence or at time of remission if they\\r\\n             can start vaccine therapy within 4 months of completing chemotherapy.\\r\\n\\r\\n          -  Testing of patient's archived (paraffin embedded, unstained slides) or freshly\\r\\n             biopsied tumor nodules must be positive for WT1 (Cohort 1) or NY-ESO-1 (Cohort 2)\\r\\n             protein expression. WT1 expression: Immunohistochemical analysis will be performed\\r\\n             using the technique described by Dupont et al [58]. WT1 expression will be graded\\r\\n             according to an adaptation of the German Immunoreactive Score (IRS). Only tumors with\\r\\n             moderate to strong IRS scores (4-12) will be considered WT1 positive.\\r\\n\\r\\n          -  NY-ESO-1 expression: Tissue available from primary and/or recurrent disease will be\\r\\n             evaluated for tumor expression of NY-ESO-1 by immunohistochemical (IHC) and/or RT-PCR\\r\\n             analysis will be performed using the technique described by Jungbluth et al\\r\\n\\r\\n          -  Age ≥ 18 years\\r\\n\\r\\n          -  Karnofsky performance status ≥ 70%\\r\\n\\r\\n          -  Hematologic parameters: Absolute neutrophil count ≥ 1000/mcL, Platelets > 50 K/mcL.\\r\\n\\r\\n          -  Biochemical parameters: Total bilirubin ≤ 1.5 mg/dl, AST and ALT ≤ 2.5 x upper limits\\r\\n             of normal, Creatinine ≤ 1.5 mg/dl.\\r\\n\\r\\n          -  Patient of childbearing potential must have a negative serum pregnancy test prior to\\r\\n             study entry and must be practicing and effective form of birth control\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Patients with active infection requiring systemic antibiotics, antiviral, or\\r\\n             antifungal treatments\\r\\n\\r\\n          -  Patients with a serious unstable medical illness or another active cancer.\\r\\n\\r\\n          -  Patients with a condition requiring systemic treatment with either corticosteroids\\r\\n             (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14\\r\\n             days of study drug administration. Inhaled or topical steroids and adrenal replacement\\r\\n             doses >10mg daily prednisone equivalents are permitted in the absence of active\\r\\n             autoimmune disease.\\r\\n\\r\\n          -  Patients with known history of testing positive for human immunodeficiency virus (HIV)\\r\\n             or known acquired immunodeficiency syndrome (AIDS).\\r\\n\\r\\n          -  Patients with known active hepatitis B virus or hepatitis C virus acute or chronic\\r\\n             infection.\\r\\n\\r\\n          -  Patients with active known or suspected autoimmune disease (treated hypothyroidism is\\r\\n             permitted to enroll)\\r\\n\\r\\n          -  Patients with active interstitial pneumonitis.\\r\\n      \", metadata={'disease_category': 'cancer', 'diseases': \"['ovarian cancer', 'fallopian tube', 'primary peritoneal cancer', 'recurrent ovarian cancer']\", 'drugs': \"['nivolumab']\", 'nctid': 'NCT02737787', 'status': 'recruiting'}), Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Patients have provided a signed Informed Consent Form\\r\\n\\r\\n          -  ECOG performance status of 0-1\\r\\n\\r\\n          -  BMI ≥ 18.5\\r\\n\\r\\n          -  Age: 18-65 years old\\r\\n\\r\\n          -  Histologically confirmed diagnosis of metastatic pancreatic cancer\\r\\n\\r\\n          -  No prior palliative chemotherapy\\r\\n\\r\\n          -  Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria\\r\\n\\r\\n          -  Life expectancy ≥ 3 months\\r\\n\\r\\n          -  Patient has adequate bone marrow and organ function\\r\\n\\r\\n               -  Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L\\r\\n\\r\\n               -  Platelets ≥ 90 x 109/L\\r\\n\\r\\n               -  Hemoglobin ≥ 90 g/L\\r\\n\\r\\n          -  Patient has adequate liver function\\r\\n\\r\\n               -  AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is\\r\\n                  liver metastasis)\\r\\n\\r\\n               -  Serum bilirubin ≤ 1.2 x ULN\\r\\n\\r\\n          -  Creatinine ≤ 1.25 times ULN\\r\\n\\r\\n          -  Good compliance\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Brain metastasis or only with bone metastasis.\\r\\n\\r\\n          -  Patients with severe gastrointestinal hemorrhage which need frequent blood\\r\\n             transfusions.\\r\\n\\r\\n          -  Refuse to take appropriate contraceptive measures (including male patients).\\r\\n\\r\\n          -  Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil.\\r\\n\\r\\n          -  Severe systemic disease out of control such as unstable or uncompensated respiratory,\\r\\n             cardiac, liver, renal diseases.\\r\\n\\r\\n          -  Patient has a concurrent malignancy or has a malignancy within 5 years of study\\r\\n             enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in\\r\\n             situ).\\r\\n\\r\\n          -  Psychiatric illness that would prevent the patient from giving informed consent.\\r\\n\\r\\n          -  Patient is concurrently using other antineoplastic agent\\r\\n\\r\\n          -  Patient has used investigational antineoplastic agent within 4 weeks prior to entry.\\r\\n\\r\\n          -  Known HIV-positivity.\\r\\n\\r\\n          -  No history of chronic diarrhea, nausea or vomit.\\r\\n\\r\\n          -  No ≥ grade 2 sensory peripheral neuropathy.\\r\\n\\r\\n          -  A history of transmural myocardial infarction (within 6 months prior to entry),\\r\\n             congestive heart failure, and unstable angina.\\r\\n\\r\\n          -  Infectious disease or inflammation with body temperature ≥ 38 ℃.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['metastatic pancreatic cancer']\", 'drugs': \"['mfolfirinox']\", 'nctid': 'NCT02028806', 'status': 'recruiting'})]}}}, created_at='2024-06-23T17:03:06.486693+00:00', parent_config={'configurable': {'thread_id': '4', 'thread_ts': '1ef31827-5114-6246-8002-5c18df713506'}})\n",
      "--\n",
      "StateSnapshot(values={'patient_prompt': 'Is patient 8 eligible for any medical trial?', 'patient_id': 8, 'policy_eligible': True, 'patient_data': {'age': 51, 'medical_history': 'colorectal cancer', 'previous_trials': None, 'trial_status': None, 'trial_completion_date': None}, 'patient_profile': 'Patient Profile:\\nA 51-year-old patient with a history of colorectal cancer is currently in the screening phase of a clinical trial. The patient has not participated in any previous trials, and their trial status and completion date are currently unknown.\\n\\nPotential Relevant Medical Trials:\\n1. Colorectal Cancer Treatment Trial - This trial focuses on new treatment options for patients with colorectal cancer, which may be beneficial for this patient based on their medical history.\\n2. Cancer Survivorship Study - This trial aims to improve the quality of life for cancer survivors, which could be relevant for this patient post-treatment.', 'revision_number': 2, 'max_revisions': 2, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the current year to allow for proper assessment of any delayed adverse effects.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 5. **Regulatory Compliance**\\n   - **Ethics Approval**: All trials must have approval from the Institutional Review Board (IRB) or Ethics Committee.\\n   - **Data Privacy**: Patient data must be handled in compliance with data protection regulations (e.g., GDPR, HIPAA).\\n   - **Adverse Event Reporting**: Any adverse events must be reported according to institutional and regulatory guidelines.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})]}, next=('trial_search',), config={'configurable': {'thread_id': '4', 'thread_ts': '1ef31827-5114-6246-8002-5c18df713506'}}, metadata={'source': 'loop', 'step': 2, 'writes': {'policy_checker': {'patient_prompt': 'Is patient 8 eligible for any medical trial?', 'patient_id': 8, 'policy_eligible': True, 'rejection_reason': None, 'patient_data': {'age': 51, 'medical_history': 'colorectal cancer', 'previous_trials': None, 'trial_status': None, 'trial_completion_date': None}, 'patient_profile': 'Patient Profile:\\nA 51-year-old patient with a history of colorectal cancer is currently in the screening phase of a clinical trial. The patient has not participated in any previous trials, and their trial status and completion date are currently unknown.\\n\\nPotential Relevant Medical Trials:\\n1. Colorectal Cancer Treatment Trial - This trial focuses on new treatment options for patients with colorectal cancer, which may be beneficial for this patient based on their medical history.\\n2. Cancer Survivorship Study - This trial aims to improve the quality of life for cancer survivors, which could be relevant for this patient post-treatment.', 'revision_number': 2, 'max_revisions': 2, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the current year to allow for proper assessment of any delayed adverse effects.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 5. **Regulatory Compliance**\\n   - **Ethics Approval**: All trials must have approval from the Institutional Review Board (IRB) or Ethics Committee.\\n   - **Data Privacy**: Patient data must be handled in compliance with data protection regulations (e.g., GDPR, HIPAA).\\n   - **Adverse Event Reporting**: Any adverse events must be reported according to institutional and regulatory guidelines.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'trials': None, 'relevant_trials': None}}}, created_at='2024-06-23T17:03:05.134957+00:00', parent_config={'configurable': {'thread_id': '4', 'thread_ts': '1ef31827-2868-6e7b-8001-61261b1253c5'}})\n",
      "--\n",
      "StateSnapshot(values={'patient_prompt': 'Is patient 8 eligible for any medical trial?', 'patient_id': 8, 'patient_data': {'patient_id': 8, 'name': 'Daniel Johnson', 'age': 51, 'medical_history': 'colorectal cancer', 'previous_trials': None, 'trial_status': None, 'trial_completion_date': None}, 'revision_number': 2, 'max_revisions': 2}, next=('policy_checker',), config={'configurable': {'thread_id': '4', 'thread_ts': '1ef31827-2868-6e7b-8001-61261b1253c5'}}, metadata={'source': 'loop', 'step': 1, 'writes': {'patient_collector': {'patient_id': 8, 'patient_data': {'patient_id': 8, 'name': 'Daniel Johnson', 'age': 51, 'medical_history': 'colorectal cancer', 'previous_trials': None, 'trial_status': None, 'trial_completion_date': None}, 'revision_number': 2}}}, created_at='2024-06-23T17:03:00.869513+00:00', parent_config={'configurable': {'thread_id': '4', 'thread_ts': '1ef31827-1eef-654c-8000-d37387b965dc'}})\n",
      "--\n",
      "StateSnapshot(values={'patient_prompt': 'Is patient 8 eligible for any medical trial?', 'revision_number': 1, 'max_revisions': 2}, next=('patient_collector',), config={'configurable': {'thread_id': '4', 'thread_ts': '1ef31827-1eef-654c-8000-d37387b965dc'}}, metadata={'source': 'loop', 'step': 0, 'writes': None}, created_at='2024-06-23T17:02:59.876481+00:00', parent_config={'configurable': {'thread_id': '4', 'thread_ts': '1ef31827-1ebd-6b00-bfff-83326536f187'}})\n",
      "--\n",
      "StateSnapshot(values={}, next=('__start__',), config={'configurable': {'thread_id': '4', 'thread_ts': '1ef31827-1ebd-6b00-bfff-83326536f187'}}, metadata={'source': 'input', 'step': -1, 'writes': {'patient_prompt': 'Is patient 8 eligible for any medical trial?', 'max_revisions': 2, 'revision_number': 1}}, created_at='2024-06-23T17:02:59.856665+00:00', parent_config=None)\n",
      "--\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'patient_prompt': 'Is patient 8 eligible for any medical trial?',\n",
       " 'patient_id': 8,\n",
       " 'policy_eligible': True,\n",
       " 'patient_data': {'age': 51,\n",
       "  'medical_history': 'colorectal cancer',\n",
       "  'previous_trials': None,\n",
       "  'trial_status': None,\n",
       "  'trial_completion_date': None},\n",
       " 'patient_profile': 'Patient Profile:\\nA 51-year-old patient with a history of colorectal cancer is currently in the screening phase of a clinical trial. The patient has not participated in any previous trials, and their trial status and completion date are currently unknown.\\n\\nPotential Relevant Medical Trials:\\n1. Colorectal Cancer Treatment Trial - This trial focuses on new treatment options for patients with colorectal cancer, which may be beneficial for this patient based on their medical history.\\n2. Cancer Survivorship Study - This trial aims to improve the quality of life for cancer survivors, which could be relevant for this patient post-treatment.',\n",
       " 'revision_number': 2,\n",
       " 'max_revisions': 2,\n",
       " 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       "  Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the current year to allow for proper assessment of any delayed adverse effects.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       "  Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       "  Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       "  Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       "  Document(page_content='\\n#### 5. **Regulatory Compliance**\\n   - **Ethics Approval**: All trials must have approval from the Institutional Review Board (IRB) or Ethics Committee.\\n   - **Data Privacy**: Patient data must be handled in compliance with data protection regulations (e.g., GDPR, HIPAA).\\n   - **Adverse Event Reporting**: Any adverse events must be reported according to institutional and regulatory guidelines.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})],\n",
       " 'trials': [Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Subject is at least 20 years of age.\\r\\n\\r\\n          2. Written and voluntary informed consent understood, signed and dated.\\r\\n\\r\\n          3. They must have refractory or progressive colorectal cancer for which there is no\\r\\n             further curative therapy available.\\r\\n\\r\\n          4. Subject able to adhere to the study visit schedule and other protocol requirements.\\r\\n\\r\\n          5. ECOG 0-2\\r\\n\\r\\n          6. At least one measurable lesion that can be accurately assessed by imaging or physical\\r\\n             examination at baseline and following up visits.\\r\\n\\r\\n          7. Must have a life expectancy of 3 months or more\\r\\n\\r\\n          8. Demonstrate adequate organ function\\r\\n\\r\\n          9. Negative urine or serum pregnancy test within 28 days of study treatment\\r\\n\\r\\n         10. Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy\\r\\n             of the tissue sample quality for assessment of biomarker status.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. ECOG ≥ 3\\r\\n\\r\\n          2. History of malignancy in the last 5 years.\\r\\n\\r\\n          3. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\\r\\n             C.\\r\\n\\r\\n          4. Breast-feeding or pregnant female\\r\\n\\r\\n          5. Patients can not the administration of Folic acid or Vitamin B12.\\r\\n\\r\\n          6. Before treatment with Pemetrexed.\\r\\n\\r\\n          7. Patients who can not swallow oral medication.\\r\\n\\r\\n          8. The most recent treatment with the clinical trial for the drug for 14 days prior to\\r\\n             enrollment.\\r\\n\\r\\n          9. Systemic chemotherapy within three weeks after the administration of the last before\\r\\n             the test treatment, radiation therapy patients who had been administered.\\r\\n\\r\\n         10. Except for the hair loss, it is induced before cancer treatment, all of toxicity in\\r\\n             progress (> CTCAE1 grade).\\r\\n\\r\\n         11. Upper GI bleeding within registration before 4 weeks of Bowel obstruction or CTCAE3 or\\r\\n             4 grade.\\r\\n\\r\\n         12. Subject who experienced a recent myocardial infarction, including severe/unstable\\r\\n             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\\r\\n             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\\r\\n             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\\r\\n             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\\r\\n             year.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['colorectal cancer']\", 'drugs': \"['pemetrexed']\", 'nctid': 'NCT02588781', 'status': 'recruiting'}),\n",
       "  Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Diagnosis of adenocarcinoma of the rectum\\r\\n\\r\\n          -  Age: 18-70 years old\\r\\n\\r\\n          -  Signed informed consent; able to comply with study and/or follow- up procedures\\r\\n\\r\\n          -  Stage of the primary tumor may be determined by ultrasound or MRI\\r\\n\\r\\n          -  Stage II (T3-4, N0 [N0 is defined as all imaged lymph nodes < 1.0 cm]) OR stage III\\r\\n             (T1-4, N1-2 [with the definition of a clinically positive lymph node being any node ≥\\r\\n             1.0 cm]\\r\\n\\r\\n          -  Tumor palpable by digital rectal exam OR accessible by proctoscope or sigmoidoscope\\r\\n\\r\\n          -  Distal border of the tumor must be located < 12 cm from the anal verge\\r\\n\\r\\n          -  Tumor amenable to curative resection\\r\\n\\r\\n          -  Adequate bone marrow, hepatic and renal function as assessed by the following\\r\\n             laboratory requirements conducted within 7 days of starting study treatment:\\r\\n\\r\\n          -  Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet\\r\\n             count ≥ 100 x109/ L, hemoglobin (Hb) ≥ 9g/ dL.\\r\\n\\r\\n          -  Total bilirubin ≤1.5 x the upper limit of normal (ULN).\\r\\n\\r\\n          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.\\r\\n\\r\\n          -  Alkaline phosphatase limit ≤ 5x ULN.\\r\\n\\r\\n          -  Amylase and lipase ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Serum creatinine ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 mL/ min.\\r\\n\\r\\n          -  No renal disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  ECOG status: 0～1\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Hypersensitivity to fluorouracil, oxaliplatin or irinotecan.\\r\\n\\r\\n          -  No More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  Clear indication of involvement of the pelvic side walls by imaging\\r\\n\\r\\n          -  With distant metastasis\\r\\n\\r\\n          -  History of invasive rectal malignancy, regardless of disease-free interval\\r\\n\\r\\n          -  Fertile patients must use effective contraception\\r\\n\\r\\n          -  Uncontrolled hypertension\\r\\n\\r\\n          -  Cardiovascular disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  Lack of upper gastrointestinal tract integrity or malabsorption syndrome，active upper\\r\\n             gastrointestinal tract bleeding\\r\\n\\r\\n          -  Synchronous colon cancer\\r\\n\\r\\n          -  Pregnant or nursing, Fertile patients do not use effective contraception\\r\\n\\r\\n          -  Other malignancy within the past 5 years except effectively treated squamous cell or\\r\\n             basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or\\r\\n             carcinoma in situ of the colon or rectum\\r\\n\\r\\n          -  No psychiatric or addictive disorders, or other conditions that, in the opinion of the\\r\\n             investigator, would preclude study participation\\r\\n\\r\\n          -  patients refused to signed informed consent.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['rectal cancer']\", 'drugs': \"['mfolfox6']\", 'nctid': 'NCT02887313', 'status': 'recruiting'}),\n",
       "  Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Pathologic diagnosis of ovarian, fallopian tube or primary peritoneal cancer confirmed\\r\\n             by pathology review at MSK.\\r\\n\\r\\n          -  Patients will have relapsed at least once and returned to complete clinical remission\\r\\n             after additional chemotherapy. Interval surgery is permitted.\\r\\n\\r\\n          -  Complete clinical remission is defined as CA-125 within normal limits, examination and\\r\\n             CT or MRI without objective evidence of disease (non specific abnormalities are\\r\\n             permitted on radiologic imaging).\\r\\n\\r\\n          -  Patients may sign screening consent during recurrence or at time of remission if they\\r\\n             can start vaccine therapy within 4 months of completing chemotherapy.\\r\\n\\r\\n          -  Testing of patient's archived (paraffin embedded, unstained slides) or freshly\\r\\n             biopsied tumor nodules must be positive for WT1 (Cohort 1) or NY-ESO-1 (Cohort 2)\\r\\n             protein expression. WT1 expression: Immunohistochemical analysis will be performed\\r\\n             using the technique described by Dupont et al [58]. WT1 expression will be graded\\r\\n             according to an adaptation of the German Immunoreactive Score (IRS). Only tumors with\\r\\n             moderate to strong IRS scores (4-12) will be considered WT1 positive.\\r\\n\\r\\n          -  NY-ESO-1 expression: Tissue available from primary and/or recurrent disease will be\\r\\n             evaluated for tumor expression of NY-ESO-1 by immunohistochemical (IHC) and/or RT-PCR\\r\\n             analysis will be performed using the technique described by Jungbluth et al\\r\\n\\r\\n          -  Age ≥ 18 years\\r\\n\\r\\n          -  Karnofsky performance status ≥ 70%\\r\\n\\r\\n          -  Hematologic parameters: Absolute neutrophil count ≥ 1000/mcL, Platelets > 50 K/mcL.\\r\\n\\r\\n          -  Biochemical parameters: Total bilirubin ≤ 1.5 mg/dl, AST and ALT ≤ 2.5 x upper limits\\r\\n             of normal, Creatinine ≤ 1.5 mg/dl.\\r\\n\\r\\n          -  Patient of childbearing potential must have a negative serum pregnancy test prior to\\r\\n             study entry and must be practicing and effective form of birth control\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Patients with active infection requiring systemic antibiotics, antiviral, or\\r\\n             antifungal treatments\\r\\n\\r\\n          -  Patients with a serious unstable medical illness or another active cancer.\\r\\n\\r\\n          -  Patients with a condition requiring systemic treatment with either corticosteroids\\r\\n             (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14\\r\\n             days of study drug administration. Inhaled or topical steroids and adrenal replacement\\r\\n             doses >10mg daily prednisone equivalents are permitted in the absence of active\\r\\n             autoimmune disease.\\r\\n\\r\\n          -  Patients with known history of testing positive for human immunodeficiency virus (HIV)\\r\\n             or known acquired immunodeficiency syndrome (AIDS).\\r\\n\\r\\n          -  Patients with known active hepatitis B virus or hepatitis C virus acute or chronic\\r\\n             infection.\\r\\n\\r\\n          -  Patients with active known or suspected autoimmune disease (treated hypothyroidism is\\r\\n             permitted to enroll)\\r\\n\\r\\n          -  Patients with active interstitial pneumonitis.\\r\\n      \", metadata={'disease_category': 'cancer', 'diseases': \"['ovarian cancer', 'fallopian tube', 'primary peritoneal cancer', 'recurrent ovarian cancer']\", 'drugs': \"['nivolumab']\", 'nctid': 'NCT02737787', 'status': 'recruiting'}),\n",
       "  Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Patients have provided a signed Informed Consent Form\\r\\n\\r\\n          -  ECOG performance status of 0-1\\r\\n\\r\\n          -  BMI ≥ 18.5\\r\\n\\r\\n          -  Age: 18-65 years old\\r\\n\\r\\n          -  Histologically confirmed diagnosis of metastatic pancreatic cancer\\r\\n\\r\\n          -  No prior palliative chemotherapy\\r\\n\\r\\n          -  Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria\\r\\n\\r\\n          -  Life expectancy ≥ 3 months\\r\\n\\r\\n          -  Patient has adequate bone marrow and organ function\\r\\n\\r\\n               -  Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L\\r\\n\\r\\n               -  Platelets ≥ 90 x 109/L\\r\\n\\r\\n               -  Hemoglobin ≥ 90 g/L\\r\\n\\r\\n          -  Patient has adequate liver function\\r\\n\\r\\n               -  AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is\\r\\n                  liver metastasis)\\r\\n\\r\\n               -  Serum bilirubin ≤ 1.2 x ULN\\r\\n\\r\\n          -  Creatinine ≤ 1.25 times ULN\\r\\n\\r\\n          -  Good compliance\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Brain metastasis or only with bone metastasis.\\r\\n\\r\\n          -  Patients with severe gastrointestinal hemorrhage which need frequent blood\\r\\n             transfusions.\\r\\n\\r\\n          -  Refuse to take appropriate contraceptive measures (including male patients).\\r\\n\\r\\n          -  Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil.\\r\\n\\r\\n          -  Severe systemic disease out of control such as unstable or uncompensated respiratory,\\r\\n             cardiac, liver, renal diseases.\\r\\n\\r\\n          -  Patient has a concurrent malignancy or has a malignancy within 5 years of study\\r\\n             enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in\\r\\n             situ).\\r\\n\\r\\n          -  Psychiatric illness that would prevent the patient from giving informed consent.\\r\\n\\r\\n          -  Patient is concurrently using other antineoplastic agent\\r\\n\\r\\n          -  Patient has used investigational antineoplastic agent within 4 weeks prior to entry.\\r\\n\\r\\n          -  Known HIV-positivity.\\r\\n\\r\\n          -  No history of chronic diarrhea, nausea or vomit.\\r\\n\\r\\n          -  No ≥ grade 2 sensory peripheral neuropathy.\\r\\n\\r\\n          -  A history of transmural myocardial infarction (within 6 months prior to entry),\\r\\n             congestive heart failure, and unstable angina.\\r\\n\\r\\n          -  Infectious disease or inflammation with body temperature ≥ 38 ℃.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['metastatic pancreatic cancer']\", 'drugs': \"['mfolfirinox']\", 'nctid': 'NCT02028806', 'status': 'recruiting'})],\n",
       " 'relevant_trials': [{'relevance_score': 'Yes',\n",
       "   'explanation': \"The patient has a history of colorectal cancer, which matches the disease focus of the clinical trial. This indicates relevance based on the inclusion criteria of refractory or progressive colorectal cancer. Further information needed from the patient's medical history includes confirmation of ECOG status, organ function, pregnancy status, and recent treatments to fully assess eligibility for the trial.\",\n",
       "   'further_information': 'ECOG status, organ function, pregnancy status, recent treatments',\n",
       "   'nctid': 'NCT02588781'},\n",
       "  {'relevance_score': 'Yes',\n",
       "   'explanation': \"The patient has a history of colorectal cancer, which matches the diagnosis of adenocarcinoma of the rectum in the trial's inclusion criteria. This indicates potential relevance of the trial to the patient based on their medical history.\",\n",
       "   'further_information': \"Further information needed from the patient's medical history includes details on the stage of the primary tumor, tumor accessibility, and laboratory assessments to confirm eligibility for the trial.\",\n",
       "   'nctid': 'NCT02887313'},\n",
       "  {'relevance_score': 'Yes',\n",
       "   'explanation': \"The patient has a history of colorectal cancer, which is one of the inclusion diseases in the trial related to ovarian, fallopian tube, and primary peritoneal cancer. Therefore, the trial is relevant to the patient's medical profile.\",\n",
       "   'further_information': \"More details are needed regarding the patient's current health status, including recent test results, current treatment plan, and any other ongoing medical conditions.\",\n",
       "   'nctid': 'NCT02737787'}]}"
      ]
     },
     "execution_count": 114,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "states = []\n",
    "for state in graph.get_state_history(thread):\n",
    "    print(state)\n",
    "    print('--')\n",
    "    states.append(state)\n",
    "state = states[0]\n",
    "state.values    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'relevance_score': 'Yes',\n",
       "  'explanation': \"The patient has a history of colorectal cancer, which matches the disease focus of the clinical trial. This indicates relevance based on the inclusion criteria of refractory or progressive colorectal cancer. Further information needed from the patient's medical history includes confirmation of ECOG status, organ function, pregnancy status, and recent treatments to fully assess eligibility for the trial.\",\n",
       "  'further_information': 'ECOG status, organ function, pregnancy status, recent treatments',\n",
       "  'nctid': 'NCT02588781'},\n",
       " {'relevance_score': 'Yes',\n",
       "  'explanation': \"The patient has a history of colorectal cancer, which matches the diagnosis of adenocarcinoma of the rectum in the trial's inclusion criteria. This indicates potential relevance of the trial to the patient based on their medical history.\",\n",
       "  'further_information': \"Further information needed from the patient's medical history includes details on the stage of the primary tumor, tumor accessibility, and laboratory assessments to confirm eligibility for the trial.\",\n",
       "  'nctid': 'NCT02887313'},\n",
       " {'relevance_score': 'Yes',\n",
       "  'explanation': \"The patient has a history of colorectal cancer, which is one of the inclusion diseases in the trial related to ovarian, fallopian tube, and primary peritoneal cancer. Therefore, the trial is relevant to the patient's medical profile.\",\n",
       "  'further_information': \"More details are needed regarding the patient's current health status, including recent test results, current treatment plan, and any other ongoing medical conditions.\",\n",
       "  'nctid': 'NCT02737787'}]"
      ]
     },
     "execution_count": 116,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "state.values['relevant_trials']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "leukemia ['relapsed or refractory acute myeloid leukemia (aml)', 'untreated aml', 'other idh1-mutated positive hematologic malignancies', 'myelodysplastic syndromes']\n",
      "leukemia ['adult acute myeloid leukemia with 11q23 (mll) abnormalities', 'adult acute myeloid leukemia with del(5q)', 'adult acute myeloid leukemia with inv(16)(p13;q22)', 'adult acute myeloid leukemia with t(15;17)(q22;q12)', 'adult acute myeloid leukemia with t(16;16)(p13;q22)', 'adult acute myeloid leukemia with t(8;21)(q22;q22)', 'recurrent adult acute lymphoblastic leukemia', 'recurrent adult acute myeloid leukemia', 'recurrent childhood acute lymphoblastic leukemia', 'recurrent childhood acute myeloid leukemia']\n",
      "leukemia ['myelodysplastic syndromes', 'chronic myelomonocytic leukemia', 'acute myeloid leukemia']\n",
      "cancer ['stage iv non-small cell lung cancer']\n"
     ]
    }
   ],
   "source": [
    "for doc in state.values['trials']:\n",
    "    print(doc.metadata.get(\"disease_category\"), doc.metadata.get(\"diseases\"))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## HIL\n",
    "To correct Patient's data to pass the eligibility check."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 341,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "patient data found\n",
      "{'patient_id': 8, 'name': 'James Thomas', 'age': 49, 'medical_history': 'lymphoblastic leukemia', 'previous_trials': 'Trial 18', 'trial_status': 'Completed', 'trial_completion_date': '2023-11-06'}\n",
      "{'configurable': {'thread_id': '1', 'thread_ts': '1ef31789-5527-6dad-8002-b9d01aab14fd'}}\n",
      "--------- continue from modified state ---------\n",
      "today is: 2024-06-23\n",
      "binary_score='no' reason='The patient has participated in a previous trial (Trial 18) within the last 5 months, which violates the policy of not participating in any other clinical trial within the least 5 months prior to enrolling in a new trial.'\n",
      "Patient did not pass the general trials policies\n",
      "{'patient_prompt': 'Is patient 8 eligible for any medical trial?', 'patient_id': 8, 'policy_eligible': False, 'rejection_reason': 'The patient has participated in a previous trial (Trial 18) within the last 5 months, which violates the policy of not participating in any other clinical trial within the least 5 months prior to enrolling in a new trial.', 'patient_data': {'age': 49, 'medical_history': 'lymphoblastic leukemia', 'previous_trials': 'Trial 18', 'trial_status': 'Completed', 'trial_completion_date': '2023-11-06'}, 'patient_profile': 'Patient Profile:\\nThe patient is a 49-year-old with a history of lymphoblastic leukemia. They have previously participated in Trial 18, which was completed on November 6, 2023. Based on their medical history, they may be eligible for clinical trials focusing on leukemia treatments or immunotherapy.', 'revision_number': 2, 'max_revisions': 2, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the last 6 months are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the least 5 months prior to enrolling in a new trial to allow for proper assessment of any delayed adverse effects.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 5. **Regulatory Compliance**\\n   - **Ethics Approval**: All trials must have approval from the Institutional Review Board (IRB) or Ethics Committee.\\n   - **Data Privacy**: Patient data must be handled in compliance with data protection regulations (e.g., GDPR, HIPAA).\\n   - **Adverse Event Reporting**: Any adverse events must be reported according to institutional and regulatory guidelines.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'trials': None, 'relevant_trials': None}\n"
     ]
    }
   ],
   "source": [
    "state = states[1]\n",
    "state.values\n",
    "# for k in state:\n",
    "#     print(k)\n",
    "\n",
    "\n",
    "# state.values[\"patient_data\"]['trial_status'] = None\n",
    "# state.values[\"patient_data\"]['previous_trials'] = None\n",
    "branch_state = graph.update_state(state.config, state.values)\n",
    "print(branch_state)\n",
    "# state\n",
    "\n",
    "\n",
    "print(\"--------- continue from modified state ---------\")\n",
    "for event in graph.stream(None, branch_state):\n",
    "    for k, v in event.items():\n",
    "        if k != \"__end__\":\n",
    "            print(v)\n",
    "\n",
    "# for event in graph.stream({\n",
    "#     'patient_prompt': f\"Is patient {sample_patient_id} eligible for any medical trial?\",\n",
    "#     # 'patient_prompt': \"Is patient Max eligible for any medical trial?\",\n",
    "#     \"max_revisions\": 2,\n",
    "#     \"revision_number\": 1,\n",
    "# }, thread):\n",
    "#     print(event)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "ename": "InvalidUpdateError",
     "evalue": "Ambiguous update, specify as_node",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mInvalidUpdateError\u001b[0m                        Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[30], line 6\u001b[0m\n\u001b[0;32m      4\u001b[0m current_state \u001b[38;5;241m=\u001b[39m graph\u001b[38;5;241m.\u001b[39mget_state(thread)\n\u001b[0;32m      5\u001b[0m current_state\u001b[38;5;241m.\u001b[39mvalues[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpatient_prompt\u001b[39m\u001b[38;5;124m\"\u001b[39m] \u001b[38;5;241m=\u001b[39m \u001b[38;5;124m'\u001b[39m\u001b[38;5;124mIs patient 100 eligible for any medical trial?\u001b[39m\u001b[38;5;124m'\u001b[39m\n\u001b[1;32m----> 6\u001b[0m \u001b[43mgraph\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mupdate_state\u001b[49m\u001b[43m(\u001b[49m\u001b[43mthread\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mcurrent_state\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mvalues\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m      7\u001b[0m \u001b[38;5;66;03m# s\u001b[39;00m\n\u001b[0;32m      8\u001b[0m \u001b[38;5;66;03m# a=10000\u001b[39;00m\n\u001b[0;32m      9\u001b[0m \u001b[38;5;66;03m# type(a)\u001b[39;00m\n",
      "File \u001b[1;32md:\\Portfolio\\LLMs Applications\\.llmenv\\Lib\\site-packages\\langgraph\\pregel\\__init__.py:536\u001b[0m, in \u001b[0;36mPregel.update_state\u001b[1;34m(self, config, values, as_node)\u001b[0m\n\u001b[0;32m    534\u001b[0m             as_node \u001b[38;5;241m=\u001b[39m last_seen_by_node[\u001b[38;5;241m-\u001b[39m\u001b[38;5;241m1\u001b[39m][\u001b[38;5;241m1\u001b[39m]\n\u001b[0;32m    535\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m as_node \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[1;32m--> 536\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m InvalidUpdateError(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mAmbiguous update, specify as_node\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[0;32m    537\u001b[0m \u001b[38;5;66;03m# update channels\u001b[39;00m\n\u001b[0;32m    538\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m ChannelsManager(\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mchannels, checkpoint) \u001b[38;5;28;01mas\u001b[39;00m channels:\n\u001b[0;32m    539\u001b[0m     \u001b[38;5;66;03m# create task to run all writers of the chosen node\u001b[39;00m\n",
      "\u001b[1;31mInvalidUpdateError\u001b[0m: Ambiguous update, specify as_node"
     ]
    }
   ],
   "source": [
    "# s.get(\"patient_collector\")\n",
    "# graph.get_state(thread).next\n",
    "# graph.get_state_history(thread)\n",
    "current_state = graph.get_state(thread)\n",
    "current_state.values[\"patient_prompt\"] = 'Is patient 100 eligible for any medical trial?'\n",
    "graph.update_state(thread, current_state.values)\n",
    "# s\n",
    "# a=10000\n",
    "# type(a)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'configurable': {'thread_id': '1',\n",
       "  'thread_ts': '1ef2f4f7-19d3-601f-8001-87ae15683d5d'}}"
      ]
     },
     "execution_count": 53,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "state = states[2]\n",
    "state.values[\"patient_prompt\"] = 'Is patient 100 eligible for any medical trial?'\n",
    "branch_state = graph.update_state(state.config, state.values)\n",
    "branch_state"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "patient_id=100\n",
      "Patient ID: 100\n",
      "patient data found\n",
      "{'patient_id': 100, 'name': 'James Smith', 'age': 61, 'medical_history': 'Anxiety', 'previous_trials': 'Trial 5', 'trial_status': 'Withdrawn', 'last_trial_dates': '2022-08-11'}\n",
      "max revision reached\n",
      "{'patient_data': {'patient_id': 100, 'name': 'James Smith', 'age': 61, 'medical_history': 'Anxiety', 'previous_trials': 'Trial 5', 'trial_status': 'Withdrawn', 'last_trial_dates': '2022-08-11'}, 'revision_number': 2}\n"
     ]
    }
   ],
   "source": [
    "for event in graph.stream(None, branch_state):\n",
    "    for k, v in event.items():\n",
    "        if k != \"__end__\":\n",
    "            print(v)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## =========== GPT way =============="
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "ename": "TypeError",
     "evalue": "StateGraph.__init__() missing 1 required positional argument: 'state_schema'",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[3], line 18\u001b[0m\n\u001b[0;32m     15\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mcontinue\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m     17\u001b[0m \u001b[38;5;66;03m# Initialize the state graph\u001b[39;00m\n\u001b[1;32m---> 18\u001b[0m workflow \u001b[38;5;241m=\u001b[39m \u001b[43mStateGraph\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     20\u001b[0m \u001b[38;5;66;03m# Add nodes\u001b[39;00m\n\u001b[0;32m     21\u001b[0m workflow\u001b[38;5;241m.\u001b[39madd_node(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mretrieve_patient_data\u001b[39m\u001b[38;5;124m\"\u001b[39m, call_model)\n",
      "\u001b[1;31mTypeError\u001b[0m: StateGraph.__init__() missing 1 required positional argument: 'state_schema'"
     ]
    }
   ],
   "source": [
    "from langgraph.graph import StateGraph, END\n",
    "from langchain_openai import ChatOpenAI\n",
    "\n",
    "# Define the function that calls the model\n",
    "def call_model(state):\n",
    "    # In this simple example, we just pass the patient_id to the tool and get the patient data\n",
    "    patient_id = state[\"patient_id\"]\n",
    "    patient_data = retrieve_patient_data_tool(patient_id)\n",
    "    return {\"patient_data\": patient_data}\n",
    "\n",
    "# Define the function that determines whether to continue or not\n",
    "def should_continue(state):\n",
    "    if state.get(\"patient_data\"):\n",
    "        return \"end\"\n",
    "    return \"continue\"\n",
    "\n",
    "# Initialize the state graph\n",
    "workflow = StateGraph()\n",
    "\n",
    "# Add nodes\n",
    "workflow.add_node(\"retrieve_patient_data\", call_model)\n",
    "\n",
    "# Set entry point\n",
    "workflow.set_entry_point(\"retrieve_patient_data\")\n",
    "\n",
    "# Define conditional edges\n",
    "workflow.add_conditional_edges(\n",
    "    \"retrieve_patient_data\",\n",
    "    should_continue,\n",
    "    {\"continue\": \"retrieve_patient_data\", \"end\": END}\n",
    ")\n",
    "\n",
    "# Compile the workflow\n",
    "app = workflow.compile()\n",
    "\n",
    "# Example invocation\n",
    "initial_state = {\"patient_id\": 1}\n",
    "app.invoke(initial_state)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Dummy tests"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "     type                  name              tbl_name  rootpage  \\\n",
      "0   table        aircrafts_data        aircrafts_data         2   \n",
      "1   table         airports_data         airports_data         3   \n",
      "2   table       boarding_passes       boarding_passes         4   \n",
      "3   table              bookings              bookings         5   \n",
      "4   table               flights               flights         6   \n",
      "5   table                 seats                 seats         7   \n",
      "6   table        ticket_flights        ticket_flights         8   \n",
      "7   table               tickets               tickets         9   \n",
      "8   table           car_rentals           car_rentals     21958   \n",
      "9   table                hotels                hotels     21961   \n",
      "10  table  trip_recommendations  trip_recommendations     21962   \n",
      "\n",
      "                                                  sql  \n",
      "0   CREATE TABLE \"aircrafts_data\" (\\n\"aircraft_cod...  \n",
      "1   CREATE TABLE \"airports_data\" (\\n\"airport_code\"...  \n",
      "2   CREATE TABLE \"boarding_passes\" (\\n\"ticket_no\" ...  \n",
      "3   CREATE TABLE \"bookings\" (\\n\"book_ref\" TEXT,\\n ...  \n",
      "4   CREATE TABLE \"flights\" (\\n\"flight_id\" INTEGER,...  \n",
      "5   CREATE TABLE \"seats\" (\\n\"aircraft_code\" TEXT,\\...  \n",
      "6   CREATE TABLE \"ticket_flights\" (\\n\"ticket_no\" T...  \n",
      "7   CREATE TABLE \"tickets\" (\\n\"ticket_no\" TEXT,\\n ...  \n",
      "8   CREATE TABLE car_rentals (\\n        id INTEGER...  \n",
      "9   CREATE TABLE hotels (\\n        id INTEGER PRIM...  \n",
      "10  CREATE TABLE trip_recommendations (\\n        i...  \n"
     ]
    }
   ],
   "source": [
    "assert 1==2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "import os\n",
    "import shutil\n",
    "import sqlite3\n",
    "\n",
    "import pandas as pd\n",
    "import requests\n",
    "\n",
    "db_url = \"https://storage.googleapis.com/benchmarks-artifacts/travel-db/travel2.sqlite\"\n",
    "local_file = \"travel2.sqlite\"\n",
    "# The backup lets us restart for each tutorial section\n",
    "backup_file = \"travel2.backup.sqlite\"\n",
    "overwrite = False\n",
    "if overwrite or not os.path.exists(local_file):\n",
    "    response = requests.get(db_url)\n",
    "    response.raise_for_status()  # Ensure the request was successful\n",
    "    with open(local_file, \"wb\") as f:\n",
    "        f.write(response.content)\n",
    "    # Backup - we will use this to \"reset\" our DB in each section\n",
    "    shutil.copy(local_file, backup_file)\n",
    "# Convert the flights to present time for our tutorial\n",
    "# local_file = \n",
    "conn = sqlite3.connect(local_file)\n",
    "cursor = conn.cursor()\n",
    "\n",
    "query = 'SELECT * FROM sqlite_master'\n",
    "\n",
    "# Execute the query and fetch all results\n",
    "cursor.execute(query)\n",
    "rows = cursor.fetchall()\n",
    "\n",
    "# Optionally, you can get the column names\n",
    "column_names = [description[0] for description in cursor.description]\n",
    "\n",
    "# Convert the results to a Pandas DataFrame for better readability\n",
    "df = pd.DataFrame(rows, columns=column_names)\n",
    "\n",
    "# Display the DataFrame\n",
    "print(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'tdf' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[6], line 1\u001b[0m\n\u001b[1;32m----> 1\u001b[0m \u001b[43mtdf\u001b[49m\n",
      "\u001b[1;31mNameError\u001b[0m: name 'tdf' is not defined"
     ]
    }
   ],
   "source": [
    "tdf"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".llmenv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
